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Identification and composition of the 
exosome
The human exosome was originally identified as an 
autoantigen in patients with the overlap syndrome 
of the systemic autoimmune disorders polymyositis 
(PM) and scleroderma (Scl). For this reason, it was 
designated the ‘PM/Scl complex’. It was found to 
represent a complex of 11-16 proteins ranging from 
18-110 kDa and due to its nucleolar localization it 
was suggested to be involved in the synthesis of 
ribosomes (1-5). Further characterization of the 
proteins carrying the main autoantigenic epitopes 
led to the identification of PM/Scl-75, a 50 kDa 
polypeptide with an aberrant migration at 75 kDa 
in SDS-PAGE due to a highly charged C-terminal 
region (6;7). The second PM/Scl complex protein 
to be identified was the 100 kDa polypeptide 
PM/Scl-100, also localizing to the nucleolus (8;9). 
Both PM/Scl-75 and PM/Scl-100 were shown to 
contain domains with a high level of similarity to 
the bacterial 3’-5’ exoribonucleases RNase PH and 
RNase D, respectively (10). In 1997, a novel complex 
involved in the maturation of pre-ribosomal RNA 
was identified in the yeast Saccharomyces cerevisiae 
which consisted of at least ten components of which 
three contained a putative S1 RNA binding domain 
(Rrp4p, Rrp40p and Csl4p), six were putative 3’-5’ 
exoribonucleases homologous to bacterial RNase 
PH (Rrp41p, Rrp42p, Rrp43p, Rrp45p, Rrp46p and 
Mtr3p), whereas Rrp44p/Dis3p was homologues to 
bacterial RNaseR. An additional polypeptide, Rrp6p 
was found to be associated with this complex in 
the nucleus and to be homologous to the bacterial 
RNaseD. Because this protein complex consisted of 
a large number of putative exoribonucleases it was 
termed the exosome and it was soon realized that the 
PM/Scl complex represents the human counterpart 
of the yeast exosome, because PM/Scl-75 and PM/
Scl-100 were homologous to Rrp45p and Rrp6p, 
respectively. The remaining components of the 
human PM/Scl complex could be identified based 
upon their homology with the other yeast exosome 
components. The association with the exosome was 
confirmed for all components, except for hDis3p, 
which up to now has not been demonstrated to be 
bound to the human exosome (see Table 1) (11-15). 
Besides in yeast and in human, the exosome has 
now been identified in a number of other organisms 
including Trypanosoma brucei, a eukaryotic 
flagellate parasite (16;17). The T. brucei exosome 
complex has a composition very similar to that 
An eukaryotic cell contains many different types of RNAs such as messenger RNAs (mRNAs), which 
are translated into proteins by the ribosome, and numerous non-coding RNAs, including ribosomal 
RNAs (rRNAs), which form the RNA component of the ribosome. Transfer RNAs (tRNAs) are small 
non-coding RNA molecules required to carry a specific amino acid to the ribosome during protein 
synthesis, whereas the small nucleolar RNAs (snoRNAs) and small nuclear RNAs (snRNAs) are involved 
in the modification of ribosomal and messenger RNAs, respectively. Recently, several new classes of 
small non-coding RNAs have been discovered, including microRNAs (miRNAs) and small interfering 
RNAs (siRNAs), which both are able to target a specific part of a mRNA transcript resulting in the 
inhibition of expression of the gene. All these classes of RNA undergo several posttranscriptional 
processing steps and surveillance activities to produce functional RNA molecules. A key component 
in the precise trimming of the 3’ ends of various RNA species as well as the degradation of RNAs that 
have been targeted by the RNA surveillance machinery is the exosome complex. In this chapter an 
overview of our current knowledge on the function and structure of the exosome complex is presented. 
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of the yeast exosome. In contrast, the Drosophila 
melanogaster exosome appeared to lack a homologue 
of Rrp43p and for the Arabidopsis thaliana, a small 
flowering plant, only two exosome components, 
AtRrp41p and AtRrp4p, have been identified so 
far. However, AtRrp41p is found in high molecular 
weight complexes, similar in size to the yeast 
exosome complex, suggesting that these complexes 
represent the complete plant exosome. The existence 
of an exosome complex in archaebacteria was 
based upon the identification of clusters of genes 
showing similarity to exosome subunits from other 
organisms. Most Archaea are found to have genes 
encoding the homologues of Rrp41p, Rrp42p, 
Rrp4p and Csl4p (18). The relatively simple 
subunit composition was confirmed for the purified 
exosome of S. solfataricus that consisted of three 
subunits Rrp41p, Rrp42p and Rrp4p, which are 
present in similar amounts, whereas Csl4p appeared 
to be present in smaller amounts (19). 
The exosome as a target in 
autoimmunity
Normally, the immune system is able to recognize 
and eliminate unwanted non-self molecules 
without attacking self components. However, in 
some cases, it fails to discriminate between self 
and non-self molecules, leading to autoimmunity. 
Disorders caused by this phenomenon are known 
as autoimmune diseases, which fall into two 
general types: localized autoimmune diseases, in 
which a single organ or tissue is damaged by the 
autoimmune process, and systemic autoimmune 
diseases in which several organs or tissues are 
affected. The latter type of autoimmune diseases 
include diseases like systemic lupus erythematosus 
(SLE), scleroderma (Scl) and polymyositis (PM). 
Autoantibodies present in sera of patients suffering 
from polymyositis were found to target an antigen of 
approximately 100kDa, which since then is referred 
to as PM/Scl-100 (4). Because these autoantibodies 
were subsequently shown to be most prevalent in 
patients with the overlap syndrome of PM and Scl 
(5;20) the human PM/Scl-100 containing protein 
complex was termed the PM/Scl complex. Anti-PM/
Scl antibodies are present in 30% of patients with the 
PM/Scl overlap syndrome, in 10% of PM patients 
and in 2-6% of Scl patients (4;20-27). Although, 
only limited information is available about the 
autoantigenic epitopes of these autoantigens, it is 
known that they are predominately associated with 
the proteins PM/Scl-100 and PM/Scl-75 (28-30). 
The major reactivity of anti-PM/Scl-100 antibodies 
appears to be directed to an alpha-helical region 
(aa 231-245) (31), although other regions of this 
protein can be recognized by autoantibodies as 
well (32;33). Nevertheless, the most sensitive way 
to detect autoantibodies directed to PM/Scl-100 is 
a recently developed peptide-based assay using the 
PM/Scl-100 epitope described above as the antigen 
(27). The autoantigenic epitope(s) of the PM/Scl-75 
protein is/are less well defined although a recent 
study has provided evidence that, in addition to the 
highly charged C-terminal region of this protein (6), 
the recently identified N-terminal region is important 
for its antigenicity (30). After the identification of the 
exosome also the targeting of other PM/Scl-complex 
proteins by autoantibodies was investigated. Most 
of the other exosome components appeared to be 
recognized by autoantibodies, although with much 
lower frequencies (34). 
Why patients develop autoantibodies against the 
exosome is unknown, but for quite a number of 
autoantigens it has been shown that they undergo 
post-translational modifications during cell death, 
which under certain circumstances may trigger the 
immune system to develop an immune response 
against these proteins (35). Interestingly, PM/Scl-
100 has been shown to be cleaved by granzyme 
B, a proteolytic enzyme acting during cytotoxic 
lymphocyte-induced death, in vitro (36), whereas 
10 11
Chapter 1 - General Introduction
the PM/Scl-75 protein was demonstrated to be 
cleaved by caspases in apoptotic cells (Chapter 6). 
Structure of the core exosome
The human exosome contains nine components 
which are shared by the cytoplasmic and nuclear 
complex and are therefore termed ‘core’ components 
(14). Six of these core components (hRrp41p, 
hRrp42p, hMtr3p, hRrp46p, PM/Scl-75 and OIP2) 
contain an RNase PH domain (RPD) belonging 
to the PDX family of exoribonucleases, whereas 
the other three components (hCsl4p, hRrp4p, 
hRrp40p) contain an S1 (and KH RNA-binding 
domain) and belong to the RRP4 exoribonuclease 
family (37) (see Table 1). The assembly of six 
RPD domains and three S1/KH domains in the 
core of the exosome was found to be very similar 
to the eubacterial polynucleotide phosphorylase 
(PNPase) complex, which mainly functions in RNA 
degradation, although it has been shown that it can 
also synthesize RNA in the presence of an excess of 
NDPs (38). The PNPase polypeptide contains two 
individual RPDs classified as RPD1 and RPD2, and 
two RNA binding domains (one KH domain and one 
S1 domain), which assemble into a homotrimeric 
complex, resulting in a total of six RPDs and 
three KH/S1 domains per PNPase trimer (39). The 
similarity of protein domains present in exosome 
subunits on the one hand and PNPase on the 
other hand suggested that their three-dimensional 
structure might also be similar. The crystal structure 
of PNPase revealed that the S1 domains form a 
crown of RNA-binding domains around the space 
in the centre of the trimer. Based upon the PNPase 
structure and taking into account the interactions 
observed between different exosome subunits in 
a mammalian two-hybrid system, a model for the 
human exosome was generated in which, hRrp42p, 
OIP2 and PM/Scl-75 subunits were classified as 
homologues of RPD1 and hRrp41p, hRrp46p and 
hMtr3p as homologues of RPD2. This results in a 
structure with six RNase PH-like subunits forming 
a hexameric ring and the three proteins with S1 (and 
KH) RNA binding domains positioned at the outer 
surface of this ring (see Fig. 1A) (39;40). 
Figure 1. The composition and structure of the exosome core complex. 
Model for the human exosome core (panel A) with RPD1-type subunits colored in different shades of green, RPD2-type subunits in 
shades of blue and S1 domain containing subunits in shades of orange. Panel B shows the crystal structure of an archaeal exosome 
core complex (from Archaeoglobus fulgidus), consisting of alternating Rrp42 (green) and Rrp41 (blue) subunits in the ring, two Rrp4 
subunits (dark orange) and one Csl4 subunit (light orange). In panel C an Rrp41-Rrp42 dimer of the archaeal exosome crystal structure 
is shown, bound to a four-nucleotide RNA molecule. The most 3’ nucleotide (n
1
) is located very close to the catalytic site of Rrp41 
(residue Asp182 is marked yellow) and the phosphate binding site (residues Ser138 and Arg139 are marked red). Note that a small part 
of the Rrp42 protein has been removed in the inset image, to allow a close-up of the inside of the RNA-binding pocket.
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Table I. Components of the core exosome complex
human 
protein
yeast 
orthologue
conserved 
domain(s)
activity exoribonuclease 
family
hCsl4p Csl4p/Ski4p S1 RNA binding1 RRP4
hRrp4p Rrp4p S1 / KH
3’-5’ hydrolytic 
exoribonuclease
RRP4
hRrp40p Rrp40p S1 / KH
3’-5’ hydrolytic 
exoribonuclease1
RRP4
hRrp42p Rrp42p RPD1
3’-5’ phosphorolytic
exoribonuclease
PDX
OIP2 Rrp43p RPD1
3’-5’ phosphorolytic
exoribonuclease
PDX
PM/Scl-75 Rrp45p RPD1
3’-5’ phosphorolytic
exoribonuclease1
PDX
hMtr3p Mtr3p RPD2
3’-5’ phosphorolytic
exoribonuclease
PDX
hRrp41p Rrp41p/Ski6p RPD2
3’-5’ phosphorolytic
exoribonuclease
PDX
hRrp46p Rrp46p RPD2
3’-5’ phosphorolytic
exoribonuclease1
PDX
hDis3p2 Rrp44p/Dis3p RNase R
3’-5’ hydrolytic 
exoribonuclease
RNase R
1 Hypothetical activity
2 Association is based on homology only
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Biophysical support for this ring-like structure was 
provided by the crystal structure of the archaeal 
exosome core, which was found to consist of a 
stable ring of Rrp41-Rrp42 heterodimers (41;42) 
containing either three copies of Rrp4 or three 
copies of Csl4 on top of the ring structure. However, 
Figure 1B indicates that it is more likely that the 
native archaeal exosome contains 2 copies of the 
Rrp4 protein and 1 copy of the Csl4 protein (43). 
In contrast to the archaeal exosome, the human 
exosome requires the interaction with the S1 domain 
proteins to maintain a stable ring structure. Although, 
the crystal structure of the human exosome revealed 
that the arrangement of the exosome components is 
consistent with the model of the human exosome 
as shown in Figure 1A, the S1 (and KH) domain 
proteins were found to be on top of the ring rather 
than on the outside of the ring (44). 
Based upon these structural data, a mechanism 
was proposed for the recognition and degradation 
of substrate RNAs by the human and archaeal 
exosome. The proteins with a S1 (and KH) domain 
are proposed to recruit substrate RNAs to the 
entrance of the channel formed by their S1 domains, 
which allows only single-stranded RNA to enter the 
central chamber. The central chamber contains the 
active sites to catalyse the phosphorolytic removal 
of 3’ nucleotides. Interestingly, Rrp41 was found 
to be the only catalytically active exoribonuclease 
in both the archaeal and human exosome (see Fig. 
1C)(43-45). 
Identification of exosome-associated 
proteins
Because every RNA molecule is a potential substrate 
for the exosome, it is believed that additional factors 
interact with the exosome in order to discriminate, 
facilitate and/or stimulate the degradation of 
different RNA substrates by the exosome. Indeed, a 
number of such proteins, which often associate with 
only a subset of exosome complexes, have been 
described in various organisms and for most, but 
not all of them, homologues have been identified in 
other eukaryotes (see Table 2). However, important 
differences in presence and function between such 
homologues can be found. For example, in yeast 
Rrp6p was found only in the nuclear exosome 
complex, whereas its human homologue PM/Scl-100 
was found in both the nuclear and the cytoplasmic 
complex. The human homologue of the yeast Dis3p 
protein, the human hDis3p protein, does not seem 
to be stably associated with the exosome (12-14;46-
49). Interestingly, in yeast Dis3p was reported to 
be solely responsible for core exosome activity 
suggesting that there are important differences 
between the exosome complexes of these two 
organisms (44;50). MPP6 was found to co-purify 
with the human exosome and to bind to PM/Scl-100 
in vitro and appears to have no yeast counterpart 
(14;51). The yeast Rrp47p protein (C1D in human) 
was found to interact with the nuclear exosome 
and to be required for processing of non-coding 
RNAs and thus may provide substrate specificity 
to the core exosome. In yeast the putative RNA 
helicase Mtr4p (KIAA0052 in human) has also been 
implicated in the specificity of the nuclear exosome 
and more recently this protein was reported to be 
a component of the TRAMP complex, which also 
contains the Trf4p/Trf5p and Air1p/Air2p proteins 
(52;53). The Ski2p protein, which like Mtr4p 
belongs to the family of DEAD box RNA helicases, 
is a component of the Ski-complex, containing 
also Ski3p, Ski7p and Ski8p. The interaction of 
the Ski-complex with the exosome is mediated by 
Ski7p in yeast but this protein appears to have no 
human homologue (54). A complete overview of 
the exosome-associated proteins identified so far is 
given in Table 2.
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human protein yeast 
orthologue
conserved 
domain(s)
activity comments
PM/Scl-100 Rrp6p RNase D
3’-5’ hydrolytic 
exoribonuclease1
in yeast only associated 
with nuclear exosome
hSki2p2 Ski2p DEAD box RNA helicase1 part of Ski-complex
hSki3p2 Ski3p TPR repeats unknown part of Ski-complex
hSki8p2 Ski8p WD40 repeats unknown
part of Ski- and hPAF 
complex
eFRS3 Ski7p GTPase unknown part of Ski-complex
KIAA0052 Mtr4p/Dob1p DEAD box RNA helicase1 part of TRAMP-complex
TRF4-23 Trf4p
PAP associated 
NTP transferase
Poly(A) polymerase part of TRAMP-complex
TRF4-13 Trf5p
PAP associated 
NTP transferase
Poly(A) polymerase part of TRAMP-complex
- Air1p RING finger RNA binding
can functionally replace 
Air2p
- Air2p RING finger RNA binding part of TRAMP-complex
MPP6 - - unknown
RHAU - DexH/D box RNA helicase
longer isoform is located 
to the nucleus
C1D3 Rrp47P C1D nucleotide binding1
associated with the 
nuclear exosome
KSRP - KH
binds AU-rich ele-
ment of an mRNA
Table 2.Exosome-associated proteins
14 15
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human protein
yeast
orthologue
conserved
domain(s)
activity comments
AUF1/hnRNP D Hrp1p3 RRM
binds AU-rich ele-
ment of an mRNA
TTP Tis11p3
Zinc finger-
CCCH
binds AU-rich ele-
ment of an mRNA
ISG204 Rex4p3 ExoI/II/III
3’-5’ 
exoribonuclease1
Ran3 Gsp1p GTPase GTPase interacts with Dis3p
CGI-373 Nip7p - unknown interacts with Dis3p
Rpp14 - -
3’-5’ phosphorolytic 
exoribonuclease
interacts with OIP2
1 Hypothetical activity
2 Unpublished observations
3 Association is based on homology only
4 Dr. N. Mechti, personal communication
Functions of the exosome
In recent years it has become clear that the exosome 
resides in the cytoplasm, the nucleoplasm and the 
nucleolus of eukaryotic cells and functions in the 
processing, surveillance or complete degradation 
of a variety of different RNA species. Most of the 
studies described below have been performed in 
yeast, but similar functions are believed to apply 
for the human exosome due to the high level of 
homology and the essential nature of most substrate 
RNAs. 
rRNA processing
Three out of four rRNAs are transcribed as a single 
precursor containing two internally transcribed 
spacers (ITS1 and ITS2) and two externally 
transcribed spacers (5’-ETS and 3’-ETS), which 
are removed by a complex series of endonucleolytic 
and exonucleolytic processing steps to produce the 
mature 18S, 5.8S, and 25S rRNAs (Fig. 2A). Yeast 
strains lacking either exosome core subunits or 
specific exosome associated proteins such as Rrp6, 
Rrp47p, Dob1p/Mtr4p, Nop53p and Gsp1p/Ran 
accumulate 5.8S rRNAs that are extended at the 
3’ end (55-58). However, the 3’ end of these 5.8S 
rRNA precursors varies between different mutants 
indicating that they do not have identical functions 
(59-61). Also in other organisms, such as T. brucei 
and human, the exosome has been shown to be 
implicated in 5.8S rRNA processing (16;62). 
Besides its involvement in 5.8S rRNA maturation 
it has been shown in yeast that exosome depletion 
leads to the accumulation of a 5’ ETS fragment 
and incompletely or incorrectly processed rRNA 
precursors as depicted in Figure 2B (55;63). This 
Table 2. (Continued)
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Rrp6
35S
A3 C2
18S 25S5.8S
5'ETS ITS1 ITS2 3'ETS
A0 A1
A2
D
pre-rRNA
A0
A1
33S
degradation of
excised 5´ETS
A. normal processing B. processing after exosome depletion
32S
A2
32S
D
27SA220S
18S
A3
1. Inhibition of cleavage sites A A A0 1 2; ;
A3
35S
27SA2
A2
23S
A3
A1 A2
23S*
A1 A2
21S*
2. Inhibition of cleavage site A3
A1
A1
A2A1A0
A0
A3
35S
20S
A3
27SA2
C2
C2
A3 C2
A2
A3
*
A3 C2
27SA2
A3
27SA3
A3
B (L)1
B (S)1
processing to B1 and B2
B1
27SB
B1
C1C2
C1C2
B1 C1C2 B2
B2
B2
25S
7S
5.8S
B2
C1
RNA degradation
RNA processing
processing of 7S rRNA
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Figure 2. Pre-rRNA processing by the exosome in S.cerevisiae.
The 35S pre-rRNA is transcribed by RNA polymerase I as a single precursor and contains two external transcribed spacers (5’-ETS and 
3’-ETS) and two internal transcribed spacers (ITS1 and ITS2), which are removed by a series of processing steps yielding the mature 
18S, 5.8S and 25S rRNAs. The exosome is involved in several of these steps either directly or indirectly. 
A). Endonucleolytic cleavage at site A
0
 in the 5’ ETS results in the 33S pre-rRNA and the 5’ part of the 5’ ETS which is completely 
degraded by the exosome. Cleavage at the A
1 
site generates the 32S pre-rRNA, which is followed by the cleavage at the A
2
 site leading 
to the 20S and 27SA
2
 pre-rRNAs. The 20S pre-rRNA is further processed by cleavage at site D to generate mature 18S rRNA. The 5’ 
end of the 27SA
2
 pre-rRNA can be processed by two alternative pathways concerning ITS1 processing, which results in either a short 
or a long form of 5.8S rRNA. Since the exosome is involved in processing of this rRNA precursor in ITS2 and this is the same for both 
ITS1 processing pathways, only the major pathway, leading to maturation of the short form of 5.8S rRNA, is included in this figure. 
The 27SA
2
 pre-rRNA is cleaved at site A
3
, which yields the 27SA
3
 pre-rRNA. This molecule is then processed by a 5’-3’ exonuclease 
to site B
1
(S) concomitant with cleavage at site B
2
 at the 3’ end of 25S rRNA, followed by cleavages at sites C
1
 and C
2
 resulting in 
the mature 25S rRNA and the 7S precursor rRNA. 3’ end processing of the 7S pre-rRNA by the exosome, generates the mature 5.8S 
rRNA. B) Mutation of one of the exosome components results in the inhibition of cleavage at either sites A
0
, A
1 
and A
2
 (1.) or at site 
A
3 
(2.). Note that after exosome depletion these processing pathways are not completely blocked. (1.) Inhibition of cleavage sites A
0 
– A
2
 results in the production of 23S pre-rRNA, which is subsequently converted to 23S* pre-rRNA, and 21S* pre-rRNA. The latter 
is formed by cleavage of the 23S* pre-rRNA at site A
1
. (2.) Inhibition of cleavage at site A3 results in a pre-rRNA which extends from 
site A
2
 to C
2
. In the absence of a functional exosome complex A
2
–* pre-rRNAs accumulate, which have heterogeneous 3’ ends between 
C
2
 and the 3’ end of the 5.8S rRNA.
suggests that the exosome participates in a quality 
control mechanism for pre-rRNA processing. 
More recently, a yeast strain lacking Rrp6p was 
found to accumulate polyadenylated rRNAs which 
reside mostly in the nucleus. Interestingly, the 
polyadenylation occurred preferentially on pre-
rRNAs. This observation led to the identification 
of the TRAMP complex, consisting of the poly(A) 
polymerase Trf4p, one of the putative RNA binding 
proteins Air1p or Air2p and the RNA helicase 
Mtr4p, which was already known to function in 
rRNA processing in concert with the exosome. This 
complex is able to stimulate exosome-dependent 
RNA processing by adding a poly(A) tail to its 
substrate RNAs (52;53). 
snRNA processing
In the nucleoplasm, a number of small RNAs 
(snRNAs) are involved in the splicing of pre-
mRNA. The primary transcripts of these small 
RNAs are post-transcriptionally processed to 
produce functional snRNAs (64). For the U1, U4 
and U5 snRNAs it has been shown that their 3’ end 
processing can be performed by the exosome and 
the associated factors Mtr4p/Dob1p and Rrp47p, 
although other exoribonucleases have been shown 
to affect the 3’ end processing of certain snRNAs as 
well (58;60;65;66).
snoRNA processing
The small nucleolar RNAs (snoRNAs) can be 
divided in two major classes. The box C/D snoRNAs, 
essential for the methylation of 2’-hydroxyl groups 
in substrate RNAs, and the box H/ACA snoRNAs, 
which are responsible for the conversion of uridine 
into pseudouridine in substrate RNAs. In higher 
eukaryotes, both 5’ and 3’ processing of pre-
snoRNAs involves exonuclease activities (67). In 
yeast, initial processing of the 3’ end of a wide 
variety of snoRNAs requires the nuclear exosome as 
well as associated proteins, such as Mtr4p/Dob1p. 
In addition, depletion of Rrp6p and Rrp47p leads 
to the accumulation of several snoRNAs that are 
3’ extended by 3 nucleotides, whereas depletion 
of other exosome components does not affect the 
trimming of these last 3 nucleotides. This suggests 
that Rrp6p and Rrp47p are required for the final 
trimming of these snoRNAs (58;60;65;68).
18 19
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In the absence of Rrp6p, Mtr4p, or core exosome 
components polyadenylation of at least some small 
nucleolar RNAs occurs. Like for rRNA processing, 
it was found that the TRAMP complex is required 
for normal processing of the U14 snoRNA and the 
U5 snRNA by the exosome (52). 
tRNA surveillance
Besides their role in the processing of small nuclear 
RNAs, the exosome and TRAMP complex are also 
implicated in a surveillance pathway in which 
aberrantly processed tRNAs are polyadenylated by 
the TRAMP complex and subsequently degraded 
by the exosome. However, the manner in which 
these complexes can discriminate between normal 
tRNAs and non-functional tRNAs remains poorly 
understood (69;70). Another link between the 
exosome and tRNA processing has been suggested 
by a yeast two-hybrid interaction between the core 
exosome component OIP2 and Rpp14, a component 
of the RNase P complex which is required for tRNA 
maturation. Both proteins were shown to possess 
exonuclease activity on precursor tRNA substrates 
in vitro, suggesting that exonucleolytic activity may 
be involved in the generation of mature tRNA 3’ 
ends (71). 
Degradation of cryptic unstable transcripts
Cryptic unstable transcripts are RNA polymerase 
II transcripts mapping to intergenic regions of the 
genome. These transcripts originate near known 
promoter elements but are instable and do not contain 
long or conserved reading frames. In yeast strains 
lacking Rrp6p, it was observed that polyadenylated 
forms of these RNAs accumulate. This suggest that 
the exosome together with the TRAMP complex 
participates in a surveillance pathway preventing 
the accumulation of inappropriate transcripts of 
intergenic regions via rapid degradation of these 
transcripts by the exosome (53). Alternatively, 
rather then being ‘noise’, it has been suggested that 
a number of these RNAs reflect an important RNA 
polymerase activity at the promoter region in order 
to regulate the transcription of downstream genes 
(72). 
mRNA degradation by the exosome
mRNA levels are determined by the balance between 
the rate of synthesis (transcription) and degradation 
of mRNA molecules. For the degradation of 
mRNAs, two cytoplasmic pathways have been 
identified, one of which involves the exosome as 
the main degradation machinery. In addition, the 
exosome has been implicated in several nuclear and 
cytoplasmic surveillance pathways for the decay of 
aberrant mRNAs.
mRNA turnover by the cytoplasmic exosome
Two main pathways exists for the degradation of 
mature wild type mRNA molecules in the cytoplasm. 
In the so called 5’-3’ pathway, deadenylation of 
the mRNA is followed by decapping, after which 
the mRNA is exonucleolytically digested by the 
5’-3’ exoribonuclease Xrn1p (73;74). In the 3’-5’ 
mRNA decay pathway, deadenylation is followed 
by degradation of the mRNA body by the human 
exosome which was demonstrated by the use of an 
in vitro mRNA decay system (14;75;76) (see Fig. 
3). In yeast it has been shown that 3’-5’ mRNA 
decay by the exosome requires the Ski-complex, 
consisting of Ski2p, Ski3p, Ski7p and Ski8p (77;78). 
Recently, homologues of yeast Ski2p, Ski3p and 
Ski8p have been identified in human cells (79), but 
it remains unclear whether the human Ski-complex 
plays a role in mRNA degradation. Since mRNA 
half-lives are known to vary from minutes to days 
it has been established that many mRNAs contain 
sequence elements in their 3’-untranslated regions 
(3’-UTR) that influence their stability (80). Among 
these, AU-rich elements (AREs) are responsible for 
targeting the transcripts for rapid decay. Several 
proteins which specifically interact with the AREs 
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are known to co-immunopurify with the exosome 
(81;82), but AREs may also recruit the exosome 
directly (76;83).
Besides general mRNA turnover, the exosome has 
also been implicated in a surveillance pathway called 
nonsense-mediated decay (NMD). In this pathway, 
mRNAs that contain premature termination codons 
are rapidly degraded to prevent the translation of 
truncated proteins that may interfere with normal 
cellular processes (48;84).
Another surveillance pathway termed ‘nonstop 
decay’ serves to eliminate mRNAs lacking a 
termination codon. In such an mRNA the ribosome 
continues translation into the 3’ UTR and the 
poly(A) tail and stalls at the 3’ end of the mRNA, or 
until it encounters an in-frame termination codon in 
the UTR. This process leads to aberrant polypeptides 
that might interfere with normal protein function. In 
both NMD and non-stop decay, exosome-mediated 
degradation is triggered, although little is known 
about the mechanisms underlying this process 
(85;86)(see Fig. 3).
Figure 3. The role of the exosome in mRNA surveillance and turnover. 
When errors occur during mRNA biogenesis, different pathways can be activated in which the exosome degrades the aberrant 
messenger. Aberrant 3’ end formation will lead either to rescue of the mRNA by the nuclear exosome or to complete degradation 
in an Rrp6-dependent manner. Errors in splicing can lead to degradation by the nuclear exosome, but the mRNA can also be 
exported to the cytoplasm where it is then degraded by the regular mRNA turnover machinery. After transport to the cytoplasm, 
the mRNA is subjected to nonsense-mediated decay (NMD) if translation terminates prematurely. Alternatively, if the normal 
stop codon is lacking, translation proceeds and ribosomes stall at the 3’ end of the mRNA, which will activate non-stop decay. 
If none of these errors are encountered, mRNAs will be translated properly and eventually degraded through regular turnover 
pathways. The lifespan of the latter mRNAs differs and is in part dependent on the presence of (de)stabilizing elements, 
like AREs, which recruit the mRNA degradation machinery including the exosome, thereby enhancing their turnover rates. 
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mRNA turnover by the nuclear exosome
A nuclear mRNA degradation pathway involving 
the exosome was identified via a mutation in 
Pap1p that caused a defect in polyadenylation of 
mRNAs resulting in significant lower quantities 
of most mRNAs. Upon mutation of the nuclear 
exosome component Rrp6p this effect was partially 
suppressed, suggesting that Rrp6p competes with 
mRNA 3’ end processing and destroys slowly or 
improperly processed pre-mRNAs (87). In agreement 
with this observation it was shown that improperly 
polyadenylated transcripts are sequestered at or near 
transcription sites in an exosome-dependent manner 
(88) (see Fig. 3). Besides improperly polyadenylated 
mRNAs, also enhanced levels of unspliced mRNAs 
are found in yeast strains with splicing defects and 
defective exosome components, suggesting that 
improperly spliced pre-mRNAs are degraded by 
the nuclear exosome (89). However, not all aberrant 
pre-mRNAs may be retained in the nucleus, since 
partially spliced pre-mRNAs have been found to be 
degraded also by a cytoplamic RNA surveillance 
pathway (90).
Regulation of exosome activity and 
specificity
In principle every RNA molecule is a potential 
substrate for the exosome. Therefore, additional 
factors are required to help the complex to 
identify its proper RNA substrate. The molecular 
mechanisms underlying the regulation of exosome 
activity are largely unknown, although several 
mechanisms have been proposed (see Fig. 4). 
The Trf4p (TRAMP) complex, for example, can 
stimulate exosome activity by adding a poly(A) tail 
to the substrate and has been shown to polyadenylate 
aberrantly processed RNAs more efficiently than 
correctly processed RNAs. It is possible that the 
TRAMP complex recognizes its preferred RNA 
Figure 4. Regulation of the exoribonucleolytic 
activity of the exosome by exosome associated 
proteins. 
The 3’ end of a substrate RNA most likely enters 
the central channel via the pore formed by the S1 
domains and is exonucleolytically degraded at the 
active sites of RBD2 subunits in the processing 
chamber (upper left). The various ways by which 
3’-5’ degradation of substrate RNAs by the core 
exosome can be regulated are schematically 
illustrated: inhibition of degradation by proteins 
bound to the substrate RNA (upper right corner); 
additional degradation/processing of (remaining) 
substrate RNA (fragments) by exosome-
associated exoribonucleases (lower left corner); 
enhancement of the efficiency of degradation 
by proteins recruiting substrate RNA molecules 
to the exosome and/or by helicases unwinding 
secondary structures in the RNA that has to be 
degraded (lower right corner).
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substrate via the altered tertiary structure of the 
RNA (69;70;91). Proteomic analysis of the purified 
TRAMP complex showed that different forms of 
the complex exist, containing Mtr4p with Trf4p or 
Trf5p and Air2p. Although another putative RNA 
binding protein, Air1p, did not co-purify with Trf4p 
or Mtr4p, however complementation experiments 
demonstrated that Air1p can replace Air2p in the 
TRAMP complex. Therefore, it is conceivable that 
different subsets of TRAMP complexes exist and 
that these play different roles in exosome-dependent 
RNA processing events. For example, Trf4p and 
Trf5p may polyadenylate different RNA substrates, 
whereas the putative RNA binding proteins Air1p and 
Air2p may recruit the exosome complex to different 
polyadenylated substrate RNAs (52). The Rrp47p 
protein was proposed to be associated with the 
nuclear exosome component Rrp6p. In accordance 
with this, genetic depletion of Rrp47p in yeast 
leads to a similar sn(o)RNA and rRNA processing 
phenotype as depletion of Rrp6p. However, Rrp47p 
is not required for Rrp6p-dependent degradation 
of aberrant pre-mRNAs in the nucleus suggesting 
that Rrp47p provides substrate specificity for the 
exosome in the processing of stable small RNA 
molecules (60). 
As described above, the degradation of mRNAs 
can proceed via two main pathways, 5’-3’ and 
3’-5’ decay, of which the latter is mediated by the 
exosome. In mammalian cells the deadenylase 
PARN has been shown to be required for exosome-
mediated mRNA decay suggesting that the exosome 
can only access mRNAs with shortened poly(A) 
tails (14). Besides the core exosome, 3’-5’ mRNA 
decay requires the Ski-complex containing the RNA 
helicase Ski2p, which is most likely required for 
unwinding the basepaired regions of the mRNA 
substrate or stimulating the dissociation of proteins 
from the 3’ UTR (78;92). 3’-5’ mRNA decay is 
further regulated by cis-acting elements in the 3’ 
UTR, such as the AU-rich element which involves 
the binding of specific ARE-binding proteins. The 
exosome has been shown to physically interact 
with several proteins of this family, including 
KSRP, AUF-1 and TTP. All these proteins stimulate 
exosome-mediated ARE-mRNA degradation in 
vitro, and are probably involved in the recruitment 
of the exosome to the RNA substrate. In contrast, the 
ARE-mRNA stabilizing factor HuR does not interact 
with the exosome (14;93-95) (see Fig. 4). Another 
protein involved in ARE mRNA degradation, the 
putative DExH RNA helicase RHAU, has been 
shown to interact with the exosome and has been 
proposed to disrupt the interaction between HuR 
and the ARE to initiate degradation of the RNA 
body (96). Recent studies have revealed that Upf 
factors interact with mRNAs in order to distinguish 
mRNAs that contain premature termination codons 
from mRNAs that do not. The Upf factors Upf1, 
Upf2, Upf3X can associate with both the exosome 
and PARN suggesting that the Upf factors recruit the 
deadenylation machinery as well as the exosome to 
degrade mRNAs containing a premature stop codon 
(48). 
Outline of this thesis
Since the first report on the human exosome 
back in 1999, this complex has been shown to be 
involved in a wide variety of processes all involving 
either the precise 3’ end trimming or the complete 
degradation of an RNA substrate. However, at the 
start of the study described in this thesis detailed 
knowledge about different exosome complexes 
and its functional regulation in different cellular 
compartments was almost completely lacking. In 
Chapter 2, the existence of different exosome-
containing complexes in the cytoplasm and nucleus 
is demonstrated by the results of glycerol gradient 
sedimentation analyses. In addition, by knock-down 
experiments it is shown that the nuclear exosome 
appears to be much more stable than the cytoplasmic 
complex. The effects of the efficient knock-down 
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of the exosome in the cytoplasmic compartment 
on the degradation of different classes of mRNA 
were determined as well. In Chapters 3 and 4, 
the cloning and characterization of three nuclear 
exosome-associated proteins, MPP6, C1D and 
hMtr4p/KIAA0052 is described. All these proteins 
appear to be involved in the 3’ end processing of 
the 5.8S rRNA. Further investigations led to the 
identification of the putative poly(A) polymerase, 
hTrf4-2p, which was shown to interact with the 
exosome and to stimulate exosome activity in vitro 
(Chapter 5). The second part of this thesis focuses 
on the autoantigenicity of the exosome and its 
associated proteins. The results of the experiments 
described in Chapter 6 demonstrate that the main 
autoantigen in PM/Scl overlap patients, PM/Scl-
75, is cleaved by caspases during apoptosis. The 
apoptotic modification of PM/Scl-75 possibly 
contributes to the generation of autoantibodies to 
this protein by creating a neo-epitope. The caspase 
cleavage site of this protein was mapped. The 
autoantigenicity of the newly identified exosome-
associated proteins described in Chapters 3 and 4 was 
assessed in Chapter 7. This led to the identification 
of C1D as a major autoantigen in patients suffering 
from the PM/Scl overlap syndrome. Finally, the 
results presented in this thesis are summarized and 
discussed more generally in Chapter 8. 
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The human exosome is a 3’-5’ exoribonuclease complex that functions both in the nucleus and in the 
cytoplasm to either degrade or process RNA. Little is known yet about potential differences among core 
exosome complexes in these different cellular compartments and the roles of the individual subunits 
in maintaining a stable and functional complex. Glycerol gradient sedimentation analyses indicated 
that a significant subset of nuclear exosomes is present in much larger complexes (60-80S) than the 
cytoplasmic exosomes (~10S). Interestingly, siRNA-mediated knock-down experiments indicated that 
the cytoplasmic exosome is down-regulated much more efficiently than the nuclear exosome. In 
addition, we observed that knock-down of hRrp41p or hRrp4p but not PM/Scl-100 or PM/Scl-75 leads to 
co-depletion of other subunits. Nevertheless, PM/Scl-100 and PM/Scl-75 are required to maintain normal 
levels of three different mRNA reporters: a wild-type β-globin mRNA, a β-globin mRNA containing an AU-
rich (ARE) instability element, and a β-globin mRNA bearing a premature termination codon (PTC). The 
increased levels of ARE- and the PTC-containing mRNAs upon down-regulation of the different exosome 
subunits, in particular PM/Scl-100, appeared to be due to decreased turnover rates. These results indicate 
that although not required for exosome stability, PM/Scl-100 and PM/Scl-75 are involved in mRNA 
degradation, either as essential subunits of a functional exosome complex or as exosome-independent 
proteins.
Introduction
The exosome is a 3’-5’ exoribonuclease complex 
that was initially identified in yeast (1). Since, 
a variety of functions have been described for 
the yeast exosome, including the processing of 
ribosomal and small nucle(ol)ar RNAs (2-4) and the 
degradation of mRNAs (5-7).
The exosome has been found to be highly conserved 
among eukaryotes, including humans (8-12). Nine 
subunits of the human exosome are considered core 
components since they are shared by the nuclear and 
the cytoplasmic forms of the complex (13). Six of 
these, hRrp41p, hRrp42p, hMtr3p, OIP2, hRrp46p, 
and PM/Scl-75 are related to the bacterial RNase 
PH. Three other components, hRrp4p, hRrp40p, 
and hCsl4p, contain an S1 RNA binding domain. 
The RNase PH proteins assemble into a hexameric 
ring (14-17) and the S1 subunits are positioned on 
top of the ring with their S1 domains faced towards 
the central pore (16;18) (see Fig. 1). The PM/Scl-
100 protein is not considered a core exosome 
component, based on its association with only the 
higher molecular mass exosome complexes (12;19) 
and the exclusively nuclear localization of its yeast 
counterpart Rrp6p (11). 
Cytoplasmic mRNA degradation usually initiates 
with deadenylation, followed by either further 
degradation of the mRNA body by the exosome 
(3’-5’ pathway) or cleavage of the 5’ cap followed 
by 5’-3’ degradation by the Xrn1p exoribonuclease 
(5’-3’ pathway). For mRNAs containing premature 
translation termination codons (PTC), a surveillance 
pathway exists termed nonsense-mediated decay 
(NMD) (3;20). mRNAs containing an AU-rich 
element (ARE) in the 3’-untranslated region 
(UTR) undergo rapid decay in the cytoplasm (21). 
Two studies provided evidence that the exosome-
dependent 3’-5’ pathway plays a major role in the 
degradation of ARE-containing mRNAs in vitro 
(13;22). A more recent in vivo analysis however, 
indicated that the 5’-3’ pathway may be the major 
mode of decay for ARE-containing mRNAs (23). 
While it has been established that different co-
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factors associate with the exosome to modulate its 
various activities, little is known about heterogeneity 
of exosome complexes in human cells and the 
importance of individual subunits for their stability. 
Here we addressed this issue by down-regulation 
of three core exosome subunits (hRrp4p, hRrp41p, 
and PM/Scl-75) and one exosome-associated factor, 
PM/Scl-100. Our data reveal not only marked 
differences between the nuclear and cytoplasmic 
exosomes, but also indicate that some subunits are 
more important for exosome stability than others. 
We also demonstrate that PM/Scl-100 plays a 
prominent role in the decay of both ARE and PTC-
containing mRNAs, either as an essential subunit 
for a fully functional exosome or as an exosome-
independent protein. 
Materials and Methods
Preparation of cell extracts
Cytoplasmic and nuclear fractions were prepared 
from HEp-2 cells by resuspension of the cells in 
lysis buffer (25 mM Tris–HCl, pH 7.5, 150 mM 
KCl, 1 mM EDTA, 0.5 mM PMSF and 1 mM DTT), 
permeabilization by the addition of digitonin to a 
final concentration of 0.025%, incubation for 10 
minutes at room temperature, and centrifugation 
at 1000 g at 4 °C. The supernatant was transferred 
to a new tube and is referred to as the cytoplasmic 
fraction. After resuspending the pellet in lysis buffer 
the nuclear fraction was prepared by sonication using 
a Branson microtip. Both extracts were clarified by 
centrifugation at 12,000 g for 10 minutes at 4 °C. 
Extracts were checked for proper fractionation using 
antisera reactive with the nuclear markers Rpp40 or 
topoisomerase I and the cytoplasmic marker eIF-
2α, respectively. For the preparation of total cell 
extracts, HEp-2 cells were directly sonicated in lysis 
buffer followed by centrifugation. 
Glycerol gradient analysis
HEp-2 cell extracts were prepared as described 
above and loaded on 5–40% (v/v) glycerol gradients 
prepared in gradient buffer (25 mM Tris–HCl, 
pH 7.5, 150 mM KCl, 1 mM DTT and 0.02% 
Triton X-100). Gradients were centrifuged in a 
Figure 1. Model of the exosome. (Left) Top view of the exosome core complex. The RNase PH-like subunits assemble into a 
hexameric ring structure. The RNase PH domains of PM/Scl-75, hRrp42p, and OIP2 are more related to each other (RPD1, light gray) 
than to that of hRrp41p, hMtr3p, and hRrp46p, which also contain a related RNase PH domain (RPD2, dark gray). The S1 RNA-
binding domain containing subunits hRrp4p, hCsl4p, and hRrp40p (white, black, and white, respectively) are positioned on top of the 
ring structure, with the S1 domains oriented toward the central pore. (Right) Side view of the exosome. Since it is currently unknown 
how PM/Scl-100 associates with the core of the exosome, this subunit has not been included.
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TH641 rotor (Sorvall) for 16 h at 25,000 r.p.m. 
at 4°C and subsequently 23 fractions per gradient 
were collected. The proteins in these fractions 
were separated by SDS–PAGE and transferred to 
nitrocellulose membranes for further analysis. 
siRNA treatment
SiRNAs were purchased from Eurogentec. 
The sequences of the siRNAs for PM/Scl-100, 
hRrp41p, hRrp4p, PM/Scl-75, and hXrn1p are 
5’-GUACAACCCAGGAUAUGUGdTdT-3’, 
5’-UGUGCAGGUGCUACAGGCAdTdT-3’, 
5’-GUUGAUCUGUGUGAAAGCUdTdT-3’, 
5’-GCCAAGAUGCUCCCAUAAUdTdT-3’, and 
5’-GUCAUGGCAAGGAGUUACCdTdT-3’, 
respectively. siRNA transfections were essentially 
done as described (19) with the exception that 
20 nM siRNA was used. As controls, cells were 
transfected with control siRNAs (a control siRNA 
from Eurogentec or an siRNA for a melanoma cell 
marker, which is not expressed in the cell line used 
in this study) or were left untreated. For the analysis 
of effects on cell growth, cells were harvested and 
counted with a Coulter AC-T series analyzer. 
Immunoblotting
For the detection of proteins on western blots, 
monoclonal anti-hRrp4p antibody (culture 
supernatant) (Modiquest, Nijmegen, The 
Netherlands) and rabbit antisera were diluted 10- 
and 1000-fold, respectively, in blocking buffer (5% 
skimmed milk, phosphate buffered saline (PBS) 
and 0.05% NP-40). As secondary antibody, horse-
radish peroxidase-conjugated rabbit anti-mouse IgG 
or swine anti-rabbit IgG (Dako Immnuoglobulins) 
were used after 1000-fold dilution in blocking 
buffer, Bound antibodies were visualized by 
chemiluminescence. Alternatively, for quantification, 
goat anti-mouse IRDye 800CW or goat anti-rabbit 
IRDye 800CW (Li-Cor Biosciences) were used at 
a 1:10,000 dilution. Quantification was performed 
with the Odyssey Infrared Imaging System.
Transfection of HEp-2 cells with β-globin mRNA 
constructs
Expression plasmids pTet-BBB and pTet-BBB+ARE 
were kindly provided by Dr. A. B. Shyu. pTet-
BBB+PTC was constructed as follows: pTet-BBB 
was digested with AccI, treatment with Klenow DNA 
polymerase and religation. This caused a frameshift 
resulting in a PTC. HEp-2 cells stably transfected 
with the plasmid pTet-tTAk (which expresses a 
tetracycline-inducible transcriptional activator) 
were cultured to 70% confluence and transfected 
as described (19). After transfection, the cells were 
seeded in 6 wells- or 24 wells plates for 24 hours 
(1.2 x 105 or 3 x 104 cells per well, respectively). 
Subsequently, the cells were transfected with 
siRNAs as described above. For the steady-state 
mRNA measurements, RNA was isolated from 
the cells 48 hours after siRNA treatment. For the 
time-course analyses, tetracycline (1 μg/ml final 
concentration) was added to the medium, and cells 
were harvested after 3, 6, 10, and 24 hours (β-globin 
WT), or 2, 3, 4, 5, 6 hours (β-globin ARE), or 2, 4, 
6, 8, 10 hours (β-globin PTC). mRNA decay curves 
were obtained with control siRNA treated cells. 
Cells treated with control, hXrn1p, PM/Scl-75, 
hRrp41p, or PM/Scl-100 siRNA were harvested at 4 
or 8 hours after transcription arrest for the β-globin 
ARE and the β-globin PTC mRNAs, respectively.
Real-time quantitative RT-PCR analysis
For real-time quantitative RT-PCR analysis, total 
RNA was isolated from HEp-2 cells using the 
TRIzol reagent (Invitrogen) and treated with 
DNaseI (Invitrogen). cDNA was generated using 
the Reverse Transcription System from Promega 
following the manufacturer´s instructions. For 
mRNA steady-state level measurements, the 18S 
rRNA was used as a control; for the mRNA turnover 
assays, the GAPDH mRNA was used as a control. 
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The following primers were used: OEVD52 5’-
AGCTGAGTGAACTGCACTGTGAC-3’ and 
OEVD31 5’-GCCTGCACCTGAGGAGTGA-3’ 
for the β-globin reporter mRNAs, and 18Sfor 5’-
TACCTGGTTGATCCTGCCAGTAGC-3’ and 
18Srev 5’-AACTGATTTAATGAGCCATTCGC-
3’ for the 18S rRNA. For the GAPDH 
mRNA, primers GAPDH forward (5’-
TGGAAGGACTCATGACCACA-3’) and GAPDH 
reverse (5’-GAGGCAGGGATGATGTTCTG-3’) 
were used. qPCR analysis was performed using the 
ABI-PRISM 7000 Sequence Detection System from 
Applied Biosystems. 
Results
Glycerol gradient sedimentation of exosome 
subunits
We and others have previously reported that human 
exosome core subunits are in part associated with 
high molecular weight complexes (1;11;12). In a 
subsequent study, we observed differential glycerol 
gradient sedimentation profiles of the core exosome 
subunit hRrp4p and the exosome-associated factor 
PM/Scl-100; hRrp4p accumulated partly in 10S 
fractions and partly in 60-80S fractions, whereas 
PM/Scl-100 was found almost exclusively in 60-
80S fractions (19). To extend this analysis, we 
investigated the sedimentation behavior of the S1 
core exosome subunits hRrp4p and hRrp40p, the 
RNase PH core exosome subunits hRrp41p, OIP2, 
and PM/Scl-75, and the exosome-associated factor 
PM/Scl-100 using nuclear and cytoplasmic extracts 
of human HEp-2 cells. The relative purity of the 
nuclear and cytoplasmic fractions was determined 
by western blotting using antibodies reactive 
with a nuclear and a cytoplasmic marker protein, 
respectively (Fig. 2A). Fractions were analyzed by 
western blotting with antibodies against the different 
exosome subunits and by agarose gelelectrophoresis 
to monitor the distribution of RNA. The U1 snRNA 
was used as a marker for 12S complexes, while the 
large rRNAs were used to identify 40S and 60S 
ribosomal subunits. In the nuclear extracts, all tested 
core exosome subunits distributed almost equally in 
~10S and 60-80S fractions. 
Figure 2. Glycerol gradient sedimentation of human exosome 
subunits. A) Purity of the nuclear and cytoplasmic fractions 
was determined by Western blotting using antibodies to human 
topoisomerase I (nuclear marker) and eIF-2α (cytoplasmic 
marker). Lanes with total (t), cytoplasmic (c), or nuclear (n) 
extract are indicated. Nuclear (B) and cytoplasmic (C) HEp-2 cell 
extracts were fractionated in 5%–40% (v/v) glycerol gradients. 
The sedimentation of hRrp4p, hRrp40p, hRrp41p, OIP2, PM/Scl-
75, and PM/Scl-100 was determined by Western blotting. The 
input (i) material is shown in the lanes on the left. The positions of 
12S, 40S, and 60S marker complexes are indicated.
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In contrast to the core subunits however, the 
nuclear PM/Scl-100 protein was mainly found in 
60-80S fractions (Fig. 2B). With the cytoplasmic 
fractions, strikingly different patterns were seen; the 
majority of all cytoplasmic core exosome subunits 
were found at ~10S (Fig. 2C). The relatively small 
amounts of PM/Scl-100 in the cytoplasmic fraction 
were almost exclusively found in ~60S fractions. 
The sedimentation profile of these cytoplasmic 
PM/Scl-100 containing complexes seems to be 
different from that observed for nuclear PM/Scl-
100 containing complexes. Also small amounts 
of exosome core subunits were found in fractions 
containing the cytoplasmic ~60S complexes. 
Taken together, these data indicate that in the 
nucleus a subset of exosomes exists in much larger 
complexes than in the cytoplasm. These complexes 
are likely enriched for PM/Scl-100, while the ~10S 
subpopulation appeared to be largely devoid of 
PM/Scl-100. For some subunits, additional bands 
were observed that migrated close to the specific 
bands. At present, we do not know whether these 
bands represent isoforms of the respective exosome 
subunits or are due to cross-reactivity of the sera 
used. 
hRrp41p and hRrp4p, but not PM/Scl-75 and 
PM/Scl-100, are required for exosome stability
The differences between nuclear and cytoplasmic 
exosomes raised the question whether heterogeneities 
among individual exosome subunits may also exist. 
To address this issue, we down-regulated different 
human exosome subunits by RNAi and tested the 
effect on the remainder of the complex. Two RNase 
PH subunits (PM/Scl-75 and hRrp41p), one S1 
subunit (hRrp4p), and one exosome-associated 
factor (PM/Scl-100) were knocked-down. HEp-2 
cells were transfected with siRNAs and cell extracts 
were prepared after 24 or 48 hours. Western blot 
analysis showed that the targeted proteins were 
efficiently down-regulated (Fig. 3A). In addition, 
the hRrp41p knock-down led to reduced levels of all 
other tested core exosome subunits except PM/Scl-
100 (Fig. 3A, lanes 7 and 8). This result suggested 
that the absence of hRrp41p led to destabilization 
of the exosome core complex and, as a result, 
degradation of its subunits. This notion is supported 
by the fact that at the mRNA level reduced levels of 
only the hRrp41p mRNA were observed, whereas 
the levels of the other exosome subunit mRNAs 
remained unaffected (data not shown). In contrast 
to the hRrp41p siRNA, no co-depletion of other 
subunits was detected with the PM/Scl-75 (lanes 5 
and 6) and the PM/Scl-100 siRNAs (lanes 9 and 10). 
Quantification of the bands confirmed that down-
regulation of PM/Scl-75 or PM/Scl-100 did not lead 
to reduced levels of other subunits (Fig. 3B). This 
was rather unexpected for PM/Scl-75, since this is 
also a component of the hexameric ring of RNase 
PH subunits at the core of the exosome complex (see 
Fig. 1). Possibly, stable exosome (sub)complexes 
can exist in the absence of PM/Scl-75. In this light 
it is interesting to note that exosome complexes 
purified from Drosophila lacked dRrp45, the 
Drosophila homologue of PM/scl-75 (10). Further 
experiments will be required to determine whether 
human exosome (sub)complexes lacking PM/scl-
75 exist. As observed for hRrp41p, knock-down of 
hRrp4p led to co-depletion of other core exosome 
subunits and also in this case PM/Scl-100 was not 
affected (Fig. 3A, lanes 13 and 14). To determine to 
what extend the co-depletion efficiency correlated 
with the depletion of the siRNA targeted subunits, 
the protein levels were quantified. This revealed that 
hRrp41p or hRrp4p down-regulation led to a similar 
reduction in the levels of other subunits (Fig. 3B). 
These data suggest that hRrp41p and hRrp4p are 
required for exosome stability, whereas PM/Scl-75 
or PM/Scl-100 depletion does not markedly affect 
the stability of other subunits. 
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We also investigated the effect of hRrp41p down-
regulation on glycerol gradient sedimentation 
profiles of other exosome subunits. In agreement 
with the results shown in Fig. 3A, reduced levels 
were observed for other subunits except PM/Scl-
100; no significant changes in the sedimentation 
profiles were seen, however (data not shown).
The different co-depletion phenotypes observed 
prompted us to investigate effects on cell growth. 
HEp-2 cells were harvested and counted 24, 48, and 
72 hours after siRNA transfection. Knock-down of 
hRrp4p, hRrp41p and PM/Scl-75 strongly inhibited 
cell growth, whereas only slight effects were seen 
during PM/Scl-100 depletion (Fig. 3C). Thus, even 
though the PM/Scl-75 knock-down does not lead 
to exosome destabilization, vital functions for cell 
growth are affected. The observation that PM/Scl-
100 knock-down only slightly affected cell growth 
suggests that similar to yeast Rrp6 (24), PM/Scl-100 
may not be essential for cell proliferation. However, 
we cannot exclude the possibility that, even though 
the knock-down was rather efficient (approx. 5-fold 
reduced protein levels), sufficient amounts of PM/
Scl-100 were still present to support cell growth.
Cytoplasmic exosomes are depleted by RNAi 
more efficiently than nuclear exosomes. 
The association of exosomes with higher order 
complexes in the nucleus raised the question 
whether turnover rates of exosomes in the nucleus 
are different from those in the cytoplasm. To 
explore this possibility, PM/Scl-75, hRrp41p and 
PM/Scl-100 were knocked-down and nuclear and 
cytoplasmic fractions were analyzed by western 
blotting. In the cytoplasmic fractions, already after 
24 hours clearly reduced levels were seen for all 
three targeted proteins (Fig. 4A, lanes 6, 7, 8). 
Strikingly however, at this time point no down-
regulation could be detected in the nuclear fractions. 
After 48 hours, a very efficient depletion was seen 
for all three proteins in the cytoplasm 
Figure 3. Depletion of exosome subunits affects cell growth. 
(A) PM/Scl-75, hRrp41p, PM/Scl-100, and hRrp4p were knocked 
down by siRNAs and the effect on the levels of various exosome 
subunits at 24 and 48 h after siRNA treatment was analyzed by 
Western blotting. As a control, a monoclonal antibody against 
γ-tubulin was used. (B) Quantification of the effect of siRNA 
treatment on the protein levels of PM/Scl-75, hRrp41p, and 
hRrp4p. The siRNAs used are indicated above the graph. The 
protein levels in extracts from cells treated with control siRNA 
were set at 100%. The mean values of three independent 
experiments are shown; standard deviations are indicated by 
error bars. (C) The effect of exosome subunit depletion on cell 
proliferation. Cells were harvested and counted 24, 48, and 72 h 
after siRNA treatment.
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(Fig. 4B, lanes 6, 7, 8), whereas in the nuclear 
fraction, only PM/Scl-100 showed significantly 
reduced levels (lane 4), while hardly any down-
regulation was detected for PM/Scl-75 and hRrp41p 
(lanes 2 and 3). 
Thus, cytoplasmic exosomes are depleted much 
more efficiently than nuclear exosomes. These 
observations suggest that either nuclear exosomes 
are more stable than cytoplasmic exosomes or that 
exosomes accumulate in the nucleus due to ongoing 
transport from the cytoplasm.
PM/Scl-75, hRrp41p, and PM/Scl-100 are 
involved in mRNA turnover
The more efficient down-regulation of the 
exosome in the cytoplasm allowed us to study the 
involvement of individual exosome components in 
RNA degradation in this compartment of the cell. 
Therefore we determined the effect of PM/Scl-
75, hRrp41p, or PM/Scl-100 depletion on mRNA 
turnover. Since hRrp41p and hRrp4p siRNAs cause 
similar exosome destabilization (Fig. 3A), hRrp4p 
was not included in these experiments. Instead, 
hXrn1p, a component of the alternative 5’-3’ mRNA 
decay pathway, was knocked-down in parallel. 
Human HEp-2 cells were first transfected with 
three different reporter constructs: (1) a construct 
expressing a wild type (WT) β-globin mRNA, (2) 
a construct expressing a β-globin mRNA with an 
ARE (from the c-fos mRNA) in its 3’-UTR, and (3) 
a β-globin mRNA construct containing a PTC in its 
coding region, making this mRNA susceptible to 
NMD (Fig. 5A). Second, the cells were transfected 
with two different control siRNAs to monitor 
nonspecific effects on reporter mRNA levels; 
no differences were seen compared to untreated 
transfected cells (data not shown). Subsequently, 
reporter mRNA expressing cells were transfected 
with siRNAs for PM/Scl-75, hRrp41p, and PM/
Scl-100, as well as an siRNA targeting hXrn1p. 
Knockdown efficiencies at 48 hours after siRNA 
transfection were verified by western blotting (Fig. 
5B). Using material from the same cells, mRNA 
levels of the reporter constructs were measured 
by real-time quantitative RT-PCR analysis; the 
18S ribosomal RNA was used for normalization 
Figure 4. Knock-down of exosome subunits is more efficient 
in the cytoplasm than in the nucleus. PM/Scl-75, hRrp41p, and 
PM/Scl-100 were down-regulated by RNAi, and subsequently 
HEp-2 nuclear and cytoplasmic fractions prepared after 24 (A) 
or 48 h (B) were analyzed by Western blotting. As controls for 
the fractionation, an antiserum to the RNase P/MRP subunit 
hRpp40p (nuclear marker) and a monoclonal antibody against 
eIF-2α (cytoplasmic marker) were used.
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(see Materials and Methods). For the WT β-globin 
mRNA, slightly increased levels were observed 
upon knock-down of the different exosome 
subunits, PM/Scl-100 depletion having the strongest 
effect (1.5 fold increased mRNA levels) (Fig. 5C). 
No significant effects were seen upon knock-down 
of hXrn1p. Much stronger effects were seen with 
the β-globin-ARE and the β-globin-PTC mRNAs, 
which may be due to the faster turnover rates of 
these transcripts, making them more sensitive 
reporters for mRNA turnover. Both the knock-down 
of hXrn1p and PM/Scl-100 cause about 4-fold 
increased mRNA levels of the ARE-containing 
transcript and 2.5-3 fold increased levels of the PTC 
transcript. Depletion of the core exosome subunits 
PM/Scl-75 and hRrp41p had less drastic effects: 
2-3 fold and about 1.5-fold increased mRNA levels 
of the ARE- and PTC-transcripts, respectively. 
Together, these data suggest that both the core 
exosome as well as PM/Scl-100 are involved in the 
turnover of all three types of mRNA. 
To discriminate between effects of exosome 
depletion on mRNA degradation and on other 
processes that influence steady-state mRNA levels, 
we performed mRNA decay analyses. Transcription 
of the reporter constructs was inhibited by the 
addition of tetracycline (see Materials and Methods) 
and mRNA turnover rates were determined. Reporter 
mRNA levels were determined at different time 
points after inhibition of transcription by real-time 
Figure 5. Knock-down of exosome core 
subunits and PM/Scl-100 increases reporter 
mRNA steady-state levels. HEp-2 cells were 
transfected with three different β-globin 
mRNA expression contructs: a wild-type 
(WT) mRNA, a mRNA containing an ARE, 
and a mRNA bearing a PTC. Subsequently, 
the cells were transfected with a control 
siRNA (lane 1), or an siRNA for hXrn1p (lane 
2), PM/Scl-75 (lane 3), hRrp41p (lane 4), or 
PM/Scl-100 (lane 5).
 A) A schematic representation of the reporter 
mRNAs used. 
B) Western blotting analysis of the knock-
downs. Protein extracts were prepared in 
parallel with the RNA isolations used for 
quantitative RT-PCR and analyzed for the 
presence of the various proteins targeted by 
RNAi. 
C) The effects of the knock-downs on 
the accumulation of the different reporter 
mRNAs were analyzed by quantitative RT-
PCR. The numbering of the bars corresponds 
to the numbering of the lanes in A. The 18S 
rRNA was used for normalization. Mean 
values and standard deviations from three 
independent experiments are shown.
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quantitative RT-PCR. As expected, the turnover of 
the wild-type β-globin mRNA was very slow, since 
this is known to be a rather stable mRNA species. 
During the first 10 hours, no significant decrease 
in wild-type β-globin mRNA levels was seen (Fig. 
6A). A much faster decay was observed for the β-
globin-ARE and the β-globin-PTC mRNAs, with 
half-lives of about 2.5 and 6 hours, respectively. To 
investigate the effect of exosome depletion on the 
degradation of these mRNAs, their levels at 4 hours 
(β-globin-ARE mRNA) or at 8 hours (β-globin-
PTC mRNA) after shutting off their transcription 
were determined. In both cases at these time points 
mRNA levels were reduced to 30-40% in the cells 
treated with a control siRNA. Due to its very low 
turnover rate, the wild-type β-globin mRNA could 
not be included in this analysis. Both for the ARE 
and for the PTC transcripts, significantly reduced 
mRNA decay rates were observed in the hXrn1p 
and the PM/Scl-100 depleted cells (Fig. 6B). Less 
dramatic effects on mRNA decay were observed 
with PM/Scl-75 and hRrp41p depletion; PM/Scl-75 
down-regulation moderately reduced the decay rate 
of the ARE transcript. These results correlate well 
with those of the mRNA steady-state measurements, 
indicating that the observed effects on the mRNA 
steady-state levels were largely due to effects on 
mRNA degradation. 
Taken together, these data indicate that both hXrn1p 
and PM/Scl-100 contribute to the turnover of the 
ARE- and the PTC- containing transcripts. 
Figure 6. Down-regulation of hXrn1p and 
exosome subunits attenuates mRNA decay. 
A) mRNA decay curves for the β-globin 
WT, the β-globin ARE, and the β-globin 
PTC transcripts. Transcription of the reporter 
constructs was inhibited by tetracycline 
addition. mRNA levels were determined 
by quantitative RT-PCR and normalized to 
endogenous GAPDH mRNA levels. 
B) Control siRNA-treated cells or cells 
treated with siRNAs for hXrn1p, PM/Scl-75, 
hRrp41p, or PM/Scl-100 were harvested 4 
or 8 h after transcription inhibition for the 
β-globin ARE and the β-globin PTC mRNAs, 
respectively. As in panel A, mRNA levels 
were determined by quantitative RT-PCR and 
normalized to endogenous GAPDH mRNA 
levels. Measurements were performed in 
triplicate; mean values and standard deviations 
are shown.
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Discussion
Previously it was reported for the T. brucei exosome 
that down-regulation of the RNase PH-type subunits 
as well as down-regulation of TbRRP6 causes 
destabilization of the exosome complex, whereas 
the S1-type subunits could be depleted without 
affecting the levels of other subunits (15). Similarly, 
our results indicate that depletion of the RNase PH 
subunit hRrp41p causes co-depletion of all other 
human exosome subunits analysed, except PM/Scl-
100. In contrast, down-regulation of PM/Scl-75 and 
PM/Scl-100 did not lead to reduced levels of other 
subunits of the human exosome, whereas for the 
T. brucei exosome these components were found 
to be required for complex stability. Moreover, 
depletion of the S1-type subunit hRrp4p did lead to 
decreased levels of other exosome subunits. These 
results indicate that a subset of exosome subunits 
is important for complex integrity, but that these 
subunits may differ between different species. The 
observation that PM/Scl-100 is dispensable for 
the integrity of the human exosome is consistent 
with the observation that this protein shows 
different glycerol gradient sedimentation patterns 
than the other human exosome subunits (Fig. 2A, 
B). Also the results of gel filtration experiments 
previously showed that the majority of PM/Scl-100 
is associated with a subset of exosome-containing 
complexes (12). The hRrp4p protein appeared to 
be required for maintenance of normal levels of 
other exosome subunits, which is consistent with 
a recent report indicating that the S1-type subunits 
are required to reconstitute stable human exosome 
complexes in vitro (25).
Surprisingly, down-regulation of PM/Scl-75 did not 
affect the levels of other exosome subunits. However, 
also in the T. brucei exosome not all RNase PH-
type subunits caused a complete disruption of the 
complex when depleted (15). Thus, it is possible that 
in the absence of PM/Scl-75 exosome complexes 
are still able to assemble. In support of this view, 
exosome complexes purified from Drosophila 
lacked dRrp45p, the Drosophila homolog of PM/
Scl-75 (10). An alternative possibility is that a 
non-exosome-associated pool of PM/Scl-75 exists, 
which may be preferentially affected by the siRNA 
treatment. Another striking observation was that 
down-regulation of exosome subunits was much 
more efficient in the cytoplasm than in the nucleus 
(Fig. 4). This phenomenon can be explained in three 
ways; (1) nuclear and cytoplasmic exosomes are 
depleted with similar efficiencies but the remaining 
exosomes accumulate in the nucleus due to ongoing 
transport from the cytoplasm; (2) nuclear exosome 
complexes may be more stable than cytoplasmic 
complexes; (3) in the cytoplasmic environment 
turnover of exosomes may be much faster than 
that in the nucleus. Additional experiments will be 
required to provide more insight into this issue. 
Regardless of the exact underlying mechanism, our 
data strongly suggest that there is no or hardly any 
export of exosomes from the nucleus.
Down-regulation of components of both the 5’-
3’ and 3’-5’ RNA degradation pathways led to 
increased levels of reporter mRNAs. The most 
prominent effects were observed after depletion 
of PM/Scl-100 and hXrn1p. These effects were 
mainly due to mRNA degradation defects rather 
than alterations at the level of transcription, 
because very similar data were obtained with cells 
in which the transcription of the reporter mRNAs 
was silenced. Our results indicate that both hXrn1p 
and PM/Scl-100 are involved in the turnover of 
ARE- and PTC-containing transcripts, while the 
role of the core exosome subunits may be less 
important. Our results are in good agreement with 
data obtained by Lejeune and collaborators (26), 
who reported an involvement of both 5’-3’ mRNA 
decay factors as well as PM/Scl-100 in the turnover 
of PTC-containing transcripts. Interestingly, also 
in this study no effect of down-regulation of a 
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core component (hRrp4p) on mRNA decay was 
observed, confirming the notion that PM/Scl-100 
has a more pronounced role in nonsense-mediated 
decay than the core exosome. For ARE-mediated 
mRNA decay, a major role for the 5’-3’ mRNA 
decay pathway was reported recently (23). Our 
results show that also PM/Scl-75 and PM/Scl-100 
are involved in ARE-mediated mRNA decay. In 
this regard it is important to note that Stoecklin and 
collaborators used a reporter containing an ARE 
from the GM-CSF mRNA, which is of a different 
class of AREs (class II) than the c-fos ARE (class I), 
which was used in our study (21). On the other hand, 
in cell extracts the human exosome was shown to 
play an important role in class II ARE-containing 
mRNA decay and PM/Scl-75 was demonstrated to 
be directly involved (22). Thus, the contribution 
of both pathways to the degradation of class I and 
class II ARE-containing mRNAs may differ. An 
important role for 3’-5’ decay in the degradation of 
class I ARE-containing mRNAs was also observed 
in another recent study (27). It was surprising that 
depletion of hRrp41p, which causes the most severe 
co-depletion effects, has the least effects on mRNA 
decay. A possible explanation for this observation 
is that PM/Scl-75 and PM/Scl-100 may at least in 
part act independently of the exosome in mRNA 
decay. In this respect it is interesting to note that 
Stoecklin et al. (23) also observed an inhibition 
of ARE-mediated mRNA decay upon PM/Scl-75 
knock-down, while depletion of two other exosome 
subunits (hRrp46p and hRrp40p) had no effect.
In conclusion, our data reveal differences among 
individual exosome subunits of the human exosome, 
both with respect to their importance for the 
integrity of the complex as well as their impact on 
mRNA decay. Moreover, they differentially affect 
cell growth. An interesting possibility is that PM/
Scl-75 and/or PM/Scl-100 may act independently 
of the exosome. 
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Introduction
The exosome complex consists of 3’-5’ 
exoribonucleases and putative RNA binding 
proteins and was originally identified in yeast during 
a study investigating the 3’ end maturation of 5.8S 
rRNA (1;2). Since, the yeast exosome has also been 
demonstrated to be required for the processing of 
small nuclear RNA (snRNA), small nucleolar RNA 
(snoRNA) and the degradation of aberrant pre-
mRNAs in the nucleus (3-6), as well as the turnover 
of mRNAs in the cytoplasm (7-11). 
In 1999, the yeast exosome components Rrp6p 
and Rrp45p were found to be homologous to the 
human PM/Scl-100 and PM/Scl-75 autoantigens. 
Moreover, human homologues of the yeast 
exosome components Rrp4p, Rrp40p, Rrp41p, and 
Rrp46p were shown to physically interact with 
the polymyositis/scleroderma (PM/Scl)-complex, 
an autoantigenic multiprotein complex containing 
PM/Scl-100 and PM/Scl-75, demonstrating that the 
yeast exosome and the human PM/Scl complex are 
very similar (12;13). Nine components of the human 
exosome were shown to be shared by the nuclear 
and cytoplasmic forms of the complex and are 
collectively referred to as the core exosome (9). Six 
of these nine proteins (hRrp41p, hRrp42p, hRrp46p, 
hMtr3p, OIP2, PM/Scl-75) show homology to the 
E. coli exonuclease RNase PH, the three other 
core exosome components (hRrp4p, hRrp40p, 
hCsl4p) contain a putative S1 RNA binding domain. 
The exosome core components assemble into a 
doughnut-like structure, characterized by a six-
membered ring formed by the RNase PH subunits 
(14-16). 
In the nucleolus, three out of the four rRNA 
molecules are transcribed as a single precursor by 
RNA polymerase I. This precursor is processed by 
a series of endo- and exonucleolytic cleavages to 
form the mature 18S, 5.8S and 25S/28S ribosomal 
RNAs (reviewed in ref. 17). In yeast, deletion of 
core exosome components as well as the nuclear 
exosome-associated co-factor Mtr4p/Dob1p leads 
to accumulation of both precursor 5.8S rRNAs 
extended at their 3’ ends and 5’ETS fragments 
(1;3;6;12;18). Moreover, deletion of one of the 
yeast exosome components prevents cleavage at the 
early pre-rRNA cleavage sites A0, A1, A2 and A3, 
leading to depletion of mature 18S and 25S rRNAs 
(3;19). These processing steps do not require 3’- 
5’ exoribonuclease activity implying an indirect 
requirement for the exosome. Also upon depletion 
of the nuclear exosome-associated exoribonuclease 
Rrp6p and co-factor Rrp47p defects in rRNA 
The exosome is a complex of 3’-5’ exoribonucleases which is involved in many RNA metabolic processes. 
To regulate these functions distinct proteins are believed to recruit the exosome to specific substrate 
RNAs. Here, we demonstrate that MPP6, a protein previously reported to co-purify with the TAP-tagged 
human exosome, accumulates in the nucleoli of HEp-2 cells and associates with a subset of nuclear 
exosomes as evidenced by co-immunoprecipitation and biochemical fractionation experiments. 
In agreement with its nucleolar accumulation, siRNA-mediated knock-down experiments revealed 
that MPP6 is involved in the generation of the 3’ end of the 5.8S rRNA. The accumulation of the same 
processing intermediates after reducing the levels of either MPP6 or exosome components strongly 
suggests that MPP6 is required for the recruitment of the exosome to the pre-rRNA. Interestingly, MPP6 
appeared to display RNA-binding activity in vitro with a preference for pyrimidine-rich sequences, and to 
bind to a.o. the ITS2 element of pre-rRNAs. Our data indicate that MPP6 is a nucleolus-specific exosome 
co-factor required for the maturation of 5.8S rRNA.
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processing are observed (5;6;20;21). However, the 
effects are distinct from depletion of core exosome 
components, indicating that the functions of Rrp6p 
and the core exosome are not identical. 
Four yeast exosome components and two human 
exosome components have proven 3’-5’ exonuclease 
activity, while the other exosome components with 
a RNase PH domain are predicted to possess such 
an activity (1;22;23). Besides the core exosome 
components, several additional exosome-associated 
proteins have been identified and these are most 
likely involved in the recruitment of the exosome 
to specific classes of substrate RNAs, its association 
with other processing complexes, or the modulation 
of its activity. An early identified exosome-
associated protein, PM/Scl-100 (Rrp6p in yeast), is 
homologous to E.coli RNase D. KIAA0052/hMtr4p, 
is a putative helicase and its yeast homologue 
Dob1p/Mtr4p acts in concert with the exosome 
in the processing of several types of nuclear 
RNA substrates. The M-phase phosphoprotein 6 
(MPP6) was found to co-purify with the human 
exosome, when the latter was isolated via a TAP-
tag purification approach (9). MPP6, which resides 
in the nucleus of interphase cells, was originally 
identified by virtue of its phosphorylation during 
mitosis (24). More recently, MPP6 was shown to 
interact with KIAA0052/hMtr4p and PM/Scl-100 
using a yeast-2-hybrid approach (25). MPP6 is the 
only exosome-associated protein currently identified 
for which no yeast counterpart is known. 
Here we show that MPP6 is associated with a subset 
of nuclear exosome complexes and that knock-
down of MPP6 leads to an accumulation of 3’ end 
extended 5.8S rRNAs, which are also accumulating 
upon knock-down of PM/Scl-100 and hRrp41p. 
Moreover, we show that MPP6 is a RNA binding 
protein in vitro, which is able to bind to (pre)-rRNAs 
and preferentially binds to poly(C) and poly(U). 
Materials and Methods
cDNA cloning and recombinant protein 
expression
The human MPP6 cDNA (GenBank accession 
number: NM_005792) was cloned by a PCR-
based approach using a placenta cDNA library and 
oligonucleotides MPP6-forward: 5’- GCGGATCC
GGAATTCAATGGCGGCCGAGAGAAAGAC- 3’ 
and MPP6-reverse: 5’- GCCCCGGGTTATCTAG
AATCCTGGGGCTTTAAGAACA-3’. The PCR 
products were cloned into the pCR4-TOPO vector 
according the manufacturer’s procedure (Invitrogen) 
and the integrity of the resulting construct was 
verified by DNA sequencing. In order to obtain the 
N-terminally GST- or His
6
-tagged MPP6 protein, the 
MPP6 open reading frame was cloned into pGEX-
4T3 (Amersham Pharmacia Biotech) and pQE32 
(Qiagen), respectively. The tagged proteins were 
expressed in Escherichia coli BL21(DE3)pLysS 
and purified by affinity chromatography using either 
glutathione-Sepharose or an immobilized nickel 
resin. The purity and quantity of the recombinant 
proteins were determined by SDS–PAGE. 
GST pull down assay
For the analysis of protein-RNA interactions, 20 
microlitres of glutathione–Sepharose (Amersham 
Pharmacia Biotech) beads (50% slurry) were 
washed three times with 200 µl of pull-down buffer 
100 [PB-100: 20 mM HEPES/KOH, pH 7.6, 100 
mM KCl, 0.5 mM EDTA, 0.05% NP-40, 1 mM 
dithiotreitol, 0.02% BSA, 0.5 mM PMSF]. GST 
or GST-MPP6 (approx. 1 µg) was coupled to the 
beads in 200 µl of PB-100 by incubating at room 
temperature for 1 h under continuous agitation. 
After centrifugation, the supernatant was discarded 
and the beads were resuspended in 100 µl pull-
down buffer. 32P-labelled RNAs and 20 U RNasin 
were added and the mixture was incubated for 1 h 
at 4°C under continuous agitation. The beads were 
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washed three times with PB-200 (composition like 
PB-100, but containing 200 mM KCl) and the co-
precipitating RNAs were extracted and analysed by 
denaturing PAGE and autoradiography.
Generation and affinity purification of rabbit 
anti-MPP6 antibodies 
GST-MPP6 fusion protein was used to immunize 
rabbit M87. The serum from rabbit M87 recognized 
recombinant His
6
-MPP6 (data not shown). Anti-
MPP6 antibodies were affinity-purified using 
His
6
-MPP6 recombinant protein coupled to 
CNBr-activated Sepharose as described by the 
manufacturer (Amersham Biosciences).
Preparation of HEp-2 cell extracts
Cytoplasmic and nuclear extracts were prepared 
from HEp-2 cells by resuspension of the harvested 
cells in lysis buffer (25 mM Tris-HCl, pH 7.5, 150 
mM KCl, 1 mM EDTA, 0.5 mM PMSF, 1 mM 
dithiothreitol), permeabilization by the addition 
of digitonin to a final concentration of 0.025%, 
incubation for 10 minutes at room temperature, and 
centrifugation at 1,000 x g. The supernatant was 
transferred to a new tube and is referred to as the 
cytoplasmic fraction. After resuspending the pellet 
in lysis buffer the nuclear extract was prepared by 
sonication using a Branson microtip. Both extracts 
were clarified by centrifugation at 12,000 x g for 10 
minutes. 
Immunoprecipitation
Per immunoprecipitation 10 µl of rabbit or patient 
serum was coupled to 10 µl of protein A-agarose 
beads (Kem-En-Tec) in IPP500 (0.5 M NaCl, 10 
mM Tris-HCl, pH 8.0, 0.05% NP-40) at room 
temperature for 1 h. Beads were washed once with 
IPP500 and twice with IPP150 (same as IPP500, but 
containing 150 mM NaCl). Subsequently, cell extract 
was added to the beads in IPP150 and incubated for 
2 h at 4 °C. After washing the beads three times with 
IPP150 the precipitated proteins were eluted by the 
addition of SDS sample buffer, separated by SDS-
PAGE and blotted on nitrocellulose membranes. 
Immunoblotting
For the detection of proteins on western blots, 
monoclonal anti-hRrp4p antibody (culture 
supernatant) (ModiQuest, Nijmegen, The 
Netherlands) and rabbit antisera were diluted 
25- and 500-fold, respectively, in blocking buffer 
(5% skimmed milk, phosphate buffered saline, 
0.05% NP-40). As secondary antibody, horseradish 
peroxidase-conjugated rabbit anti-mouse IgG or 
swine anti-rabbit IgG (Dako Immunoglobulins) 
were used after 2500-fold dilution in blocking 
buffer. Bound antibodies were visualized by 
chemiluminescence. 
Northern blot analysis
Total RNA from HEp-2 cells was extracted 48 h 
after transfection with or without siRNA using 
the TRIzol reagent (Invitrogen). Per sample 5 µg 
of total RNA was separated on a denaturing 6% 
polyacrylamide gel, and after transfer to Hybond 
N+ membranes (Amersham Biosciences) the 
blots were hybridized with several 32P-labelled 
antisense RNA probes in hybridization solution 
(6x SSC, 10x Denhardt’s, 100 µg/ml herring sperm 
DNA, 0.1% SDS). After overnight incubation at 
65 °C, the blots were washed three times with 2x 
SSC/0.1% SDS and analyzed by autoradiography. 
Oligonucleotides used in this study are 5’ETS-1: 
5’-CGCGCGAGAGAACAGCAGGC-3’, 5’ETS-
2: 5’-TCGTGATTCTCGTCCATCCTCCGAC-3’. 
The antisense 5.8S rRNA probe was generated by 
linearizing a pGEM-3Zf(+) plasmid containing a 
full length 5.8S rRNA EcoRI-BamHI PCR product 
with EcoRI and in vitro transcription by SP6 RNA 
polymerase. A pCR4-TOPO vector containing a 
XhoI-SalI PCR product that covers the most 5’ 300 
nucleotides of the ITS2 was linearized with XhoI 
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and transcribed by T7 RNA polymerase to yield a 
337 nts antisense probe. The antisense ITS1 probe 
was generated as described by Cohen et al. (26) 
Transient transfection of HEp-2 cells and 
fluorescence microscopy
For transfection, the cDNAs encoding hMtr3p and 
MPP6 were cloned into EGFP vectors (Clontech) 
allowing expression of the protein fused to the C-
terminus of the EGFP protein. HEp-2 cells were 
grown to 70% confluency in Dulbecco’s modified 
Eagle’s medium containing 10% FCS (DMEM+). 
For fluorescence microscopy approximately 3 x 
106 cells were transfected with 10 µg of plasmid 
DNA in 800 µl DMEM+ by electroporation at 260V 
and 950µF. The cells were seeded on coverslips 
and cultured overnight. Subsequently, the cells 
were washed twice with PBS and fixed with 4% 
paraformaldehyde in PBS for 20 minutes. After 
fixation, cells were washed three times with PBS 
and mounted with 50% glycerol in PBS. The EGFP 
fusion proteins were visualized by fluorescence 
microscopy. 
For siRNA transfection approximately 3 x 105 cells 
were grown in DMEM+. Per transfection 100 pmol 
of siRNA was transfected into HEp-2 cells using 
Oligofectamine transfection reagent (Invitrogen), 
as described by the manufacturer with the exception 
that during transfection 10% FCS was present in the 
medium. As a control, cells were treated in the same 
way but without adding siRNA to the transfection 
reagent.
siRNAs 
Three MPP6 siRNA duplexes were designed 
based upon the coding region of the human 
MPP6 sequence (GenBank accession number: 
NM_005792). The 21 nucleotide siRNA duplexes 
containing dTdT overhangs were purchased 
from IDT (Coralville, IA, USA): siMPP6-1: 5’-
GAGCACUGGUACUUGGAUUTT -3’; siMPP6-
2: 5’-CAGUAGAGCUUGAUGUGUCTT –3’; 
siMPP6-3: 5’-GAUAUGAGACCUUGGUGGGTT-
3’. SiRNAs against human hRrp41p and PM/Scl-
100 were previously described by LeJeune et al. 
(27). As a control an siRNA specific for a melanoma 
cell marker, which is not expressed in the cell lines 
used in this study, was used.
Glycerol gradient analysis
HEp-2 cell extracts were prepared as described 
above and loaded on 5-40% (v/v) glycerol gradients 
prepared in gradient buffer (25 mM Tris-HCl, pH 
7.5, 150 mM KCl, 1 mM dithiothreitol, 0.02% 
Triton X-100). Gradients were centrifuged in a 
TH641 rotor (Sorvall) for 16 h at 25,000 rpm at 
4 °C and subsequently 23 fractions per gradient 
were collected. The proteins in these fractions 
were separated by SDS-PAGE and transferred to 
nitrocellulose membranes for further analysis. 
RNase protection assay
Total RNA was extracted from HEp-2 cells 
transfected with siRNAs as described above and 
resuspended in 100 µl of hybridization buffer (40 
mM PIPES, pH6.4, 400 mM NaCl, 1 mM EDTA, 
80% formamide). A radiolabeled antisense ITS2 
probe was synthesized by in vitro transcription, 
treated with RNase-free DNase I (Invitrogen) for 
15 minutes at 37°C and after precipitation dissolved 
in hybridization buffer. Subsequently, an excess of 
probe RNA was hybridized with 5 µg of total RNA 
overnight at 52 °C. Free probe and non-protected 
RNA was digested in ribonuclease digestion buffer 
(10 mM Tris-HCl, pH7.4, 300 mM NaCl, 5 mM 
EDTA) containing 40 µg/ml ribonuclease A and 
2 µg/ml ribonuclease T1 for 1 hour at 37°C. The 
protected RNA was purified, dissolved in RNA 
loading buffer and analyzed on a 10% sequencing 
gel and visualized by autoradiography. 
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Results
The MPP6 protein localizes to the nucleoli and 
interacts with the nuclear exosome 
During TAP-tag purifications of the human exosome, 
MPP6 was found to co-fractionate with the human 
exosome (9). To investigate whether MPP6 is truly 
associated with the human exosome, its subcellular 
localization and interaction with the human 
exosome complex were studied in more detail. HEp-
2 cells were transiently transfected with constructs 
coding for the EGFP-fusion proteins of MPP6 and 
hMtr3p as well as EGFP alone as a control. Twenty-
four hours later the subcellular localization of these 
proteins was examined by fluorescence microscopy. 
EGFP was found throughout the cell, whereas MPP6 
and hMtr3p both accumulated in the nucleoli (Fig. 
1). As has been observed before for other exosome 
core proteins, a weak but significant staining of 
the nucleoplasm was observed for EGFP-hMtr3p 
in addition to the nucleolar staining (Fig. 1F). To 
confirm the association of MPP6 with the human 
exosome, co-immunoprecipitation experiments 
were performed using a total HEp-2 cell extract and 
three anti-PM/Scl-positive patient sera.
These sera are strongly reactive with the exosome 
components PM/Scl-75 and PM/Scl-100 and to a 
lesser extent with other exosome components, but 
not with the MPP6 protein. Three anti-PM/Scl-
negative sera served as controls (28;29). After 
immunoprecipitation, the precipitated material was 
analyzed by western blotting using the rabbit anti-
MPP6 antiserum. The results show that MPP6 is 
precipitated with all anti-PM/Scl-positive sera (Fig. 
2A, lanes 1-3) but not with the anti-PM/Scl negative 
sera (Fig. 2A, lanes 4-6). 
Figure 1. Subcellular localization of MPP6.
HEp-2 cells were transfected with constructs encoding EGFP 
alone (A, D), EGFP-MPP6 (B, E) and EGFP-hMtr3p (C, F) and 
after 24 hours the cells were fixed in 4% paraformaldehyde/PBS 
and the expressed fusion proteins were analyzed by fluorescence 
microscopy. Phase-contrast and fluorescence images are displayed 
in panels A-C and D-F, respectively. Each bar corresponds to 10 µm.
Figure 2. MPP6 is associated with nuclear exosome 
complexes. 
A) HEp-2 cell extracts were subjected to immunoprecipitation 
with three anti-PM/Scl-positive (lanes 1-3) and three anti-PM/
Scl-negative patient sera (lanes 4-6). Precipitated proteins were 
analyzed by western blotting using a rabbit anti-MPP6 serum. 
The positions of molecular mass markers (kDa) are indicated 
on the left.
B) Reciprocal experiment in which a normal rabbit serum (lanes 
2, 6, 10), a polyclonal anti-MPP6 serum (lanes 3, 7, 11) and a 
polyclonal anti-hRrp40p serum (lanes 4, 8, 12) were used for 
immunoprecipitations. A monoclonal antibody to hRrp4p was 
used for the detection of a co-precipitated exosome component. 
For the immunoprecipitations total (lanes 1-4), nuclear (lanes 5-
8) and cytoplasmic (lanes 9-12) HEp-2 cell extracts were used. 
Input material (10%) of the extracts was loaded in lanes 1, 5 and 
9, respectively. The positions of molecular mass markers (kDa) 
are indicated on the left. 
BA C
D E F
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In the reciprocal experiment, the anti-MPP6 
antiserum was used for immunoprecipitation of 
human exosome components from a total, nuclear 
and cytoplasmic HEp-2 cell extract. Co-precipitation 
of the exosome was monitored with a monoclonal 
antibody to the human exosome component hRrp4p. 
As expected, an antibody to the core exosome 
component hRrp40p co-precipitated hRrp4p from 
all three extracts (Fig. 2B, lanes 4, 8 and 12). Anti-
MPP6, on the other hand, co-precipitated hRrp4p 
from the total as well as the nuclear extract (Fig. 2B, 
lanes 3 and 7), but not from the cytoplasmic extract 
(Fig. 2B, lane 11). The normal rabbit serum failed 
to precipitate hRrp4p from all three extracts (Fig. 
2B, lanes 2, 6 and 10). Taken together, these results 
indicate that MPP6 is a nuclear protein, which 
associates with the exosome in the nucleoli.
MPP6 co-sediments with nuclear exosome 
complexes at 60-80S in glycerol gradients 
Previous reports have shown that human exosome 
core components are in part associated with 
high molecular weight complexes. (1;12;13). To 
determine the size of MPP6-associated complexes, 
nuclear and cytoplasmic extracts from HEp-2 cells 
were fractionated by glycerol gradient sedimentation. 
Fractions were analyzed by western blotting with 
rabbit anti-MPP6, anti-hRrp4p and anti-PM/Scl-
100 antisera and by agarose gel electrophoresis to 
monitor the distribution of RNA. The U1 snRNA 
was used as marker for 12S complexes, whereas 
the large ribosomal RNAs were used to identify 40S 
and 60S ribosomal subunits. The results in Figure 3 
show that for the cytoplasmic extract the majority of 
hRrp4p was present in fractions 2-7 corresponding 
Figure 3. MPP6 predominantly co-sediments with nuclear exosome complexes at 60-80S in glycerol gradients. 
Cytoplasmic (A) and nuclear (B) extracts from HEp-2 cells were fractionated in a 5-40% (v/v) glycerol gradient. The sedimentation of 
hRrp4p, MPP6 and PM/Scl-100 was determined by immunoblotting. The sedimentation of the large ribosomal RNAs was determined 
by agarose gel electrophoresis and ethidium bromide staining and used as markers (40S and 60S) in the gradient. U1 snRNA was used 
as marker for 12S complexes. 
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to approx. 10S, whereas PM/Scl-100 and MPP6 
were almost completely absent from these fractions 
(Fig. 3A). Interestingly, all three proteins, including 
MPP6 were detected in cytoplasmic 60S complexes, 
in spite of the fact that the immunofluorescence and 
immunoprecipitation data did not show any MPP6 in 
the cytoplasm. For the nuclear extract hRrp4p also 
sedimented in 10S complexes, but approximately 
half of the nuclear hRrp4p molecules was found in 
complexes corresponding to 60-80S as well (Fig. 
3B). The majority of both PM/Scl-100 and MPP6 
co-sedimented with hRrp4p in 60-80S fractions, 
whereas these proteins were hardly or not detected 
at 10S. These data indicate that MPP6, together 
with PM/Scl-100, is mainly associated with higher 
molecular weight complexes in the nucleus.
Knock-down of MPP6 leads to accumulation of 
5.8S rRNA precursors extended at the 3’ end
The nucleolar accumulation of MPP6, as well as 
its association with pre-rRNA sized complexes in 
the nucleus suggested that MPP6 might play a role 
in the biogenesis of ribosomes. Based upon the 
situation in yeast, the precursor of ribosomal RNA 
has been proposed to be one of the major substrates 
for the nuclear exosome in human cells. In yeast it 
has been demonstrated that the maturation of the 
3’end of the 5.8S rRNA requires the exosome, the 
exosome-associated TRAMP complex and several 
other co-factors (3;5;6;18-20;30-33). To investigate 
the role of MPP6 and the human exosome in the 
processing of pre-rRNA, RNAi experiments were 
performed. SiRNAs were designed and synthesized 
Figure 4. Knock-down of MPP6 by RNAi leads to the accumulation of 5.8S rRNA precursors. 
A) HEp-2 cells were transiently transfected with three different siRNAs to MPP6 (100 pmol), control siRNA or buffer (mock). Cells 
were harvested 2 days after transfection and 75 µg of total protein was analyzed by western blotting using a polyclonal anti-MPP6 
serum or a polyclonal anti-hRrp41p serum (control).
B) Northern analysis of 5.8S rRNA processing upon MPP6 knock-down. 5 µg of total RNA from (mock) transfected cells was 
analyzed by northern blot hybridization using radiolabeled probes specific for 5.8S rRNA (left) or ITS2 (right). The relative positions 
of these probes, and also the other probes used, with respect to the primary rRNA transcript are depicted in the scheme below the 
autoradiographs. Note that the size of the probes is not proportional to that of the pre-rRNA. As a control, a U6 snRNA probe was 
used. The positions of 5.8S rRNA and its precursors (I and II) are indicated. The asterisk in the right panel points to a weak cross-
hybridisation of the ITS2 probe with the mature 5.8S rRNA
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for MPP6 and as a control, an siRNA specific for a 
melanoma marker protein was included. The effect 
of each MPP6-siRNA was assayed by transfection 
of HEp-2 cells with each of these siRNAs and two 
days after transfection protein as well as RNA was 
isolated. The efficiency of MPP6 knock-down was 
assessed by western blotting. A polyclonal antibody 
to hRrp41p was used as a control. The results 
in Figure 4A show that all three MPP6-siRNAs 
led to significantly reduced levels of the MPP6 
protein at 48 hours after transfection, while the 
levels of hRrp41p remained unaffected (Fig. 4A). 
Subsequently, RNA isolated from MPP6 siRNA-
treated cells was analyzed by gel electrophoresis 
and northern blot hybridization using radiolabeled 
probes specific for different regions of the pre-rRNA 
(Fig. 4B). The results demonstrate that knock-down 
of MPP6 leads to the accumulation of 5.8S rRNA 
precursors, which hybridize with the ITS2 probe 
in addition to the 5.8S coding sequence probe 
(Fig. 4B). These processing intermediates were 
not detected with a probe specific for ITS1 (data 
not shown), which indicates that the precursors 
accumulating upon MPP6 knock-down are extended 
at their 3’ end. Also, no accumulation of processing 
intermediates was detected using the probes specific 
for 5’ETS (data not shown). Hybridization with a U6 
snRNA probe, which was used as a control, showed 
that there were no significant loading differences 
between the different samples (Fig. 4B, lanes 1-10). 
Note that under these conditions the total amount 
of mature 5.8S rRNA was not significantly reduced. 
Based upon the role of the exosome in the 
maturation of the 3’ end of 5.8S rRNA in yeast 
and the association of MPP6 with the exosome 
in the nucleus, we hypothesized that the observed 
accumulation of processing intermediates 
resulting from MPP6 knock-down might be due 
to the abrogation of the function of the exosome. 
However, the effects of abrogation of the function 
of the human exosome on 5.8S rRNA maturation 
have not been documented so far. 
Figure 5. MPP6, hRrp41p and PM/Scl-100 knock-down lead 
to the accumulation of the same 5.8S rRNA precursors. 
A) HEp-2 cells were transiently transfected with control siRNA 
(100 pmol), MPP6-2 siRNA (100 pmol), hRrp41p siRNA (200 
pmol) and PM/Scl-100 siRNA (100 pmol). Thirty-six hours after 
transfection cells were retransfected with the same amount of 
siRNA and after an additional 36 hours the cells were harvested. 
The proteins were analyzed by western blotting using 75 µg of 
total protein extracts from transfected cells and a polyclonal anti-
MPP6 serum, a polyclonal anti-hRrp41p serum, and a polyclonal 
anti-PM/Scl-100 serum. A polyclonal anti-hRpp40 serum was 
used as a control. 
B) A radiolabeled anti-sense ITS2 probe, complementary to the 
first 300 nucleotides of ITS2, was hybridized to 5 µg of total 
RNA from siRNA treated cells. After digestion with RNase 
A and RNase T1 the RNA was analyzed on a 10% denaturing 
polyacrylamide gel. The radiolabeled ITS2 probe was loaded in 
lane 1. As a control, the same probe was incubated with 5 µg 
of yeast total RNA and further treated by the same procedure 
(lane 6). Lanes 4-6 show protected RNAs from cells treated with 
control, MPP6-2, hRrp41p and PM/Scl-100 siRNA, respectively. 
The positions of the 5.8S precursor rRNAs (I and II) are 
indicated. Positions of marker RNAs are indicated on the left.
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To shed more light on this issue the effect of 
MPP6 RNAi on the 3’ end of the 5.8S rRNA was 
compared with those of knock-down of the exosome 
components hRrp41p and PM/Scl-100 in an RNase 
protection assay. The reduction in protein levels 
was monitored by western blotting, which indeed 
confirmed the efficiency of the siRNAs used (Fig. 
5A). The RNAs isolated from the cells treated with 
the MPP6, hRrp41p and PM/Scl-100 siRNAs were 
hybridized with a probe comprising the sequence 
complementary to the most 5’ 300 nucleotides of 
ITS2. After RNase digestion, the reaction products 
were analyzed by denaturing polyacrylamide gel 
electrophoresis (Fig. 5B). Precursor RNAs detected 
in this experiment were of similar size as those 
observed in the northern blot hybridization. Note 
that low levels of precursor I were observed also 
in the cells treated with the control siRNA, whereas 
precursor II products were only detected for RNA 
from MPP6 and exosome knock-down cells. 
The size of the products of the RNase protection 
experiments indicated that the 3’ ends of the 
processing intermediates are located approximately 
156 nts and 250 nts downstream of the 3’ end of the 
mature 5.8S rRNA. Hybridization of the probe with 
yeast total RNA indicated that the signals observed 
in lanes 2-5 are specific and not due to background 
signals resulting from self-complementary 
sequences within the probe (lane 6). 
MPP6 interacts with RNA in vitro and binds 
preferentially to polypyrimidines
The results of the experiments described above 
suggest that the exosome and MPP6 are involved 
in the same processing steps in ITS2 to generate the 
mature 3’ end of the human 5.8S rRNA. This raises 
the question how they cooperate in this process. 
The activities that are predicted to be involved are 
Figure 6. GST-tagged MPP6 binds to in vitro 
transcribed RNAs and prefers polypyrimidines.
A) GST and GST-MPP6 recombinant proteins were 
incubated with radiolabeled, in vitro transcribed full-length 
5.8S rRNA, ITS2 rRNA (a fragment corresponding to the 
most 5’ 300 nucleotides) and RNase MRP RNA. Binding 
to these RNAs was assayed by GST pull-down followed by 
denaturing gel electrophoresis and autoradiography. Five 
percent of the input RNA was loaded in lanes 1. Lanes 2 
and 3 contain the material precipitated by GST alone and 
GST-MPP6, respectively.
B) Binding of GST and GST-MPP6 fusion proteins to 
radiolabeled homopolynucleotides was analyzed as 
described above and the bound RNAs were quantified in 
a scintillation counter. The binding efficiency of GST or 
GST-MPP6 with poly(A), poly(C), poly(G), poly(U) and 
poly(C)-poly(I) is depicted as a percentage of input RNA 
(RBE: relative binding efficiency). These results are the 
averages of two independent experiments.
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RNA-binding for the recognition of processing sites 
in ITS2, endoribonuclease activities for cleavage(s) 
in ITS2, 3’- 5’ exoribonuclease for trimming of 
the cleaved precursor RNA, and RNA helicase 
activities for resolving secondary structures that 
interfere with nucleolytic processing. Several 
exosome components have been shown to contain 
3’- 5’ exoribonuclease activity, but the recombinant 
MPP6 did not appear to have such an activity (data 
not shown). The amino acid sequence of MPP6 
is also devoid of endoribonuclease and helicase 
motifs. Therefore, we investigated whether MPP6 
can bind to RNA. GST pull-down experiments 
were performed with GST-tagged MPP6 protein 
and three distinct 32P-labelled, in vitro transcribed 
RNAs, 5.8S rRNA, a transcript containing part of 
the ITS2 and the RNA component of RNase MRP. 
As shown in Figure 6A, GST-MPP6 bound to all 
three RNAs efficiently (compare lanes 3 with the 
corresponding lanes 1), in contrast to GST, which 
did not precipitate any of the RNAs (lanes 2). In 
addition, a GST pull down experiment using a 
HEp-2 cell extract showed that GST-MPP6 was able 
to associate with RNAs in this extract including 
5.8S rRNA and 5.8S rRNA precursors (data not 
shown). These data demonstrate that MPP6 does 
contain RNA-binding activity and suggest that the 
specificity of binding may be low. To study this in 
more detail, a similar experiment was performed 
with different radiolabelled homopolynucleotides. 
The results showed that GST-MPP6 preferentially 
binds to poly(C) and poly(U). No binding to poly(A) 
could be detected and the relatively weak binding 
to poly(G) should be interpreted with care, because 
also GST displayed some binding to poly(G) and 
poly(G) is known to adopt higher order structures 
which may affect background levels. GST-MPP6 
also did not appear to bind to poly(C)-poly(I), 
which was included as a double-stranded RNA in 
these analyses (Fig. 6B). 
Discussion
In this study we have characterized the previously 
identified association of MPP6 with exosome 
complexes in human cells. The association with the 
exosome was confirmed by co-immunoprecipitation 
experiments and shown to be restricted to the 
nuclear compartment, more specifically the 
nucleoli. In logarithmically growing HEp-2 cells 
the majority of MPP6 appeared to be associated 
with 60-80S complexes which most likely represent 
pre-ribosomes and knock-down experiments indeed 
demonstrated that MPP6 participates, in conjunction 
with the exosome, in the processing of human pre-
rRNA.
The association of MPP6 with the nuclear 
exosome
Although the highest concentrations of human core 
exosome components can be detected in the nucleolus 
by immunofluorescence microscopy, subcellular 
fractionation experiments have shown that core 
exosome components are present in both nuclear 
and cytoplasmic fractions (12;13;34-37). Like 
other exosome components hMtr3p, the subcellular 
distribution of which has not been described before, 
showed a nuclear fluorescence pattern, with an 
accumulation in the nucleoli. MPP6 also displayed 
a subcellular localization which is mainly restricted 
to the nucle(ol)us both by fluorescence microscopy 
and biochemical fractionation. The relatively low 
level of co-precipitation of hRrp4p with anti-MPP6 
in comparison with anti-hRrp40p from nuclear 
extracts indicated that only a relatively small 
fraction of nuclear exosome complexes is stably 
associated with MPP6. This is substantiated by 
the results of co-immunoprecipitation experiments 
performed with anti-EGFP antibodies using extracts 
from transiently transfected HEp-2 cells expressing 
EGFP-tagged MPP6 or, as a reference, EGFP-
tagged hCsl4p (data not shown). Fractionation of the 
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nuclear extract by glycerol gradient sedimentation 
revealed that MPP6 is not associated with the low 
molecular weight exosome complexes at ~10S, but 
only associates with the exosome complexes at 60-
80S. Also the majority of PM/Scl-100 appeared to 
be associated with 60-80S complexes in the nuclear 
extract. 
In yeast, the exosome has been shown to function 
in pre-rRNA, pre-sn(o)RNA and pre-mRNA 
processing and/or degradation in the nucleus, 
whereas in the cytoplasm it is involved in mRNA 
degradation (38). Currently, it is unclear whether 
the small, though significant fraction of MPP6, PM/
Scl-100 and hRrp4p molecules in the cytoplasmic 
extract that sediment at 60S are associated with a 
cytoplasmic complex, or whether this is due to some 
leakage of nuclear material to the cytoplasm during 
preparation of the extracts. Interestingly, the high 
molecular weight peak in the cytoplasmic material is 
observed at 60S, whereas the peak with the nuclear 
material extends from 60S to 80S, suggesting that 
they might represent different complexes.
Because neither co-immunoprecipitation nor 
density gradient sedimentation data demonstrate 
a direct interaction of MPP6 with the exosome, 
the possibility exists that other proteins mediate 
their interaction, especially because it only seems 
to occur in the large preribosomal complexes. 
The results of an analysis of possible interactions 
between MPP6 and exosome core components in 
a mammalian two-hybrid system were all negative 
(our unpublished data). However, yeast two-hybrid 
data have suggested direct interactions of MPP6 
with both PM/Scl-100 and hMtr4p (25). Moreover, 
all three proteins have also been identified as 
components of the nucleolar proteome (http://
www.lamondlab.com/NOPdb/). Therefore, it seems 
most likely that the interaction of MPP6 with the 
exosome depends on its binding to PM/Scl-100, 
which is believed to interact directly with the core 
of the exosome.
Still, the almost exclusive association of the MPP6 
protein with nuclear 60-80S complexes strongly 
suggested that MPP6 is specifically involved in the 
function of the exosome in pre-rRNA processing. 
Indeed, we found that upon knock-down of MPP6 
the maturation of 5.8S rRNA is affected. The 
accumulation of the same processing intermediates 
in cells with reduced levels of either MPP6 or the 
exosome components hRrp41p and PM/Scl-100 
provides further evidence that they act in concert in 
these processing steps.
The role of MPP6 in the maturation of the 3’ end 
of the 5.8S rRNA
Although the exosome complex has been shown 
to function in a wide variety of RNA processing 
pathways, it is still largely unknown how the 
exosome recognizes its different substrates and 
how these substrates are subsequently subjected 
to either precise 3’ end processing or complete 
degradation. Most likely, other proteins, which 
transiently associate with the exosome, mediate 
the recruitment of the exosome to specific substrate 
RNAs. In mammalian cells so far no evidence has 
been presented for the involvement of the exosome 
in ribosomal RNA processing pathways. Our data 
show for the first time that the human exosome, like 
the yeast exosome, is required for the maturation 
of the 3’end of the 5.8S rRNA. Both the hRrp41p 
and PM/Scl-100 proteins appeared to be involved 
in this process. In yeast depletion of Rrp6p and 
core exosome components (including Rrp41p) 
have distinct effects on pre-rRNA processing, 
because their depletion leads to the accumulation 
of different processing intermediates. Based upon 
these observations a hand-over mechanism was 
proposed, in which the core exosome components 
remove ITS2 nucleotides up to a position 30 
nucleotides beyond the 3’ end of the 5.8S rRNA 
and Rrp6p then takes over and processes most of the 
remaining ITS2 nucleotides (3;20). In contrast to the 
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situation in yeast, our data did not reveal differences 
in the accumulation of 5.8S rRNA precursors after 
knocking-down PM/Scl-100 or hRrp41p. Although 
the functional activities of these proteins may have 
changed over time, we believe that these differences 
are more likely explained by the depletion of the 
whole exosome from the site of processing. The 
accumulation of the same processing intermediates 
after MPP6 knock-down supports this idea. 
Furthermore, the observed accumulation of 
distinct 5.8S intermediates indicates that there are 
endonucleolytic cleavage sites within the human 
ITS2, which are not affected by MPP6 or exosome 
knock-down. These putative cleavage sites are 
approx.156 nts and 250 nts downstream of the 3’ 
end of the 5.8S rRNA coding sequence and might 
give rise to the 8S and 12S pre-rRNAs previously 
observed in other mammalian cells (39-41). 
A database search did not reveal an MPP6 
homologue in the yeast Saccharomyces cerevisiae, 
but the amino acid sequence of the hypothetical 
protein SPACUNK4.11c of Schizosaccharomyces 
pombe is a putative homologue of MPP6 (27% 
identity; 39% similarity). This indicates that there 
might be differences in pre-rRNA architecture 
between both yeast strains which require at least in 
part distinct processing machineries.
There are no known protein motifs that can be 
discerned in the primary structure of MPP6 which 
could give a clue about its function. The only 
sequence motif that can be discerned is a bipartite 
nuclear localization signal (aa 116-132). The 
bacterially expressed recombinant GST-MPP6 
fusion protein did not display 3’ - 5’ exoribonuclease 
activity in vitro (our unpublished results). On the 
other hand, our in vitro RNA-binding experiments 
show that MPP6 is able to interact with the 
5.8S-proximal ITS2 region of pre-rRNA, and 
displays a binding preference for polypyrimidines. 
Interestingly, the 3’ end of the 5.8S precursor II, 
which accumulates upon MPP6 knock-down,
Figure 7. Model for the role of MPP6 in pre-rRNA 
processing.
Before, or directly after cleavage of the pre-rRNA in ITS2 by a 
yet unknown endoribonuclease, MPP6 binds to oligopyrimidine 
stretches in the ITS2 RNA and subsequently recruit the PM/
Scl-100-containing exosome and probably several additional 
factors, like hMtr4p or an hMTR4p containing complex. This is 
in agreement with the reported two-hybrid interactions between 
MPP6 and PM/Scl-100 and between MPP6 and hMtr4p (25). 
The exosome will then process the ITS2 RNA to generate the 
mature 5.8S rRNA. MPP6 may either remain associated with 
the processing complex or dissociate once the exosome starts 
the digestion. 
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 contains an oligopyrimidine tract (~20 nucleotides). 
The effects on pre-rRNA processing suggest that 
MPP6 is an essential co-factor for the exosome 
in the nucleolus. Nevertheless, our RNA-binding 
data show that the binding specificity of MPP6 is 
low, implying that this protein may bind to various 
other RNAs and may also be involved in the 3’ end 
processing of other RNAs. 
The reduction of MPP6 levels did not significantly 
affect the expression levels or subcellular localization 
of exosome components (data not shown), 
indicating that MPP6 is probably not required for 
exosome assembly nor for its subcellular targeting. 
Taken together, our data support a model in which 
MPP6 mediates the recruitment of the exosome to 
the ITS2 for further processing (Fig. 7). The RNA 
binding properties of MPP6 suggest that MPP6 
first interacts with the pre-rRNA, thereby creating 
a binding site for the PM/Scl-100-containing 
exosome. The exosome subsequently processes 
ITS2, and at this stage MPP6 may either remain 
associated or may be released from the exosome at 
the start of the exonucleolytic digestion. Recently, 
the Mtr4p-containing TRAMP complex was shown 
to be involved in exosome-mediated pre-rRNA 
processing in yeast (31-33). It would therefore be 
interesting to investigate whether MPP6 also plays 
a role in the association of the human counterpart of 
the TRAMP complex with the pre-rRNA-exosome 
complex. 
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Introduction
The human exosome is a complex with 3’-5’ 
exoribonuclease activity, consisting of nine core 
components and the stably associated component 
PM/Scl-100, which is more abundant in but not 
restricted to the nucleus (1;2). Six of the core 
components (hRrp41p, hRrp42p, hRrp46p, hMtr3p, 
OIP2 and PM/Scl-75) contain an RNase PH domain, 
which assemble into a hexameric ring structure, 
whereas the three remaining components (hRrp4p, 
hRrp40p and hCsl4p) containing a S1 (and KH) 
RNA binding domain that are positioned at the outer 
surface of this ring (3-8). 
A variety of nuclear functions have been described 
for the yeast exosome, including 3’ end processing 
of sn(o)RNAs (9;10) and the degradation of aberrant 
pre-mRNAs (11-13) and pre-tRNAs (14;15). In the 
nucleolus of eukaryotes, the18S, 5.8S and 25S/28S 
rRNAs are transcribed as a single precursor by 
RNA polymerase I. After transcription, maturation 
of rRNAs is achieved by a complex processing 
pathway in which many nucleotide-modification 
events occur and in which the two internally 
transcribed spacers (ITS1 and ITS2) and two 
externally transcribed spacers (5’-ETS and 3’-
ETS) are removed (16;17). In yeast, depletion of 
exosome components as well as several associated 
proteins such as Rrp47p and Mtr4p resulted in the 
accumulation of 3’-extended 5.8S rRNAs, elevated 
levels of 5’ ETS fragments, and polyadenylated 
(pre-)rRNAs. Exosome depletion also indirectly 
affected early pre-rRNA cleavage events at A(0), 
A(1), A(2) and A(3) leading to a reduction of the 
mature 18S and 25S rRNAs (9;18-25). 
Besides the core exosome components, several 
cytoplasmic and nuclear exosome-associated 
proteins have been identified which are most likely 
required for the recruitment of the exosome to 
specific substrate RNAs, its association with other 
processing complexes, or the modulation of its in 
vivo activity. Nuclear exosome–associated proteins 
include human MPP6, a protein required for the 
maturation of the 5.8S rRNA, and yeast Rrp47p 
(also known as C1D and Lrp1p), which functions in 
sn(o)RNA and pre-rRNA processing (2;26;27). The 
putative human homologue of yeast Rrp47p/C1D/
Lrp1p is the C1D protein, which has previously 
been identified as a DNA-binding protein involved 
in DNA double-strand break repair by activating 
The exosome is a complex of 3’-5’ exoribonucleases and RNA binding proteins, which is involved in 
processing or degradation of different classes of RNA. Previously, the characterization of purified exosome 
complexes from yeast and human cells suggested that C1D and KIAA0052/hMtr4p are associated with 
the exosome and thus might regulate its functional activities. Subcellular localisation experiments 
demonstrated that C1D and KIAA0052/hMtr4p colocalize with exosome subunit PM/Scl-100 in the 
nucleoli of HEp-2 cells. Additionally, the nucleolar accumulation of C1D appeared to be dependent on PM/
Scl-100. Protein-protein interaction studies showed that C1D binds to PM/Scl-100, whereas KIAA0052/
hMtr4p was found to interact with MPP6, a previously identified exosome associated protein. Moreover, 
we demonstrate that C1D, MPP6 and PM/Scl-100 form a stable trimeric complex in vitro. Knock-down 
of C1D, MPP6 and KIAA0052/hMtr4p by RNAi resulted in the accumulation of 3’ extended 5.8S rRNA 
precursors, showing that these proteins are required for rRNA processing. Interestingly, C1D appeared 
to contain RNA-binding activity with a potential preference for structured RNAs. Taken together, our 
results are consistent with a role for the exosome-associate proteins C1D, MPP6, and KIAA052/hMtr4p 
in the recruitment of the exosome to pre-rRNA to mediate the 3’ end processing of the 5.8S rRNA.
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a DNA-dependent protein kinase (28;29). The 
putative RNA helicase Mtr4p is another auxiliary 
protein required for most of the functions of the 
nuclear exosome in yeast (9;30). The Mtr4p protein 
is also part of the recently identified TRAMP 
complex, which is required for the activation of 
the nuclear exosome in vivo by polyadenylation of 
target RNAs (15;21). The KIAA0052 protein is the 
putative human homologue of Mtr4p and was found 
to co-purify with the human exosome (31). 
In this study, we investigated the exosome 
association and function of C1D and KIAA0052, 
which hereafter will be referred to as hMtr4p, in 
human cells. Our data indicate that PM/Scl-100 
mediates the association of hMtr4p, C1D and MPP6 
with the exosome and that hMtr4p and the complex 
formed by PM/Scl-100, C1D and MPP6 are required 
for the maturation of 5.8S rRNA.
Materials and Methods
cDNA cloning 
The cDNA of human C1D was obtained by a PCR-
based approach using a teratocarcinoma cDNA 
library and oligonucleotides C1D-forward, 5’-CGT
CGACTTCTCGAGATGGCAGGTGAAGAAATT
AATG-3’ and C1D-reverse, 5’-AGCGGCCGCTTA
CCCGGGACTTTTACTTTTTCCTTTATTGG-3’. 
The human hMtr4p cDNA sequence was isolated by 
PCR from clone IRATp970F0129D6 provided by 
the I.M.A.G.E. consortium using oligonucleotides 
hMtr4p-forward, 5’-GCGACGATATCCTCGAGC
ATGGCGGACGCATTCGGAGA-3’ and hMtr4p-
reverse 5’-GCGTCGGTACCCTACAAGTAGAG
GCTGGCA-3’. The resulting PCR products were 
cloned into the pCR4-TOPO vector according the 
manufacturer’s procedure (Invitrogen). 
Immunoprecipitation
Polyclonal rabbit anti-EGFP antibodies were coupled 
to protein A-agarose beads (Kem-En-Tec) in IPP500 
(500 mM NaCl, 10 mM Tris–HCl, pH 8.0 and 
0.05% Nonidet P-40 (NP-40) ) at room temperature 
for 1 h. Beads were washed once with IPP500 and 
twice with IPP150 (same as IPP500, but containing 
150 mM NaCl). For each immunoprecipitation, cell 
extract was incubated with the antibody-coupled 
beads for 2 h at 4 oC. After washing the beads four 
times with IPP150 the precipitated proteins were 
separated by 10% SDS–PAGE and analyzed by 
immunoblotting.
Western blot analysis
For western blot analysis, proteins were separated 
by SDS-PAGE and transferred to nitrocellulose 
membranes. After blocking, the blots were incubated 
with autoimmune patient antisera or monoclonal 
anti-hRrp4p antibodies (culture supernatant) 
(ModiQuest, Nijmegen, The Netherlands) , diluted 
1000- and 25-fold, respectively, in blocking buffer 
(5% skimmed milk, 0.05% NP-40 in PBS). As 
secondary antibodies horseradish peroxidase-
conjugated rabbit anti-human IgG or goat anti-mouse 
IgG (Dako Immunoglobulins) were used, 2500-fold 
diluted in blocking buffer. Bound antibodies were 
visualized by chemiluminescence detection.
Expression and purification of recombinant 
proteins
For prokaryotic expression, the C1D and MPP6 
cDNAs were cloned into the pGEX4 vector, 
resulting in sequences encoding glutathione S-
transferase (GST)-tagged recombinant proteins. 
The GST fusion proteins were expressed and 
purified essentially as described previously (32). 
After induction of protein expression with IPTG the 
bacteria were grown at room temperature to enhance 
the production of soluble protein. The proteins were 
purified using a reduced glutathione affinity resin in 
the presence of 0.2% empigen and stored at –70 oC 
after the addition of glycerol (final concentration 
10%).
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In vitro transcription and translation
The open reading frames of PM/Scl-100, MPP6 
and C1D were cloned into the pCI-neo vector 
(Promega), in frame with the vesicular stomatitis 
virus G epitope (VSV-G tag). The resulting pCI-
neo5’VSV constructs of PM/Scl-100, MPP6 and 
C1D as well as a pCR4-TOPO- hMtr4p construct 
were transcribed and translated in the presence of 
35S-methionine using the TnT coupled transcription/
translation kit (Promega). 
Transient transfection and fluorescence 
microscopy
The cDNAs were cloned into suitable pEGFP 
vectors (Clontech) allowing expression of the 
protein fused to the C-terminus of the EGFP protein. 
HEp-2 cells were grown to 70% confluency in 
DMEM containing 10% fetal calf serum (FCS) 
(DMEM+). For immunoprecipitation, approx. 10 
x 106 cells were transfected with 30 µg of plasmid 
DNA in 1600µl of DMEM+ by electroporation 
at 260 V and 950 µF using a Gene-Pulsar II 
(Bio-Rad). After transfection, cells were seeded 
in 75-cm2 culture flasks and cultured overnight. 
The trypsinized cells were washed with PBS, 
resuspended in 750 µl of lysis buffer (25 mM Tris-
HCl, pH 7.5, 150 mM KCl, 2 mM EDTA, 1 mM 
dithiotreitol (DTT), 0.5 mM PMSF and 0.05% 
NP-40) and homogenized by sonication using a 
Branson micro-tip. For fluorescence microscopy 
approx. 3 x 106 cells were transfected with 10 µg of 
plasmid DNA in 800 µl DMEM+ by electroporation 
as described above. The cells were seeded on 
coverslips and cultured overnight. Subsequently, 
the cells were washed twice with PBS and fixed 
with 4% paraformaldehyde in PBS for 20 min. After 
fixation, cells were washed three times with PBS 
and mounted with 50% glycerol in PBS. The EGFP-
fusion proteins were visualized by fluorescence 
microscopy using a Leica DM IRBE confocal 
microscope. For colocalization experiments, HEp-2 
cells were transfected with pEGFP-C1D or pEGFP-
hMtr4p and grown on coverslips for 24h. Cells were 
fixed with methanol for 5 min at 20 °C, briefly rinsed 
in acetone, air-dried and incubated for 1 h at room 
temperature with anti-PM/Scl-100 rabbit serum 
(diluted 1:100 in PBS), followed by washing and 
incubation with secondary Texas Red-conjugated 
donkey anti-rabbit IgG. The cells were analyzed by 
confocal fluorescence microscopy.
siRNA transfection experiments  
The 21 nt siRNA duplexes used in this study 
are based upon the coding region of the gene of 
interest, containing dTdT overhangs and were 
obtained from Eurogentec (Belgium): siC1D, 5’-
GUUGGAUCCACUUGAACAATT-3’; siPM/Scl-
75, 5’-GCCAAGAUGCUCCCAUAAUTT-3’; 
sihMtr4p, 5’-GCCUAUGCACUUCAAAUGATT-
3’. The siRNAs against human MPP6 and PM/Scl-
100 were described previously (1;2). The siRNA 
negative control (OR-0030-NEG05) was obtained 
from Eurogentec, Belgium. Per transfection 
approx. 3 x 105 HEp-2 cells were transfected with 
100 pmol of each siRNA using Oligofectamine 
transfection reagent (Invitrogen), as described by 
the manufacturer with the exception that during 
transfection 10% FCS was present in the medium. 
Total RNA was extracted 48 h after transfection 
using the TRIzol reagent (Invitrogen). Per sample 5 
µg of total RNA was separated on a denaturing 7% 
polyacrylamide gel, and after transfer to Hybond N+ 
membranes (Amersham Biosciences) the blots were 
hybridized with 32P-labelled antisense RNA probes 
in hybridization solution (6x SSC, 10x Denhardt’s, 
100 µg/ml sheared herring sperm DNA and 0.1% 
SDS). After overnight incubation at 65°C, the blots 
were washed three times with 2x SSC/0.1% SDS 
and analyzed by autoradiography. To study the 
subcellular localization of C1D in siRNA treated 
cells, HEp-2 cells were transfected with C1D-EGFP 
as described above. After 16 h cells were treated 
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with 100 pmol of siRNA and cultured overnight. 
Subsequently, the cells were washed twice with PBS, 
fixed with 4% paraformaldehyde in PBS for 20 min 
and mounted in PBS/glycerol. Expressed proteins 
were visualized by fluorescence microscopy using a 
Leica DM4000B microscope. 
GST-pull down
GST-fusion protein (approx. 1 µg) was immobilized 
on glutathione-Sepharose beads (Amersham 
Pharmacia Biotech), washed with pull-down buffer 
PB-100 (PB-100: 20 mM HEPES-KOH, pH 7.6, 
100 mM KCl, 0.5 mM EDTA, 0.05% NP-40, 1 mM 
DTT, 5 mM MgCl
2
, 0.02% BSA, 0.5mM PMSF) 
and incubated with in vitro translated, 35S-labelled 
protein at 4 °C for 2 h under continuous agitation. 
After incubation, the beads were washed three 
times with PB-150 (composition like PB-100, but 
containing 150 mM KCl) and the bound proteins 
were analysed by SDS–PAGE and autoradiography. 
In case of protein–RNA interactions, immobilized 
GST-C1D was resuspended in 200 µl of PB-200 
(composition like PB-100, but containing 200 mM 
KCl and lacking MgCl
2
). After addition of the 32P-
labelled RNAs and 20 U of RNasin (Promega) 
the mixture was incubated for 1 h at 4°C under 
continuous agitation. The beads were washed four 
times with PB-200 and the co-precipitating RNAs 
were extracted and analyzed by denaturing PAGE 
and autoradiography.
Results
C1D and hMtr4p co-localize with PM/Scl-100 in 
the nucleoli of HEp-2 cells
To determine the subcellular localization of C1D and 
hMtr4p, HEp-2 cells were transiently transfected 
with constructs encoding EGFP-tagged C1D, 
hMtr4p, MPP6, or the core exosome component 
PM/Scl-75. After 24 hours the EGFP fusion 
proteins were visualized by confocal fluorescence 
microscopy (see Fig. 1). In agreement with previous 
observations, EGFP-PM/Scl-75 and EGFP-MPP6 
accumulated in the nucleoli, whereas also a weak 
but significant staining of the nucleoplasm was
Figure 1. C1D and hMtr4p co-localize with PM/Scl-100 in the 
nucleoli of HEp-2 cells.
A) HEp-2 cells were transiently transfected with cDNA constructs 
encoding EGFP alone, EGFP-PM/Scl-75, EGFP-MPP6, EGFP-
C1D or EGFP- hMtr4p. Twenty four hours after transfection 
the cells were fixed and EGFP or EGFP-fusion proteins were 
visualized by confocal fluorescence microscopy. 
B) HEp-2 cells were transfected with cDNA constructs encoding 
C1D and hMtr4p fused to the C-terminus of EGFP; 24 hours 
after transfection cells were fixed and incubated with rabbit anti-
PM/Scl-100 antibodies, which were visualized by Texas Red-
conjugated secondary antibodies (left panels). The localization 
of EGFP-tagged C1D and hMtr4p is shown in the middle panels, 
and the corresponding merged images are shown on the right.
A
B
EGFP EGFP-PM/Scl-75 EGFP-MPP6
EGFP-hMtr4pEGFP-C1D
EGFP-C1DPM/Scl-100 merged
PM/Scl-100 EGFP-hMtr4p merged
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observed for both proteins (2;33) A very similar 
staining pattern was observed for both EGFP-
C1D and EGFP-hMtr4p. Thus, the subcellular 
distribution of C1D and hMtr4p is consistent with 
their putative exosome association.
To investigate this more thoroughly, HEp-2 cells 
were transfected with either EGFP-C1D or EGFP-
hMtr4p and also stained with an antibody to the 
exosome subunit PM/Scl-100. As shown in Figure 
1B, a nearly complete colocalization of EGFP-C1D 
and EGFP-hMtr4p with PM/Scl-100 in the nucleoli 
of these cells was observed. In the nucleoplasm 
there appears to be less extensive colocalization, 
which might be due to the low levels of protein 
present in this subcellular compartment and/or to 
overexpression of the EGFP-fusion proteins. 
Interaction of C1D and hMtr4p with the 
exosome
To investigate whether C1D is indeed associated 
with the human exosome, immunoprecipitations 
with anti-EGFP antibodies were performed with 
lysates from HEp-2 cells expressing EGFP-tagged 
C1D, PM/Scl-75, or EGFP alone as a negative 
control. Co-precipitated material was analyzed 
by western blotting using a human patient serum 
(known to be reactive with PM/Scl-100) and 
a monoclonal antibody to the human exosome 
component hRrp4p. As expected, both PM/Scl-100 
and hRrp4p were co-precipitated with the EGFP-
PM/Scl-75 protein (Fig. 2A, lane 3). PM/Scl-100 
and hRrp4p also appeared to be co-precipitated 
with EGFP-C1D (lane 4), although the efficiency of 
hRrp4p co-precipitation was much lower than that 
observed with EGFP-PM/Scl-75. With the EGFP 
protein alone no co-precipitation of hRrp4p and PM/
Scl-100 was detected (lane 2). This result suggests 
that C1D is preferentially associated with exosome 
complexes containing PM/Scl-100. To substantiate 
the direct interaction of C1D and MPP6, another 
protein reported to interact with PM/Scl-100 (5), 
with PM/Scl-100, immunoprecipitations were 
performed using recombinant His-tagged PM/
Scl-100 and in vitro translated glyseraldehyde-3-
phosphate dehydrogenase (GAPDH), C1D and 
MPP6. As shown in Figure 2B, precipitation of 
His-PM/Scl-100 by anti-PM/Scl-100 antibodies 
resulted in the efficient co-precipitation of C1D 
(lane 6) and, albeit to a lesser extent, MPP6 (lane 
9), but not GAPDH (lane 3). In lanes 2, 5 and 8 
anti-PM/Scl-100 antibodies were incubated with 
the in vitro translated proteins in the absence of 
His-PM/Scl-100 demonstrating that the antibodies 
are not reactive with either of these proteins. In 
the reciprocal experiment, precipitation of GST-
fusion proteins using glutathione-Sepharose beads 
resulted in the co-precipitation of in vitro translated 
PM/Scl-100 with both GST-C1D and, although less 
efficiently, with GST-MPP6, but not with GST alone 
(Fig. 2C). 
To identify protein-protein interactions of hMtr4p 
with the exosome, GST-pull down assays were 
performed using GST-fusion proteins of several 
exosome components and auxiliary proteins and 
in vitro translated hMtr4p. The only protein found 
to specifically interact with hMtr4p was GST-
MPP6 as shown in Figure 2D, whereas none of the 
other proteins analyzed (C1D, hRrp4p, hRrp40p, 
hRrp41p, hRrp42p, hRr46p, hMtr3p, OIP2 and 
hCsl4p) were able to precipitate hMtr4p (data not 
shown). Because the in vitro translated protein 
samples contain RNA, the possibility existed that 
the observed protein-protein interactions between 
GST-MPP6 and hMtr4 as well as GST-C1D and 
PM/Scl-100 might be RNA-mediated. Similar GST-
pull down experiments were performed with in vitro 
translated proteins samples which were treated with 
RNase A and RNase T1. The results demonstrated 
that these protein-protein interactions were not 
affected by RNase treatment, even though control 
experiments showed that the RNAs were efficiently 
degraded (data not shown). 
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PM/Scl-100, C1D and MPP6 form a 
heterotrimeric complex
The finding that both MPP6 and C1D interact with 
PM/Scl-100 prompted us to examine the possibility 
that MPP6 and C1D bind simultaneously to PM/Scl-
100. GST-pull-down experiments were performed 
using GST-C1D and in vitro translated C1D, MPP6 
and PM/Scl-100 proteins. As can be seen in Figure 
3, no detectable interaction was found between GST-
C1D and in vitro translated C1D or MPP6 (lanes 5 
and 6). In contrast, GST-C1D efficiently interacted 
with PM/Scl-100 as observed before (lane 7).
Figure 2. Association of C1D, MPP6 and hMtr4p with components of the exosome.
A) Co-immunoprecipitations were performed using anti-EGFP antibodies and extracts of HEp-2 cells transiently transfected with 
expression constructs for either EGFP alone (lane 2), EGFP-PM/Scl-75c-α (lane 3) or EGFP-C1D (lane 4). In the first lane, total 
extract from non-transfected HEp-2 cells was separated. The precipitated proteins were analyzed by western blotting, using anti-PM/
Scl-positive patient serum R212 (upper part of the blot) or a monoclonal antibody to hRrp4p (lower part of the blot). Arrows indicate 
the positions of PM/Scl-100 and hRrp4p. The positions of molecular weight markers are indicated on the left. 
B) Bacterially expressed, recombinant His-tagged PM/Scl-100 was immobilized using anti-PM/Scl-100 antibodies and incubated with 
either 35S-labeled, in vitro translated GAPDH (lane 1), C1D (lane 4) or MPP6 (lane 7). Co-precipitated proteins were analyzed by SDS-
PAGE and autoradiography. The positions of these proteins are indicated with arrows and the positions of molecular weight markers 
are indicated on the left. Lanes 3, 6 and 9 show proteins co-precipitated with His-PM/Scl-100. In lanes 2, 5 and 8 material from control 
incubations, in which no recombinant His-PM/Scl-100 was added, was analysed. 
C) Glutathione-Sepharose beads were used to precipitate GST (lane 2), GST-C1D (lane 3) or GST-MPP6 (lane 4), which were 
incubated with 35S-labeled, in vitro translated PM/Scl-100. After precipitation, bound PM/Scl-100 was analyzed by SDS-PAGE and 
autoradiography. In lane 1 10% of the amount of labeled PM/Scl-100 used per incubation was loaded. On the left the positions of 
molecular weight markers are indicated. 
D) Similar experiments as described in C, but now with 35S-labeled, in vitro translated hMtr4p instead of PM/Scl-100. 
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When both radiolabeled PM/Scl-100 and MPP6 
were incubated with GST-C1D, not only PM/Scl-
100 but also MPP6 was recovered in the precipitate 
(lane 8), demonstrating that C1D, MPP6 and 
PM/Scl-100 form a heterotrimeric complex in 
vitro. With the control, GST alone, no detectable 
interaction was observed with radiolabeled C1D, 
MPP6 or PM/Scl-100 (lane 4). 
PM/Scl-100 is required for the nucleolar 
localization of C1D 
Both MPP6 and PM/Scl-100 contain a putative 
nuclear localization signal. C1D on the other hand 
does not have such a sequence motif raising the 
question whether PM/Scl-100 and/or MPP6 is/are 
required for the nuclear localization of C1D. To 
investigate this possibility, we transfected HEp-2 
cells with a C1D-EGFP construct and after overnight 
incubation the cells were treated with siRNAs 
directed against PM/Scl-75, MPP6, and PM/Scl-
100, or a control siRNA. The reduction in protein 
levels was monitored by western blotting, which 
confirmed the efficiency of the siRNAs used (Fig. 
4A). The results shown in Figure 4B demonstrate 
that upon knock-down of PM/Scl-100 the nucleolar 
accumulation of C1D is abrogated, whereas its 
localization was not affected upon knock-down of 
PM/Scl-75 or MPP6. Also when the HEp-2 cells 
were transfected with the control siRNA, no change 
in the localization of C1D was observed. Although 
these results suggest that PM/Scl-100 is required for 
nucleolar localization of C1D, it is also possible that 
PM/Scl-100 knock-down reduced the stability of 
C1D-EGFP which might result in a cleaved EGFP 
fragment and the fluorescence pattern as observed 
in Figure 4B, panel PM/Scl-100 siRNA. To rule out 
the latter possibility, cell extracts of the transfected 
HEp-2 cells were analyzed by western blotting 
using anti-EGFP antibodies. The results shown in 
Figure 4C demonstrate that knock-down of PM/
Scl-100 did neither result in the detection of EGFP-
containing degradation products nor in a significant 
change of the amount of full-length C1D-EGFP. In 
this regard, it is also important to note that knock-
down of PM/Scl-100 did not result in co-depletion 
of other exosome components, such as hRrp4p, 
hRrp41p, hRrp46p or PM/Scl-75. Taken together, 
these data show that the nucleolar accumulation of 
C1D is depending on its interaction with PM/Scl-
100. Knock-down of exosome components PM/Scl-
75 or PM/Scl-100 had no effect on the subcellular 
localization of hMtr4p and MPP6 in similar 
experiments (data not shown).
C1D and hMtr4p are required for the maturation 
of the 5.8S rRNA
The nucleolar accumulation of both C1D and 
hMtr4p, as well as their association with the 
exosome suggested that both proteins might play 
Figure 3. C1D, MPP6 and PM/Scl-100 form a trimeric 
complex in vitro.
GST-tagged C1D was incubated with either 35S-labeled, in vitro 
translated C1D (lane 5), MPP6 (lane 6), PM/Scl-100 (lane 7) 
or MPP6 and PM/Scl-100 (lane 8). As a control GST alone 
was incubated with all three labeled proteins (lane 4). After 
incubation, GST(-C1D)-containing complexes were precipitated 
with glutathione-Sepharose beads and analyzed by SDS-PAGE 
and autoradiography. In lanes 1-3, the in vitro translated C1D, 
MPP6 and PM/Scl-100 proteins were analyzed. 
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a role in the processing of pre-rRNAs. In yeast, it 
has been demonstrated that the maturation of the 3’ 
end of the 5.8S rRNA requires the exosome as well 
as several auxiliary proteins including Rrp47p and 
Mtr4p (9;26;30). Recently, we demonstrated that the 
exosome and MPP6 are involved in this process in 
human cells (2).
To investigate the involvement of C1D and hMtr4p 
in pre-rRNA processing, RNAi experiments were 
performed by transfection of HEp-2 cells with 
siRNAs directed against PM/Scl-100, MPP6, 
hMtr4p or C1D. Two days later RNA was isolated 
and analyzed by northern blot hybridization using 
a radiolabeled probe specific for the 5.8S rRNA 
(Fig. 5, left). The results demonstrate that knock-
down of all 4 proteins leads to the accumulation 
of similar 5.8S rRNA precursors. The size of the 
faster migrating processing intermediate seemed 
to differ slightly between the RNAs from the cells 
in which these proteins were depleted. The same 
processing intermediates were detected with a probe 
specific for ITS2, which indicates that these 5.8S 
Figure 4. Nucleolar accumulation of C1D requires PM/Scl-100.
HEp-2 cells were transfected with a construct encoding C1D fused to the N-terminus of EGFP and 16 hours after transfection cells 
were treated with a control siRNA (lanes 1, 3, 5), or siRNAs targeting PM/Scl-75 (lane 2), MPP6 (lane 4) or PM/Scl-100 (lane 6). A) 
After 24 hours cells were harvested and total cell extracts were analyzed by western blotting using a polyclonal anti-PM/Scl-75 serum 
(lanes 1-2), a polyclonal anti-MPP6 serum (lanes 3-4), and a polyclonal anti-PM/Scl-100 serum (lanes 5-6). A mouse monoclonal 
antibody to gamma tubulin was used as a control. B) Twenty four hours after siRNA treatment cells were fixed and the expressed 
C1D-EGFP fusion protein was visualized by fluorescence microscopy. Panel control siRNA, cells treated with a control siRNA; panel 
PM/Scl-75 siRNA, cells treated with the siRNA targeting PM/Scl-75; panel MPP6 siRNA, cells treated with the siRNA targeting 
MPP6; panel PM/Scl-100 siRNA, cells treated with the siRNA targeting PM/Scl-100. C) To investigate the integrity of the C1D-EGFP 
fusion protein upon PM/Scl-100 siRNA-mediated knock-down, extracts were prepared from the transfected HEp-2 cells and analysed 
by western blotting using a polyclonal anti-EGFP antiserum. A mouse monoclonal antibody directed against gamma tubulin was used 
as a control.
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rRNA precursors are extended at their 3’ end (Fig. 5, 
upper right). Probing for other ribosomal processing 
intermediates such as 5’ ETS fragments did not 
result in detectable accumulation of processing 
intermediates corresponding to this part of the 
primary transcript (data not shown). 
C1D is an RNA-binding protein 
The results of the experiments described above 
demonstrate that the exosome together with MPP6, 
C1D and hMtr4p forms a multi-subunit complex 
involved in the 3’-5’ processing of nucleolar and 
possibly also nuclear RNA. This raises the question 
how these different components cooperate in this 
process. MPP6 has been shown to contain RNA-
binding activity with preference for pyrimidine-rich 
sequences, which is predicted to be involved for the 
recruitment of the exosome to RNA substrates (2). 
The Mtr4p protein is a putative RNA helicase which 
is most likely required for resolving secondary 
structures that inhibit nucleolytic processing by the 
exosome (30). The C1D protein has been reported 
to be a member of the family of non-histone 
polypeptides involved in higher order chromatin 
folding (28), of which some have been found to be 
associated with highly repetitive DNA sequences 
(34). We conducted GST pull-down experiments to 
investigate whether C1D is also able to bind to RNA. 
GST-C1D was immobilized using glutathione-
Sepharose beads, incubated with different 32P-
Figure 5. Knock-down of hMtr4p and 
C1D leads to the accumulation of 5.8S 
rRNA precursors.
HEp-2 cells were transiently transfected 
with siRNAs directed to PM/Scl-100 
(lane 2), MPP6 (lane 3), hMtr4p (lane 
4), C1D (lane 5) or with a control siRNA 
(lane 1). Cells were harvested 2 days after 
transfection and 2.5 µg of total RNA was 
analysed by northern blot hybridization 
using radiolabelled probes specific for 
5.8S rRNA (left) or ITS-2 (upper right). 
As a control, a U6 snRNA probe was used 
(lower right). The positions of the 5.8S 
rRNA precursors are indicated by arrows 
and the position of mature 5.8S rRNA is 
indicated with an asterisk.
Figure 6. C1D binds RNA in vitro.
GST and GST-C1D were incubated with radiolabeled 
homopolynucleotides and bound RNAs were quantified 
in a scintillation counter. The binding efficiency of GST 
and GST-MPP6 to poly(A), poly(C), poly(G), poly(U) 
and poly(I)–poly(C) is depicted as a percentage of input 
RNA (RBE: relative binding efficiency). These results are 
the average values of two independent experiments.
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labeled homopolynucleotides and the bound RNAs 
were quantified in a scintillation counter. The results 
in Figure 6 show that GST-C1D binds efficiently 
to poly(G), whereas no binding to poly(A), 
poly(C), poly(U) or poly(I)–poly(C) was observed. 
Additional experiments showed that C1D indeed 
binds to G-rich RNAs such as the ITS-1, but also 
to tRNAs, which lack G-rich sequences suggesting 
that the structure of the RNA may be important for 
C1D binding as well (data not shown).
Discussion
Although, the molecular mechanisms by which the 
exosome is recruited to different RNA substrates 
is poorly understood, it is believed that in most 
cases auxiliary proteins are involved. Also the 
processing or degradation of RNAs by the exosome 
may require additional proteins, such as helicases 
to resolve stable structures in the substrates. Here, 
we report the characterization of the association 
of the human C1D and hMtr4p proteins with 
the exosome and their involvement in pre-rRNA 
processing. Our data demonstrate that both C1D and 
hMtr4p accumulate in the nucleus with the highest 
concentrations found in the nucleoli. In addition, 
the results of our experiments provide insight into 
the way these proteins associate with the exosome. 
hMtr4p interacts with MPP6, which in turn binds to 
PM/Scl-100, C1D appeared to bind directly to PM/
Scl-100. The binding of MPP6 and C1D to PM/Scl-
100 is not mutually exclusive. The involvement of 
hMtr4p, MPP6 and C1D with exosome–mediated 
processing of pre-rRNA may be explained by the 
putative RNA helicase activity of hMtr4p and the 
RNA-binding capacity of MPP6 and C1D. 
Identification of C1D and hMtr4p as auxiliary 
proteins for the human exosome 
Strong support for the association of hMtr4p with 
the human exosome was already obtained several 
years ago by the co-purification of this protein 
with the TAP-tagged exosome complex from 
human cells (31). The exosome association of C1D 
was predicted based upon the interaction of its 
yeast counterpart Rrp47p with the yeast exosome 
(26;35). The relatively low level of co-precipitation 
of hRrp4p with EGFP-C1D in comparison with 
PM/Scl-100 (Fig. 2A) suggests that C1D is 
preferentially associated with exosome complexes 
containing PM/Scl-100. This is further supported by 
the direct interaction between C1D and PM/Scl-100 
in both GST pull-down experiments. Moreover, in 
a mammalian two-hybrid system C1D interacted 
with PM/Scl-100, but failed to interact with all other 
exosome subunits (data not shown). The binding of 
MPP6 to both hMtr4p and PM/Scl-100 is consistent 
with previously published yeast two-hybrid data 
(5). In combination with the observation that C1D 
and MPP6 can bind simultaneously to PM/Scl-
100, these data strongly suggest that the complex 
of C1D, MPP6 and PM/Scl-100 interacts with the 
exosome by virtue of the binding of PM/Scl-100 
with the exosome. In this model, hMtr4p associates 
via its interaction with MPP6, although we have 
not yet succeeded to demonstrate the simultaneous 
binding of PM/Scl-100 and hMtr4p to MPP6. In 
agreement with this mode of assembly, the depletion 
of C1D or MPP6 did not interfere with the ability 
of PM/Scl-100 to interact with the core exosome, 
as monitored by hRrp4p co-immunoprecipitation 
(data not shown). The PM/Scl-100 protein is a 
putative 3’-5’ exoribonuclease with a conserved 
RNase D and HRDC (helicase and RNase D C-
terminal) domain (36). Although, no known protein 
motifs can be identified in the primary structure of 
C1D, the protein was proposed to bind to the 3’-
overhanging ends of DNA during repair (28;29). 
Here, we demonstrate that the nucleic acid binding 
capacity of C1D is not restricted to DNA, but that it 
also efficiently binds to structured RNAs including 
poly(G). Interestingly, we recently reported that 
74 75
Chapter 4 - C1D and hMtr4p are exosome-associated proteins
MPP6 is also a RNA-binding protein, which 
preferentially binds to pyrimidine homopolymers 
(2). Thus, various RNA-binding specificities are 
associated with the exosome via PM/Scl-100 and 
therefore it will be interesting to investigate whether 
these contribute to the selectivity of PM/Scl-100 
and/or the exosome for substrate RNAs. 
PM/Scl-100 is required for the nucleolar 
accumulation of C1D 
Nuclear entry of exosome-associated proteins 
may be facilitated by protein-protein interactions 
occurring in the cytoplasm and may proceed via a 
piggy-back mechanism. Knock-down of exosome 
components or one of the auxiliary proteins did not 
affect the subcellular localization of hMtr4p and 
MPP6 (data not shown). Thus, these proteins seem 
to be capable to enter the nucleus independently of 
their association with components of the exosome. 
Knock-down of PM/Scl-100, on the other hand, led 
to reduced expression levels of C1D and abrogated 
the nucleolar accumulation of C1D. The PM/Scl-
100 protein contains a putative nuclear localization 
signal (NLS; aa 752-758, AKKRERA). Since C1D 
binds very efficiently to PM/Scl-100, it is likely 
that C1D is dependent on PM/Scl-100 to enter the 
nuclei and to accumulate in the nucleoli. The MPP6 
protein binds less efficiently to PM/Scl-100 in vitro 
and appears to enter the nucleus independently 
of PM/Scl-100, which might mediated by the 
putative bipartite NLS (aa 116–132) in MPP6. 
Taken together, these data suggest that the identified 
exosome associated proteins are transported to the 
nuclei via distinct mechanisms. 
5.8S rRNA processing requires multiple human 
exosome auxiliary proteins
In yeast, the exosome was initially identified 
as a complex required for the exonucleolytic 3’ 
end maturation of the 5.8S rRNA (22). Later, 
it became evident that even for this relatively 
simple processing step the core exosome requires 
additional protein factors, such as Rrp6p, Rrp47p 
and Mtr4p (9;19;26;30). Here we have shown that 
besides the core exosome and PM/Scl-100 at least 
three additional proteins, C1D, MPP6 and hMtr4p 
are involved in 5.8S rRNA maturation in human 
cells. In yeast, the depletion of core exosome 
components, Rrp6p, Rrp47p or Mtr4p result in the 
accumulation of different 5.8S rRNA processing 
intermediates (18;19;26;30). In the human 
system no major differences in the accumulation 
of 5.8S rRNA precursors were observed after 
knock-down of PM/Scl-100, C1D and hMtr4p. 
Previously, accumulation of similar precursors 
was also observed after depletion of hRrp41p and 
the exosome associated protein MPP6 (2). The 
observed differences between the yeast and human 
systems may be explained by the depletion of the 
whole exosome from the site of processing upon 
knock-down of auxiliary proteins of the exosome in 
the human system. 
Besides rRNA processing yeast Rrp47p and 
Mtr4p were shown to be involved in the 3’ end 
processing of many small nuclear and nucleolar 
RNAs (9;21;25;26;30;37;38). Although we have 
extensively investigated whether similar defects 
in 3’ end processing of such sn(o)RNAs upon 
knock-down of MPP6, C1D or hMtr4p occur in 
human cells, we failed to detect any accumulating 
precursors. In yeast, it has been shown that for 
several exosome substrates, such as the U4 and 
U5 snRNA, other 3’-5’ exoribonucleases can be 
involved in the 3’ end maturation of these RNAs 
as well (39). Currently, it is unknown whether the 
failure to detect such processing intermediates in 
human cells is due to processing factor redundancy 
or to the low abundance of sn(o) RNA precursors in 
these cells. 
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Introduction
The human exosome is a complex consisting of 
nine core components. Six of these, hRrp41p, 
hRrp42p, OIP2, PM/Scl-75, hRrp46p, and hMtr3p, 
are homologous to bacterial RNase PH, which is 
a phosphorolytic 3’-5’ exoribonuclease. The three 
remaining exosome subunits, hCsl4p, hRrp4p, 
and hRrp40p, contain S1 and/or KH domains and 
are believed to bind RNA (1). Based on 2-hybrid 
interactions and the crystal structure of the complex 
reconstituted by these nine components it was found 
that the six RNase PH-type subunits form a ring-
structure, which is stabilized by with the binding of 
the S1 proteins which are located at one side of the 
ring structure (2-5). Interestingly, the yeast exosome 
contains an additional exosome subunit, Dis3p, 
which is reported to be the only catalytically active 
exoribonuclease of the yeast exosome complex (4;6-
8). In human cells, hDis3p has never been found to 
be associated with exosome complexes and the 
catalytic activity has been reported to be restricted to 
hRrp41p-PM/Scl-75 (4;9). Another stably exosome-
associated protein is PM/Scl-100 (Rrp6p in yeast), 
which shares sequence similarity to RNase D. 
Rrp6 is associated with nuclear exosomes in yeast, 
whereas in human cells PM/Scl-100 appears to be 
also present in the cytoplasm (10-12).
The exosome has been demonstrated to be required 
for a variety of processes including the 3’-end 
processing of nuclear RNAs such as the 5.8S 
ribosomal RNA and small nucle(ol)ar RNAs, as 
well as the degradation of aberrant rRNAs, tRNAs 
and pre-mRNAs in the nucleus, whereas in the 
cytoplasm the exosome is implicated in the decay of 
mRNAs (reviewed in (13))
Until recently, it was assumed that the 3’-end of 
a substrate RNA provides the entry site for the 
exosome, and that degradation proceeds to the 
mature 3’-end of the substrate or to the end of the 
RNA in the case of a degradative pathway. However, 
recent studies have shown that exosome-dependent 
degradation of hypomodified tRNA precursors in 
yeast is enhanced by polyadenylation of the target 
RNA by the nuclear poly(A) polymerase, Trf4p 
(14-16). 
Further studies have shown that Trf4p is present in a 
complex containing also the putative RNA binding 
proteins Air1/2p, and the RNA helicase Mtr4p. 
This complex, termed the TRAMP (Trf4p-Air1/2p-
Mtr4p polyadenylation)-complex, was shown to 
stimulate the degradative activities of the exosome 
in vitro (17). Additional analyses have identified 
several RNA substrates of the TRAMP complex 
The human exosome is a complex containing 3’-5’ exoribonuclease activity, which participates in RNA 
maturation as well as RNA surveillance pathways. RNA degradation by the exosome requires auxiliary 
proteins to mediate exosome recruitment to substrate RNAs and to regulate or stimulate its activity. 
Recently, it has been shown in yeast that the nuclear poly(A) polymerase Trf4p is involved in exosome 
mediated degradation of several classes of nuclear RNAs by polyadenylation of the RNA substrates. Here 
we report the cloning and characterization of a putative human homologue of Trf4p termed hTrf4-2p. 
We show that hTrf4-2p is a nuclear protein of 75 kDa, which is associated with a subset of exosome 
complexes. Consistent with this observation, glycerol gradient sedimentation experiments revealed that 
hTrf4-2p co-sediments with the exosome at approximately 10S and 60-80S. Knock-down of hTrf4-2p 
by RNAi resulted in reduced activity of the exosome immunoaffinity-purified from siRNA treated cells. 
Taken together, the exosome-associated hTrf4-2p protein appears to be required for optimal exosome 
activity in vitro strongly suggesting that hTrf4-2p is a human orthologue of Trf4p. 
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in vivo, including (aberrant) snoRNAs precursors 
and processing intermediates (17;18), cryptic 
transcripts generated by RNA polymerase II (19), 
and ribosomal RNA precursors (20). Interestingly, 
pre-ribosomes which are unable to enter the 
cytoplasm were found to be polyadenylated and 
become concentrated in subnucleolar foci, together 
with exosome and TRAMP components (21). 
Besides Trf4p another poly(A) polymerase, Trf5p, 
was shown to form a complex with Mtr4p and 
Air1p, which is designated TRAMP5-complex, and 
was shown to be functionally related to the Trf4p-
containing TRAMP-complex (18;20). 
Although poly(A)-tails were believed to be 
mainly important for the stability of the RNA, the 
identification of the TRAMP complex in yeast has 
shown that poly(A) tails can also stimulate RNA 
decay by the exosome in several surveillance and 
processing pathways. In human cells, so far only 
one report has shown that heteropolymeric poly(A)-
rich sequences can be added to different rRNAs 
(22). However, the enzyme(s) responsible for the 
generation of these tails have not been identified 
yet. 
To address the potential involvement of an RNA 
tailing enzyme in exosome-mediated RNA decay in 
human cells, we decided to clone and characterize 
human homologues of the yeast Trf4/5p proteins. 
The results of our analyses indicate that one of 
these proteins, termed hTrf4-2p, is associated with 
the exosome and is required for optimal exosome 
activity. 
Materials and methods
Bioinformatics
Prediction of functional domains was done using 
the Pfam database of Hidden Markov Models (23). 
Sequence database searching was performed by 
BLAST using GenBank databases containing either 
ESTs or genomic sequence information. 
cDNA cloning of hTrf4-2p
Database searches resulted in the identification of 
a cDNA sequence encoding the complete human 
hTrf4-2p protein of which the amino acid sequence 
shared a significant sequence homology with 
the yeast Trf4p protein. The 3’ part of the hTrf4-
2p ORF was cloned by a PCR approach from a 
teratocarcinoma cDNA library using primers Trf4-
2-Fo3: 5’-CGGATCCAGAATTCAGTGAAGC
AGGCCTTTGATATGCA-3’, containing besides 
BamHI and EcoRI sites a StuI site of the hTrf4-2p 
sequence and Trf4-2-Re: 5’- GGTCGACTTAGG
TACCTCTACAGAGGTCTGAGAGGGGC -3’, 
introducing a KpnI site directly upstream of the 
stopcodon and a SalI site immediately downstream 
of the stopcodon. The remaining part of the hTrf4-
2p ORF was isolated by PCR from HEp-2 cDNA 
using oligonucleotides Trf4-2-Fo: 5’-CGGATCCA
GAATTCGATGTATCGCTCCGGGGAGCGCC-
3’, introducing BamHI and EcoRI restriction sites 
upstream of the startcodon, and Trf4-2-Re3: 5’- G
TCGACGGTACCGCATAATCAAAGGCCTGCTT
CACT-3’, containing the hTrf4-2p StuI site and in 
addition KpnI and SalI sites downstream the hTrf4-
2p sequence. The PCR products were cloned in the 
pCR4-TOPO vector (pCR4-hTrf4-2p-3’ and pCR4-
hTrf4-2p-5’, respectively). A full-length hTrf4-2p 
cDNA clone was generated by inserting the StuI-
KpnI fragment of pCR4-Trf4-2p-3’ into the StuI and 
KpnI digested pCR4-hTrf4-2p-5’ plasmid. 
In vitro transcription and translation
The open reading frame of hTrf4-2p was cloned 
into the pCI-neo vector (Promega), in frame with a 
vesicular stomatitis virus G epitope coding sequence 
(VSV-G tag). The resulting pCI-neo-5’ VSV-hTrf4-
2p construct was transcribed and translated in the 
presence of 35S-methionine using the TnT coupled 
transcription/translation kit (Promega).
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Transient transfection of COS-1 cells and 
fluorescence microscopy
The cDNA of hTrf4-2p was cloned into the pEGFP-
C1 (Clontech) resulting in a pEGFP-hTrf4-2p 
construct. COS-1 cells were grown to 70% confluency 
in DMEM containing 10% fetal calf serum (FCS) 
(DMEM+). For fluorescence microscopy approx. 3 
x 106 cells were transfected with 10 µg of pEGFP-
hTr4-2 plasmid DNA in 800 µl of ice-cold PBS 
by electroporation as described above. The cells 
were seeded on coverslips and cultured overnight. 
Subsequently, the cells were washed twice with 
PBS and fixed with 4% paraformaldehyde in PBS 
for 20 min. After fixation, cells were washed three 
times with PBS and mounted with 50% glycerol in 
PBS. The EGFP-fusion proteins were visualized by 
fluorescence microscopy using an Olympus BH2 
microscope. For immunoprecipitation and glycerol 
gradient sedimentation analysis, approx. 10 x 106 
cells were transfected with 30 µg of pCI-neo-
5’VSV-hTrf4-2p plasmid DNA in 1600 µl of ice-
cold PBS by electroporation at 300 V and 125 µF 
using a Gene-Pulsar II (Bio-Rad). After transfection, 
cells were seeded in 75-cm2 culture flasks and 
cultured overnight in DMEM+. The trypsinized 
cells were washed with PBS, resuspended in 750 µl 
of lysis buffer (25 mM Tris-HCl, pH 7.5, 150 mM 
KCl, 2 mM EDTA, 1 mM dithiotreitol (DTT), 0.5 
mM phenylmethylsulfonyl fluoride (PMSF) and 
0.05% Nonidet P-40 (NP-40)) and homogenized by 
sonication using a Branson micro-tip. 
Glycerol gradient sedimentation 
COS-1 cell extracts were prepared from cells 
transiently transfected with either 5’VSV-PM/
Scl-75 or 5’VSV-hTrf4-2p and loaded on 5-40% 
(v/v) glycerol gradients prepared in gradient buffer 
(25 mM Tris-HCl, pH 7.5, 150 mM KCl, 1 mM 
dithiothreitol, 0.02% Triton X-100). Gradients 
were centrifuged in a TH641 rotor (Sorvall) for 
16 h at 25,000 rpm at 4 °C and subsequently 23 
fractions per gradient were collected. The proteins 
in these fractions were separated by SDS-PAGE and 
transferred to nitrocellulose membranes for western 
blot analysis. 
Immunoprecipitations
Anti-VSV mouse monoclonal antibodies were 
coupled to protein-G agarose beads (Pierce) in 
IPP500 (500 mM NaCl, 10 mM Tris-HCl, pH 
8.0, 0.05% NP-40) by incubation for 1 h at room 
temperature. Beads were washed once with with 
IPP500, and twice with IPP150 (composition similar 
to IPP500, but containing 150 mM NaCl instead of 
500 mM). For each immunoprecipitation, cell extract 
was incubated with the antibody-coupled beads for 
2 h at 4o C. Subsequently, beads were washed four 
times with IPP150, and co-immunoprecipitated 
proteins were analyzed by western blot analysis. 
Western blot analysis
For western blot analysis, proteins were separated 
by SDS-PAGE, and transferred to nitrocellulose 
membranes. In order to visualize the proteins, 
blots were incubated with 500-fold diluted rabbit 
sera in blocking buffer (5% skimmed milk, PBS, 
0.05% NP-40). As secondary antibody, horseradish 
peroxidase-conjugated swine anti-rabbit IgG (Dako 
Immunoglobulins) was used, 2500-fold diluted in 
blocking buffer. Bound antibodies were visualized 
by chemiluminescence. 
Exoribonuclease activity assay
Immunoprecipitated complexes (bound to the 
beads) were washed once with buffer A (10 mM 
Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl
2 
, 1 
mM Na
2
HPO
4, 
0.5 mM MnCl
2
, 0.5 mM DTT). 
Substrate solution (approx. 100 ng of 32P-labeled 
RNA substrate in 40 µl of buffer A, containing 1 
mM of NTPs) was added to the protein G beads, and 
the suspension was incubated at 37 °C. Formamide 
loading buffer was added to 10 µl samples taken 
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at regular timepoints, heated for 2 minutes at 70 
°C and placed on ice. Samples were analyzed by 
denaturing polyacrylamide gel electrophoresis 
followed by autoradiography. One RNA substrate 
consisted of a human 5.8S rRNA containing in 
addition 50 nts of the ITS2 (internal transcribed 
spacer 2) at the 3’-end. This substrate was generated 
by linearizing a corresponding plasmid construct 
with BamHI followed by in vitro transcription 
using T7 RNA polymerase. Another RNA substrate 
of 37 nts was transcribed in vitro using T3 RNA 
polymerase and XbaI-linearized pBS(-) plasmid as 
template (Stratagene). Both RNA substrates were 
radiolabeled using [32P] UTP (Amersham Pharmacia 
Biotech). 
RNA interference 
An siRNA duplex (containing 3’ dTdT overhangs) 
was generated based upon the coding region of the 
human hTrf4-2p sequence described above: siTrf4-
2, 5’- UGGCAGUCAGUUUCCUUCAdTdT-3’. 
The siRNA for human PM/Scl-100 was identical 
to that described previously by LeJeune and 
collaborators (11). Approximately 3 x 105 HEp-2 
cells were transfected with 100 pmol of siRNA using 
Oligofectamine transfection reagent (Invitrogen), as 
described by the manufacturer with the exception 
that during transfection 10% FCS was present in the 
medium. 
Results
Identification and cloning of a cDNA encoding 
hTrf4-2p
Database searches using the yeast Trf4p and Trf5p 
amino acid sequences revealed a number of EST 
sequences from different organisms that shared 
a high degree of sequence homology including 
several human sequences encoding two different 
proteins which were previously designated hTrf4-
1p (GenBank acc. nr. AAH84567) encoded by 
an open reading frame of 542 amino acids, and 
hTrf4-2p (GenBank acc. nr. NP_001035374) 
encoded by an open reading frame of 489 amino 
acids (24). The latter appeared to be incomplete 
since screening of human EST databases revealed 
several sequences that correspond to a hTrf4-2p 
polypeptide containing 142 additional amino acids 
at the N-terminus (GenBank acc. nr. DB452779) 
resulting in an open reading frame of 631 amino 
acids. For the cDNAs of both hTrf4-1p and 
hTrf4-2p no in-frame stop codons were present 
in the sequences directly upstream of the putative 
translational start codon. However, additional 
screenings of human EST databases did not result 
in longer open reading frames suggesting that these 
cDNAs encode the complete human homologues 
of Trf4/5p. A multiple sequence alignment of these 
sequences as well as the yeast Trf4p and Trf5p 
sequences is shown in Figure 1. Further analysis 
of the sequences by pattern and profile searches 
revealed a highly conserved NTP transferase and 
PAP-associated domain, which are present in the 
central region of both hTrf4-1p and hTrf4-2p. A 
putative nuclear localization signal was identified in 
the C-terminal part of these proteins. Nevertheless, 
the sequence comparison did not allow conclusions 
on the mutual relationship between hTrf4-1p or 
hTrf4-2p and the yeast Trf4p or Trf5p proteins, due 
to low sequence conservation outside the conserved 
NTP transferase and poly(A) polymerase (PAP) 
associated domains (see Fig. 1). Several attempts 
to obtain a cDNA clone corresponding to hTrf4-
1p using various cDNA libraries failed. However, 
a cDNA fragment corresponding to the C-terminal 
region of hTrf4-2p was isolated by a PCR approach 
from a teratocarcinoma cDNA library; the remaining 
5’ region of the hTrf4-2p sequence was isolated 
from a HEp-2 cDNA preparation. The hTrf4-2p 
DNA fragments were subsequently combined in a 
single construct to obtain a full-length cDNA (see 
Materials & Methods).
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Figure 1. Sequence alignment of Trf4p, Trf5p and their human homologs
Amino acid sequences encoding Saccharomyces cerevisiae (sc) Trf4p and Trf5p and Homo sapiens (hs) hTrf4-1p and hTrf4-2p were 
aligned using ClustalW and conserved amino acids were highlighted by Boxshade. Identical amino acids in at least three of the 
sequences are marked by black boxes and similar amino acids are marked by gray boxes. The conserved NTP-transferase and PAP 
(poly(A)polymerase) associated domain are underlined by solid and dotted lines, respectively. The putative NLS is also underlined.
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The hTrf4-2p protein accumulates in the 
nucleoplasm
The human hTrf4-2p protein has a calculated 
molecular mass of 69.5 kDa and a predicted 
isoelectric point of 8.9. Expression of the N-
terminally VSV-tagged hTrf4-2p cDNA in an in vitro 
translation system resulted in a protein migrating at 
approximately 75 kDa in SDS-PAGE. Some minor 
translation products, migrating at 60-70 kDa and 35-
37 kDa were observed as well. These are probably 
due to either internal initiation of translation, which 
is known to occur relatively frequently in such in 
vitro translation systems, or to partial degradation 
of the full-length polypeptide (Fig. 2A, lane 1). As 
a control the PM/Scl-100 was translated in parallel, 
which, as expected, resulted in a protein migrating 
at 100 kDa. Also in this case some minor translation 
products observed (Fig. 2A, lane 2). To investigate 
the subcellular localization of hTrf4-2p, COS-1 cells 
were transiently transfected with a construct coding 
for the EGFP-hTrf4-2p fusion protein and EGFP 
alone as a control. 
To be able to compare the localization with that of the 
exosome, an EGFP-hMtr3p encoding construct was 
used.The sub-cellular localization of these proteins 
was determined by fluorescence microscopy 24 hrs 
after transfection. As shown in Figure 2B, EGFP-
hTrf4-2p was found in the nucleoplasm, whereas 
no staining was observed in either cytoplasm or 
nucleoli. Localization experiments using a construct 
in which the EGFP-protein was fused to the C-
terminus of hTrf4-2p (hTrf4-2p-EGFP) showed a 
similar subcellular distribution (data not shown). 
The EGFP-tagged exosome core component, 
EGFP-hMtr3p, accumulated in the nucleolus as 
well as the nucleoplasm of the cell, as has been 
reported previously for other exosome components, 
whereas EGFP was, as expected, found throughout 
the cytoplasm and nucleus of the cell. Although, 
we can not completely exclude the possibility that 
the EGFP-tag affects the subcellular localization 
of hTrf4-2p, our data suggest that the subcellular 
localization of hTrf4-2p only partially overlaps with 
that of exosome complexes.
hTrf4-2p is associated with the exosome 
To investigate whether hTrf4-2p is associated with 
the exosome, immunoprecipitations with anti-VSV-
tag antibodies were performed with lysates from 
COS-1 cells transfected with constructs encoding 
VSV-tagged hTrf4-2p, VSV-tagged PM/Scl-75, or 
a construct containing only the VSV-tag sequence 
as a negative control. Co-precipitated material was 
analyzed by western blotting using a rabbit serum 
directed against the exosome core component 
hRrp41p. As expected, hRrp41p was co-precipitated 
with the VSV-PM/Scl-75 protein (Fig. 3, lanes 
4-5). Interestingly, hRrp41p also appeared to be 
stably associated with VSV-hTrf4-2p, which was 
substantiated by the observation that washing with a 
buffer containing 500 mM NaCl did not abrogate the 
interaction (lanes 6-7). The efficiency of hRrp41p 
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Figure 2. The hTrf4-2p ORF encodes 
a nuclear protein of 75 kDa
A) In vitro translated, 35S labeled 
hTrf4-2p (lane 1) and PM/Scl-100 
(lane 2) were separated by SDS-PAGE 
and analyzed by autoradiography. The 
position of molecular weight markers 
is indicated on the left. 
B) COS-1 cells were transfected with 
constructs encoding EGFP alone 
(left), EGFP-hTrf4-2p (middle) and 
EGFP-hMtr3p (right). After 24 hours 
the cells were fixed and the expressed 
(fusion) proteins were analyzed by 
fluorescence microscopy. 
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co-precipitation appeared to be slightly lower than 
that observed with VSV-PM/Scl-75, which may be 
related to the association of hTrf4-2p with only a 
subset of exosome complexes. With lysates from the 
VSV-control transfected cells no co-precipitation of 
hRrp41p was detected (lanes 2-3). 
hTrf4-2p co-sediments with exosome complexes 
in glycerol gradients
Nuclear exosome components were previously 
shown to be associated with both 10S and 60-80S 
complexes (7;10;12). To obtain more insight in the 
(subset of) exosome complexes containing hTrf4-
2p, lysates of COS-1 cells expressing VSV-tagged 
hTrf4-2p or PM/Scl-75 were fractionated by glycerol 
gradient sedimentation. Fractions were analysed by 
western blotting using a monoclonal anti-VSV 
antibody, or a rabbit anti-hRrp40p serum. Agarose 
gel electrophoresis of deproteinized fractions was 
performed to monitor the distribution of marker 
RNAs, which were detected either by ethidium 
bromide staining or by northern blot hybridization. 
The U1 snRNA was used as a marker for 12S 
complexes, whereas the large rRNAs were used to 
identify 40S and 60S ribosomal subunits. The results 
in Figure 4 show that the majority of VSV-hTrf4-2p 
was present in fractions 2–8. Additionally, a small 
but significant amount was found in complexes 
sedimenting faster than 60S complexes (fractions 
19-23). Interestingly, the sedimentation pattern of 
VSV-hTrf4-2p was almost indistinguishable from 
that of VSV-PM/Scl-75. Exosome core component 
hRrp40p was found in similar fractions although the 
relative amount of hRrp40p in the 60-80S fractions is 
higher in comparison with VSV-hTrf4-2p and VSV-
PM/Scl-75. This might be due to overexpression of 
Figure 3. Interaction of hTrf4-2p with the human exosome 
Co-immunoprecipitations were performed with anti-VSV-tag 
antibodies using extracts of COS-1 cells transiently transfected 
with either VSV alone (lanes 2-3), VSV-PM/Scl-75 (lanes 4-5) or 
VSV-hTrf4-2p (lanes 6-7). Above the figure it is indicated if the 
proteins were precipitated in the presence of 150 mM (lanes 2, 
4 and 6) or 500 mM of NaCl (lanes 3, 5 and 7). In the first lane, 
a total extract from COS-1 cells was separated. The precipitated 
proteins were analyzed by western blotting, using anti-hRrp41p 
antibodies. The arrow on the right indicates the position of 
hRrp41p, whereas the positions of molecular weight markers are 
indicated on the left. 
hRrp40p
VSV-PM/Scl-75
VSV-hTrf4-2p
i 1 5 10 15 20 23
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5%
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Figure 4. Co-sedimentation of hTrf4-2p with exosome complexes in glycerol gradients. 
Extracts from COS-1 cells transiently expressing VSV-hTrf4-2p or VSV-PM/Scl-75 were fractionated in 5-40% (v/v) glycerol 
gradients. The sedimentation of the expressed fusion proteins was determined by immunoblotting using monoclonal anti-VSV-tag 
antibodies. The sedimentation of endogenous hRrp40p was determined by anti-hRrp40p antibodies. The fractionation of the 18S and 
28S ribosomal RNAs (corresponding to 40S and 60S complexes) was monitored by agarose gel electrophoresis and ethidium bromide 
staining and used as markers in the gradient. The U1 snRNA was used as marker for 12S complexes. 
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the VSV-tagged PM/Scl-75 and hTrf4-2p proteins, 
resulting in more ‘free’ protein in the lower 
molecular weight fractions. Taken together, these 
data indicate that hTrf4-2p is associated with high 
molecular weight complexes and co-sediments with 
core exosome components, which is in agreement 
with the co-immunoprecipitation data. 
Knock-down of hTrf4-2p results in reduced 
exosome activity 
Previously, it has been demonstrated that 
the exoribonuclease activity is preserved in 
immunoaffinity-purified exosome-complexes 
(10;25). Because our co-immunoprecipitation 
experiments strongly suggest that hTrf4-2p is 
present in such samples (see Fig. 3), we investigated 
if the exosome activity in this experimental setup 
is dependent on hTrf4-2p. Immunoprecipitations 
with anti-PM/Scl-100 antibodies were performed 
using lysates of HEp-2 cells treated with siRNAs 
directed against hTrf4-2p, PM/Scl-100 and EGFP 
as a control, and the immunoprecipitated material 
was used in the in vitro exonuclease activity assay. 
As shown in Figure 5A, in comparison to the 
control (lanes 2-4) knock-down of PM/Scl-100 
resulted in less exoribonuclease activity when 
using a radiolabelled 5.8S rRNA extended by 50 
nts of ITS2 as a RNA substrate (lanes 8-10). Also 
upon knock-down of hTrf4-2p a reduction of the 
exoribonuclease activity was observed, which was 
as least as strong as that observed upon knock-down 
of PM/Scl-100 (lanes 5-7). These data suggest that 
hTrf4-2p contributes to the activity of PM/Scl-100 
containing exosome complexes. Also when another 
(unstructured) RNA substrate was used, hTrf4-2p 
appeared to be required for optimal exosome-
associated exoribonuclease activity (Fig. 5B, lane 
2).
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Figure 5. Exoribonuclease activity of exosome complexes 
upon hTrf4-2p knock-down.
A) Extracts were prepared from HEp-2 cells transfected with 
siRNAs directed against EGFP (lanes 2-4), hTrf4-2p (lanes 
5-7) and PM/Scl-100 (lanes 8-10). Immunoprecipitations of 
exosome complexes from these extracts were performed with 
anti-PM/Scl-100 antibodies and the precipitated complexes 
were analyzed for exoribonuclease activity by incubation with a 
uniformly 32P-labeled 5.8S rRNA containing 50 nts of the ITS2 at 
its 3’ end (206 nts in total) at 37 oC. Samples were taken after 30, 
60 and 90 minutes and analyzed by denaturing polyacrylamide 
gel electrophoresis followed by autoradiography. As a control 
the input RNA was incubated for 90 minutes at 37 oC (lane 1). 
The arrow indicates the full-length substrate RNA. B) Similar 
experiment as described above using a 37 nts RNA substrate, 
which was obtained by in vitro transcription of a XbaI-linearized 
pBS(-) plasmid. Substrate RNA was incubated with (lanes 2-3) or 
without (lane 1) immunoprecipitated exosome for 90 minutes at 
37 oC. The arrow indicates the full-length substrate RNA.
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Discussion
In this study we describe the cloning and 
characterization of a putative human orthologue 
of the yeast Trf4p and Trf5p proteins, which have 
been reported to be associated with a nuclear 
poly(A)polymerase complex required for activation 
of the exosome in several RNA surveillance 
pathways. The human Trf4-2 gene was found to 
encode a protein which localizes to the nucleoplasm. 
Our data also show that hTr4-2p is associated with 
the human exosome and that knock-down of this 
protein resulted in reduced exosome activity in 
vitro.
Identification of hTrf4-2p 
Our database searches with the yeast Trf4p and 
Trf5p sequences led to the identification of human 
homologues of these proteins, termed hTrf4-1p 
and hTrf4-2p. However, as a consequence of the 
relatively low level of sequence conservation outside 
the conserved NTP-transferase and PAP-associated 
domains, it was impossible to assign hTrf4-1p and 
hTrf4-2p to Trf4p and Trf5p, respectively. Several 
attempts to obtain an hTrf4-1p cDNA failed, which 
might be due to cell-type specific expression of 
this protein, since the cDNA libraries we used 
were derived from a limited number of cell-types. 
Additionally, an siRNA duplex targeting hTrf4-1p 
did neither result in a distinct phenotype nor in 
reduced exosome activity in vitro (data not shown). 
Therefore, it seems likely that the hTrf4-1p protein 
will not play a major role in exosome-related 
polyadenylation. Notably, in the yeast S. pombe 
only one orthologue of Trf4/5p has been identified 
so far (26).
Association of hTrf4-2p with the human 
exosome
In the yeast S. cerevisiae, both Trf4p and Trf5p 
have been reported to be implicated in the 
polyadenylation of nuclear RNAs, such as aberrant 
pre-rRNAs, and to localize to the nucleoplasm as 
well as the nucleoli (21;26). The results of our 
gradient sedimentation experiments suggested that 
a fraction of the hTrf4-2p protein is associated with 
pre-ribosomal 60-80S complexes. Therefore, hTrf4-
2p may be involved in the function of the exosome 
in pre-rRNA surveillance as has been reported for 
the yeast Trf4p and Trf5p proteins (15;17;20;21;26). 
However, hTrf4-2p localized exclusively to the 
nucleoplasm (Fig. 2B), and was not among the 
proteins identified by mass spectrometry of purified 
nucleoli (27). The possibility that the EGFP-tag at 
either the C- or N-terminus of the hTrf4-2p protein 
interferes with its nucleolar accumulation can not be 
excluded and antibodies will have to be generated to 
solve this issue. 
The co-precipitation of hRrp41p with VSV-hTrf4-
2p appeared to be less effective than that with VSV-
PM/Scl-75, which suggests that hTrf4-2p is only 
associated with a fraction of the exosome complexes 
present in the cell. Nevertheless, the interaction was 
stable under stringent conditions, and the gradient 
sedimentation analysis showed that hTrf4-2p co-
sedimentated with exosome complexes at 12S as 
well as 60-80S. These observations suggest that the 
requirement for hTrf4-2p might not be restricted 
to a single exosome function. Since neither the 
co-immunoprecipitation nor the density gradient 
sedimentation data demonstrate a direct interaction 
of hTrf4-2p with the exosome, the possibility 
exists that other proteins mediate their interaction. 
Consistent with an indirect interaction are the 
results of GST-pull down experiments to identify 
protein-protein interactions between hTrf4-2p and 
individual exosome core components which were 
all negative (data not shown). A protein that might 
be involved in hTrf4-2p association is the putative 
RNA helicase hMtr4p, since its yeast orthologue, 
Mtr4p, was found to co-purify with Trf4/5p. hMtr4p 
co-purified with the human exosome and was shown 
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to interact with MPP6, which in turn was found to 
interact with PM/Scl-100 (28). Therefore, it seems 
likely that the interaction of hTrf4-2p with the 
exosome is mediated by binding to hMtr4p and/or 
MPP6. 
Exosome activity upon knock-down of hTrf4-2p
The results of our exoribonuclease activity assay 
suggest that hTrf4-2p can stimulate RNA degradation 
by the exosome in vitro. This might be due to the 
putative poly(A)polymerase activity of hTrf4-2p, 
which could add a short single stranded poly(A) 
tail to the substrate RNA serving as a signal for 
exosome activation and potentially making the RNA 
a better substrate for 3’ degradation. Subsequently, 
the activated exosome could deadenylate the RNA 
and degrade the ‘stable body’ of the substrate RNA. 
Initial experiments to demonstrate that the human 
hTrf4-2p protein has RNA polymerase activity 
failed (data not shown). Surprisingly, in yeast, 
the Trf4p complex was able to stimulate in vitro 
degradation of a RNA substrate by the exosome in 
the absence of added ATP. Exosome activity was 
also only slightly reduced by catalytically inactive 
Trf4p showing that polyadenylation is not essential 
for activated degradation. Therefore, the possibility 
that human hTrf4-2p is catalytically inactive, but 
functional as a stimulator of exosome activity, can 
not be ruled out (17;19). In this scenario, hTrf4-2p 
(together with hMtr4p?) might remodel the substrate 
RNA bringing it in close proximity of the catalytic 
site of the exosome which triggers 3’ decay. 
Previous reports in yeast have shown that Trf4p 
and Trf5p function in several RNA surveillance 
and processing pathways, although it should be 
noted that most RNA substrates of Trf4/5p have 
been identified in mutant yeast strains in which such 
RNA precursors are stabilized (reviewed in (29)). 
Our preliminary experiments to detect similar RNA 
processing defects upon knock-down of hTrf4-2p in 
human cells were not successful (data not shown). 
Currently, it is unclear if the failure to detect 
processing intermediates is due to processing factor 
redundancy or due to the low abundance of RNA 
precursors in human cells. 
Taken together, the exosome-associated hTrf4-2p 
protein appears to stimulate exosome activity, most 
likely in concert with other exosome-associated 
proteins, such as RNA helicases (hMtr4p, hSki2p) 
and RNA-binding proteins (C1D, MPP6). 
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Introduction
Systemic autoimmune diseases are characterized by 
the presence of autoantibodies reactive with a wide 
variety of autoantigens. Why these autoantibodies, 
which escape the normal mechanisms ensuring self 
tolerance, are made is still not fully understood. 
However, the occurrence of modified self-antigens 
during (either apoptotic or necrotic) cell death in 
combination with a defective clearance of dead cells 
has been proposed to play a role in the development 
of autoimmunity (reviewed in (1;2)). In apoptotic 
cells many autoantigenic proteins or complexes 
can be modified by processes such as (de)-
phosphorylation, citrullination, nucleolytic cleavage 
or proteolytic cleavage by caspases (reviewed in 
(3)). The modification and redistribution of these 
proteins might generate antigenic determinants 
to which no tolerance exists, thereby eliciting a 
primary immune response. Via epitope spreading, 
the initial response, directed to the neo-epitope 
resulting from the modification, could evolve to a 
secondary response in which antibodies arise that 
are reactive with other, unmodified parts of the 
protein or with proteins that are associated with the 
modified antigen (1;4). 
Patients suffering from myositis and scleroderma 
(Scl), which is called the polymyositis/scleroderma 
overlap syndrome (PM/Scl), produce antibodies 
against a variety of autoantigens. Some of these 
are also found in patients suffering from myositis 
or scleroderma alone. Autoantibodies recognizing 
the so-called PM/Scl autoantigen are found in 
24-31% of all patients with PM/Scl (5-8), and in 
only 2-6% of patients suffering from myositis or 
scleroderma alone (7;9). Of all patients positive 
for anti-PM/Scl antibodies, between 43% and 88% 
are diagnosed with a myositis/scleroderma overlap 
syndrome (7;10). The PM/Scl autoantigen is the 
human homologue of the yeast exosome, which 
consists of at least nine core proteins, all displaying 
exoribonuclease characteristics. The exosome has 
been shown to be involved in the degradation and 
processing of many different RNA species (11;12). 
Although the nuclear exosome component PM/Scl-
100 and the two core exosome components PM/
Scl-75 and hRrp4p carry the main autoantigenic 
epitopes, autoantibodies directed to PM-Scl-75 
appear to be the most prevalent in patients with 
the polymyositis/scleroderma overlap syndrome 
(8). The cDNA-derived amino acid sequence for 
PM/Scl-75 was published in 1991 and is now 
referred to as PM/Scl-75a-α. A splicing variant of 
PM/Scl-75a containing an additional exon in the 
Recent studies have implicated the dying cell as a potential reservoir of modified autoantigens that might 
initiate and drive systemic autoimmunity in susceptible hosts. A number of subunits of the exosome, a 
complex of 3’-5’ exoribonucleases which functions in a variety of cellular processes, are recognized by 
the so-called anti-PM/Scl autoantibodies, found predominantly in patients suffering from an overlap 
syndrome of myositis and scleroderma. Here we show that one of these subunits, PM/Scl-75, is cleaved 
during apoptosis. PM/Scl-75 cleavage is inhibited by several different caspase inhibitors. The analysis 
of PM/Scl-75 cleavage by recombinant caspase proteins shows that PM/Scl-75 is efficiently cleaved 
by caspase-1, to a lesser extent by caspase-8 and relatively inefficiently by caspase-3 and caspase-7. 
Cleavage of the PM/Scl-75 protein occurs in the C-terminal part of the protein at Asp369 (IILD369↓G), 
and at least a fraction of the resulting N-terminal fragments of PM/Scl-75 remains associated with the 
exosome. Finally, the implications of PM/Scl-75 cleavage for exosome function and the generation of 
anti-PM/Scl-75 autoantibodies are discussed.
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C-terminal region of the protein is known as PM/
Scl-75a-β (13). More recently, we found that the 
PM/Scl-75a cDNA sequence is probably incomplete 
and identified a PM/Scl-75 cDNA (referred to as 
PM/Scl-75c) encoding an additional N-terminal part 
that is required for the association to the exosome 
complex (14). 
Until now, none of the subunits of the exosome 
complex had been shown to be modified during 
apoptosis, prompting us to investigate the molecular 
characteristics of exosome subunits in apoptotic 
cells. Here, we demonstrate that the PM/Scl-75 
protein is cleaved in a caspase dependent manner 
during apoptosis and that this cleavage occurs in 
the C-terminal domain of the protein at residue 
Asp369.
Materials and methods 
Cell lines
Jurkat cells (human T-cell leukemia, ATCC CRL-
2570), Peer cells (human T-cell leukemia) and 
CCRF-CEM cells (human T-cell lymphoblastic 
leukemia, ATCC CCL-119) were grown in RPMI-
1640 medium (Gibco-BRL) supplemented with 
10% heat-inactivated fetal calf serum, 1mM sodium-
pyruvate, penicillin, and streptomycin. Jurkat cells 
stably transfected with Bcl-2 (Jurkat/Bcl-2) or with 
the empty transfection vector (Jurkat/Neo) were 
cultured in the same medium with the addition of 
200 µg/ml G418 (Gibco-BRL). 
Induction of cell death
To induce apoptosis, Jurkat cells were treated with 
the agonistic anti-Fas monoclonal antibody 7C11 as 
described previously (15;16). Peer and CCRF-CEM 
cells were treated with 0.5 µg/ml actinomycin D, 
10 µg/ml anisomycin, 100 µg/ml cycloheximide or 
400 nM staurosporin. CCRF-CEM cells were also 
treated with the anti-Fas antibody. The efficiency of 
apoptosis induction was assessed by flow cytometry 
using annexin V-FITC and propidium iodide (PI) 
staining as described previously (15). After 8 h 
generally more than 90% of the cells were apoptotic. 
After harvesting the dying cells, cells were washed 
two times with PBS and used immediately or 
stored at -70º C. For experiments utilizing the 
cell-permeable tetrapeptide caspase inhibitors 
(Calbiochem), Jurkat cells were cultured for 1 h 
in the presence of 2 or 20 µM Ac-YVAD-CMK, 
Z-DEVD-FMK, Z-IETD-FMK, or Z-LEHD-FMK 
(irreversible inhibitors of caspases-1, -3/-7, -8, and 
-9, respectively) as described previously (16). The 
specificity of these inhibitors is based on in vitro 
assays with purified caspases. Their specificity in a 
cellular context is difficult to define. Subsequently, 
apoptosis was induced by the addition of anti-Fas 
monoclonal antibody followed by harvesting the 
cells after 8 h of incubation.
Western blot analysis
Cells were lysed on ice for 30 min in NP-40 lysis 
buffer (25 mM Tris-HCl, pH 7.5, 1% NP-40, 100 mM 
KCl, 10 mM MgCl
2
, 1 mM dithiothreitol (DTT)), 
containing a protease inhibitor cocktail (Complete, 
Roche). Cell lysates were centrifuged for 15 min 
at 4º C (12,000g) and the supernatants were used 
immediately or stored at -70º C. Protein extracts of 
1x106 cells were analyzed by 10% SDS-PAGE and 
western blotting using SLE patient serum Ven96 (a 
patient serum reactive with many exosome subunits, 
an anti-PM/Scl-100 rabbit serum (17) or an anti-
PM/Scl-75 rabbit or mouse serum (18), followed by 
detection via HRP-conjugated secondary antibodies 
and visualization by chemiluminescence.
Immunoprecipitation
Protein A–agarose beads (20 µl of 50% slurry) 
were coated with 20 µl of Ven96 patient serum, 
anti-hRrp46p rabbit serum(17) or anti-PM/Scl-75 
(18) rabbit serum. Incubations were performed 
overnight at 4º C in IPP500 (500 mM NaCl, 10 mM 
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Tris-HCl, pH 8.0, 0.1% NP-40) by end-over-end 
rotation. After washing the beads three times with 
IPP150 (composition like IPP500, but containing 
150 mM NaCl), the beads were incubated with 20 
µl (2x106 cell equivalents) of Jurkat extract (control 
or apoptotic) in IPP150 by end-over-end rotation for 
2 h at 4º C. After three wash steps with IPP150, the 
beads were resuspended in protein sample buffer 
and immunoprecipitated proteins analysed by SDS-
PAGE and western blotting.
Plasmids
The cDNAs of PM/Scl-75a-α (accession number 
M58460) and PM/Scl-75c-β (accession number 
AJ505989) (14) were cloned into the EcoRI and 
XbaI sites of the pCI-neo vector (Promega), 
containing an in-frame VSV-G tag at either the 5’ 
or the 3’ end of the cDNAs. For identification of the 
caspase cleavage site, mutant cDNAs of PM/Scl-75 
were generated, encoding substitution mutants in 
which one of the aspartic acids at positions 272, 
304, 307, 349, 352, 357, 358, 363, 369, 374 and 
381 were substituted by alanine. All mutants were 
generated by a megaprimed PCR-based approach 
using a PM/Scl-75 cDNA as a template and 
specific primers overlapping the regions that were 
mutated. The resulting PCR products were purified, 
and cloned into the pCR4-TOPO (Invitrogen) 
or pCI-neo vector. The integrity of the mutant 
constructs was confirmed by DNA sequencing. The 
resulting cDNAs were used as template for in vitro 
transcription/translation of the respective proteins.
In vitro cleavage assay
Proteins were generated by in vitro transcription/
translation using the TnT T7-coupled rabbit 
reticulocyte lysate system (Promega) as described 
by the manufacturer. For detection of the translation 
products, 35S-methionine was added to the 
translation reactions. In vitro translated proteins 
were incubated with 200 nM of the purified murine 
recombinant caspases in a total volume of 25 µl CFS 
buffer (220 mM mannitol, 68 mM sucrose, 2 mM 
NaCl, 2.5 mM KH
2
PO
4
, 10 mM HEPES, pH 7.4, 1 
mM aprotinin, 1 mM leupeptin, and 1 mM PMSF, 
supplemented with 10 mM DTT) for 1.5 h at 37º C. 
The resulting cleavage products were analyzed by 
10% SDS-PAGE and western blotting followed by 
autoradiography.
Results
Cleavage of PM/Scl-75 during apoptosis
To study the potential modification of human 
exosome components during apoptosis, Jurkat cells 
were treated with the agonistic anti-Fas antibody 
7C11 and cell extracts were analyzed by western 
blotting using a patient serum (Ven96) known to 
be reactive with the major autoantigenic exosome 
components PM/Scl-100, PM/Scl-75 and hRrp4p. 
The results of this analysis demonstrated that the 
intensity of the PM/Scl-75 band was strongly 
reduced after the induction of apoptosis, whereas 
the signals of PM/Scl-100 and hRrp4p were only 
slightly diminished (data not shown). To analyze 
this phenomenon in more detail, a similar blot 
was analyzed with a rabbit serum raised against 
PM/Scl-75 (Fig. 1A). The result confirmed that 
the majority of full-length PM/Scl-75 disappeared 
during apoptosis, concomitant with the appearance 
of a faster migrating polypeptide at approximately 
45 kDa (Fig. 1A, lane 3). To investigate whether 
production of this putative PM/Scl-75 cleavage 
fragment was indeed dependent on the induction of 
apoptosis, the cleavage of PM/Scl-75 was analyzed 
in anti-Fas stimulated normal Jurkat cells (Jurkat/
Neo) and Jurkat cells overexpressing Bcl-2 (Jurkat/
Bcl-2). In the Jurkat/Bcl-2 cells the induction of 
apoptosis has been demonstrated to be delayed 
considerably by preventing cytochrome c release 
and caspase activation (15). Indeed, the PM/Scl-75 
cleavage product was produced in the Jurkat/Neo 
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cells, but could not be detected in de Jurkat/Bcl-2 
cells, not even after 8 hours of anti-Fas treatment 
(Fig. 1B).
To investigate whether cleavage of PM/Scl-75 
also occurred in other cells and upon exposure 
to other apoptotic stimuli, we analyzed lysates of 
other cell lines as well as lysates from lymphocytes 
isolated from peripheral blood in which apoptosis 
had been induced in various ways. CCRF-CEM 
cells were exposed to actinomycin D, anisomycin, 
cycloheximide, staurosporin or anti-Fas antibodies 
and Peer cells were cultured in the presence of 
actinomycin D, anisomycin, cycloheximide or 
staurosporin, and after 8 hours extracts of these cells 
were analyzed by western blotting (Fig. 2). Except 
for the actinomycin D (lane 2) and cycloheximide 
treated CCRF-CEM cells (lane 4), a reduction of the 
full-length PM/Scl-75 signals and the appearance of 
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Figure 1. Cleavage of the PM/Scl-75 protein during anti-Fas induced apoptosis.
Jurkat cells were treated with the anti-Fas monoclonal antibody 7C11 for the indicated time periods. Protein extracts were analyzed by 
10% SDS-PAGE and western blotting using a polyclonal anti-PM/Scl-75 rabbit serum (A). Jurkat/Neo and Jurkat/Bcl-2 were treated 
with the anti-Fas monoclonal antibody 7C11 for the indicated time periods. Protein extracts were analyzed by 10% SDS-PAGE and 
western blotting using the anti-PM/Scl-75 rabbit serum.(B). In each panel, the positions of molecular weight markers are indicated on 
the right and the positions of the relevant polypeptides on the left. Closed arrowheads indicate full-length proteins, open arrowheads 
indicate cleavage products and the asterisk indicates a cross-reactivity of the anti-PM/Scl-75 serum with an unknown protein. 
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Figure 2. Cleavage of the PM/Scl-75 protein in various cell types treated with different apoptosis inducers. 
CCRF-CEM cells were treated with actinomycin D (A), anisomycin (AN), cycloheximide (C), staurosporin (S) or anti-Fas mAb 7C11 
(α-Fas), Peer cells were treated with actinomycin D (A), anisomycin (AN), cycloheximide (C) or staurosporin (S). Cell extracts were 
analyzed by 10% SDS-PAGE and western blotting using the anti-PM/Scl-75 rabbit serum. In lanes 1 and 7 extracts from mock-treated 
cells were loaded. The positions of molecular weight markers are indicated on the right and the positions of the relevant polypeptides 
on the left. Closed arrowheads indicate full-length proteins and open arrowheads indicate cleavage products, whereas the asterisk 
indicates a cross-reactivity with an unidentified protein
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the cleavage product of PM/Scl-75 was detected in 
all lysates indicating that PM/Scl-75 cleavage is a 
general phenomenon in apoptotic cells. As can be 
seen in Figure 1 and Figure 2 the anti-PM/Scl-75 
rabbit serum also showed reactivity with a number 
of yet unidentified proteins. Apoptotic modification 
of PM/Scl-75 was also observed in the lysates 
from the lymphocytes upon treatment with anti-
Fas antibodies or ionomycin for 6 hours (data not 
shown).
Association of the PM/Scl-75 cleavage fragment 
with the exosome complex
The most obvious explanation of the results 
described above is that PM/Scl-75 is cleaved by a 
protease that is activated in apoptotic cells, resulting 
in two proteolytic fragments. Because the rabbit 
antiserum is only reactive with the 45 kDa fragment, 
our data do not exclude the possibility that the other 
fragment is further degraded. PM/Scl-75 is one of 
the core components of the exosome complex and 
the majority of PM/Scl-75 molecules in a cell is 
believed to be associated with this complex. To 
analyze if the apoptotic cleavage fragment of PM/
Scl-75 can associate with the exosome complex, 
immunoprecipitations were performed using 
extracts from control and apoptotic Jurkat cells. 
The results in Figure 3 show that not only anti-
PM/Scl-75 rabbit serum and patient serum Ven96, 
but also rabbit antibodies to hRrp46p, another 
exosome core subunit, (co-)precipitated both the 
wild-type and the cleaved PM/Scl-75 protein. Note 
that in this experiment PM/Scl-75 was visualized 
by a polyclonal mouse serum raised against the 
recombinant protein. This result indicates that at 
least a subset of cleaved PM/Scl-75 molecules either 
binds to the exosome or remains associated with the 
core of the exosome. 
PM/Scl-75 cleavage is caspase mediated
Because the activation of caspases is a common 
feature of apoptotic cells and because activated 
caspases are capable of cleaving a large number of 
(autoantigenic) proteins, it was investigated whether 
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Figure 3. The apoptotic cleavage product of PM/Scl-75 remains associated with the exosome. 
Immunoprecipitations from control (0 hrs) and apoptotic (8 hrs incubated with anti-Fas antibody) Jurkat cell extracts were performed 
using normal rabbit serum (lanes 3 and 4), anti-PM/Scl-75 (lanes 5 and 6) and anti-hRrp46p (lanes 7 and 8) rabbit sera, and patient 
serum Ven96 (lanes 9 and 10). In lanes 1 and 2 input samples, 20% of the total control and apoptotic cell extracts, respectively, were 
loaded. Immunoprecipitates were analyzed by 10% SDS-PAGE and western blotting using a polyclonal anti-PM/Scl-75 mouse serum. 
The positions of the PM/Scl-75 protein (closed arrowhead), its cleavage product (open arrowhead) as well as a cross-reactivity of the 
anti-PM/scl-75 serum (asterisk) are indicated on the left. The positions of molecular weight markers are indicated on the right.
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caspase activation was required for cleavage of PM/
Scl-75. Jurkat cells were cultured in the presence of 
various inhibitors of caspases for 1 hour prior to the 
induction of apoptosis by anti-Fas. Four different 
tetrapeptide caspase inhibitors were used, Ac-
YVAD-CMK for group I caspases (caspase-1-like), 
Z-DEVD-FMK for group II caspases (caspase-3-
like), or Z-IETD-FMK (caspase-8) and Z-LEHD-
FMK (caspase-9) for group III caspases. Rabbit 
anti-PM/Scl-75 antiserum was used to analyze 
the cleavage of PM/Scl-75 in these cells. The 
cleavage of PM/Scl-75 was completely inhibited 
in the presence of 2 or 20 µM of Ac-YVAD-CMK, 
Z-DEVD-FMK, or Z-IETD-FMK inhibitors (Fig. 
4, lanes 4–9). In the presence of the Z-LEHD-
FMK inhibitor, PM/Scl-75 cleavage was partially 
inhibited at 2 µM and completely inhibited in the 
presence of a 10-fold higher concentration (Fig. 4, 
lanes 10–11). As a control for the inhibitory activity 
of the tetrapeptide inhibitors, the cell extracts were 
also analyzed for U1-70K and Sm-F cleavage. The 
inhibition of cleavage of both caspase substrates 
appeared to be very similar to that observed for PM/
Scl-75 (data not shown). These results suggest that 
caspases, or other proteases activated downstream 
of the caspase-cascade, are involved in the apoptotic 
cleavage of PM/Scl-75. 
Cleavage of PM/Scl-75 by different caspases
To determine whether PM/Scl-75 is a direct 
substrate for caspases, in vitro translated PM/Scl-75 
was incubated with recombinant murine caspase-1, -
2, -3, -7, -8 and -11. Four of these caspases appeared 
to be able to cleave PM/Scl-75, resulting in cleavage 
products similar in size to the in vivo generated 
fragment (Fig. 5A). However, the efficiencies by 
which this protein is cleaved by the recombinant 
caspases showed marked differences. Caspase-
1 very efficiently cleaved PM/Scl-75, whereas 
decreasing efficiencies were observed for caspase-8, 
caspase-7 and caspase-3. The recombinant caspases 
-2 and -11 did not result in detectable levels of 
PM/Scl-75 cleavage (Fig. 5A, lanes 3 and 7). As a 
control for caspase activity, all recombinant caspases 
were incubated with a specific fluorogenic substrate 
(Fig. 5B). Since caspase-8 plays a key role in death 
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Figure 4. Inhibition of PM/Scl-75 cleavage by caspase inhibitors. 
Jurkat cells were cultured for 1h at 37 °C in the presence of four cell permeable tetrapeptide caspase inhibitors: 2 µM (lanes 4, 6, 8, 
10) or 20 µM (lanes 5, 7, 9, 11) of inhibitors of caspase-1 (YVAD), caspase-3 (DEVD), caspase-8 (IETD) and caspase-9 (LEHD). 
Subsequently, cells were cultured for 8 hours in the presence of anti-Fas mAb. In lane 1 control extract from mock-treated Jurkat 
cells was loaded. In lanes 2 and 3 extracts from control and apoptotic (8h anti-Fas mAb) Jurkat cells, respectively, were analyzed. 
Total protein extracts were analyzed by 10% SDS-PAGE and western blotting using the anti-PM/Scl-75 rabbit serum. The positions 
of molecular weight markers are indicated on the right and the positions of the relevant polypeptides on the left. Closed arrowheads 
indicate full-length proteins, open arrowheads indicate cleavage products and the asterisk indicate cross-reactivity of the anti-PM/Scl-
75 serum.
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domain receptor mediated apoptosis, it was tested 
whether caspase-8 is essential for the cleavage of 
PM/Scl-75 in apoptotic cells. Therefore, caspase-8-
deficient Jurkat cells (ATCC CRL-2571) were used 
to analyze the apoptotic processing of PM/Scl-75. 
These cells become apoptotic when treated with 
staurosporin in combination with cycloheximide. 
Despite the absence of caspase-8, upon induction of 
apoptosis the same cleavage pattern was observed 
as in control cells containing caspase-8 (data not 
shown). This suggests that, in agreement with the in 
vitro proteolysis results, other caspases contribute to 
the cleavage of PM/Scl-75 in apoptotic cells.
Identification of the caspase cleavage site in PM/
Scl-75
The association of the 45 kDa PM/Scl-75 fragment 
with the exosome (see above) suggested that this 
fragment represents the N-terminal part of the 
protein, because in this region the RNase PH domain 
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Figure 5. Cleavage of PM/Scl-75 by 
recombinant caspases. 
A) In vitro translated 35S-labeled PM/Scl-
75 was incubated with 200 nM of purified 
murine recombinant caspases-1, -2, -3, -7, 
-8 or -11 for 1.5 h at 37ºC. The resulting 
reaction products were analyzed by 10% 
SDS-PAGE, followed by autoradiography. 
In the first lane the mock-incubated protein 
was loaded. The closed arrowhead marks the 
full-length proteins and the open arrowhead 
marks the cleavage products. Note that in this 
experiment the pCI-neo-VSV-PM/Scl-75c-α 
cDNA was used for in vitro transcription-
translation of PM/Scl-75. 
B) As a control for caspase activity the 
recombinant caspases were incubated with 50 
µM of fluorogenic substrate in 200 µl of CFS 
buffer. The release of fluorescent 7-amino-4-
methylcoumarin was monitored for 1 h at 37 
°C at 2-min time intervals in a fluorometer. 
Data are expressed as the increase in 
fluorescence as a function of time.
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is located, which is involved in the association with 
the exosome complex (14). Immunoprecipitations 
performed with caspase-1 cleaved in vitro translated 
PM/Scl-75 carrying a VSV-G-tag at either the N- or 
C-terminus indeed showed that the 45 kDa fragment 
could only be precipitated when the VSV-tag was 
attached to the N-terminus of the protein (data not 
shown). These data indicate that the major caspase 
cleavage site in PM/Scl-75 is located in the C-
terminal domain of the protein.
To determine the exact position of the cleavage site 
in PM/Scl-75, substitution mutants were generated 
in which the aspartic acids marked in Figure 6A 
were substituted by alanine residues. Aspartic 
acid residues were chosen because each of the 
caspases requires this amino acid at the cleavage 
site and thus substitution by alanine is expected to 
interfere with cleavage. After incubation with the 
recombinant caspase–3 or –8, the specific cleavage 
product was no longer observed with the PM/Scl-
75 protein containing the substitution at position 
369 (D369A) (Fig. 6B, lanes 9 and 14), whereas 
the other mutations did not influence the cleavage 
of PM/Scl-75 by these caspases. Also when this 
mutant was incubated with caspase–1 the cleavage 
of PM/Scl-75 was abolished (data not shown). 
Taken together, these data suggest that the IILD369↓
G sequence represents the caspase cleavage site in 
the PM/Scl-75 protein during apoptosis.
Discussion
Although many different autoantibodies have been 
identified in a variety of autoimmune diseases, 
the mechanism that leads to the production of 
most of these autoreactive antibodies is still 
unknown. During the last decade a substantial 
number of autoantigens have been shown to be 
modified during apoptosis and/or necrosis. This 
has led to the hypothesis that intracellular, modified 
autoantigens are exposed to the immune system 
because of massive cell death and/or inefficient 
removal of dying cells, which could elicit a primary 
immune response targeting the modification on the 
autoantigen. In a secondary response, also other 
parts of the autoantigenic molecule or its interacting 
partners might be targeted by the immune system as 
a result of epitope spreading (1). Patients with the 
PM/Scl overlap syndrome often develop antibodies 
against a number of components of the human 
PM/Scl or exosome complex, especially against 
PM/Scl-100, PM/Scl-75 and hRrp4p (19). Here, 
we show for the first time that one of the exosome 
subunits, PM/Scl-75, is specifically modified during 
apoptosis. The generation of a PM/Scl-75 fragment 
in apoptotic lysates of caspase-8-deficient Jurkat 
cells, the results from the caspase inhibitor studies 
in anti-Fas treated cells, and the in vitro cleavage 
of PM/Scl-75 by different caspases resulting in a 
similar cleavage pattern all suggest that several 
caspases are implicated in the proteolytic cleavage 
of PM/Scl-75. However, we cannot exclude the 
possibility that cleavage of PM/Scl-75 is not directly 
performed by caspases, and is an indirect effect of 
the activation of other proteases during apoptosis. 
The cleavage of PM/Scl-75 occurs in the C-terminal 
part of the protein at the unconventional caspase 
cleavage site IILD369↓G. However, cleavage of other 
autoantigens such as DNA topoisomerase I and Sm-
F, have also been reported to be cleaved by caspases 
at unconventional sites (16;20;21). 
Consistent with the observation that the C-terminal 
part of the protein is cleaved during apoptosis, 
leaving the RNase PH domain intact, a subset of 
cleaved PM/Scl-75 molecules remains associated 
with the core of the exosome complex (Fig. 3). A 
very similar situation has been described for the 
Sm-F protein, which is apoptotically cleaved while 
remaining associated with the heptameric ring of the 
Sm complex (16). Based on interactions between 
exosome components and structural similarity with 
the bacterial protein polynucleotide phosphorylase 
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(PNPase), a model was generated for the structure of 
the human exosome. In this model the six proteins 
containing an RNase PH domain form the core of the 
exosome, which adopts a hexameric ring structure 
(22). This model is strongly supported by the 
crystal structures of the archaeal, yeast and human 
exosome (23-26). Interestingly, the crystal structure 
of the human exosome shows that the C-terminal 
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RNase PH domain
81 ELSQMAAPAFEPGRQSDLLVKLNRLMERCLRNSKCIDTESLCVVAGEKVWQIRVDLHLLNHDGNIID AASIAAIVALCHF
161 RRPDVSVQGDEVTLYTPEERDPVPLSIHHMPICVSFAFFQQGTYLLVDPNEREERVMDGLLVIAMNKHREICTIQSSGGI
NLS
401 ILEPDKNPKKIRTQTTSAKQEKAPSKKPVKRRKKKRAAN
241 MLLKDQVLRCSKIAGVKVAEITELILKALENDQKVRKEGGKFGFAESIANQRITAFKMEKAPIDTSDVEEKAEEIIAEAE
D374A 
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Figure 6. Mapping of the caspase cleavage site in PM/Scl-75. 
A) Amino acid sequence of PM/Scl-75 (α variant). The RNase PH domain, the NLS, the N-termini of both published sequences, PM/
Scl-75a (13) and PM/Scl-75c (14), and the position (*) where the β splice-variant contains a 17 amino acid insertion are indicated. Note 
that the numbering of the amino acid positions corresponds to that of PM/Scl-75c-α. All aspartic acid residues, which were replaced 
by alanines are highlighted in black. The mutants that were used in the experiment shown in panel B are marked by arrows (D349A, 
D363A, D374A) and the identified cleavage site by arrowheads (D369A).
B) Cleavage of PM/Scl-75 mutants by recombinant caspases. In vitro translated 35S-labeled PM/Scl-75c-α and mutants of the protein 
in which the aspartic acid residues at positions 347 (D347A), 363 (D363A), 368 (D369A) or 374 (D374A) were changed into alanine 
residues,were incubated with purified murine recombinant caspases -3 or -8 for 1.5h at 37ºC. The resulting reaction products were 
analyzed by SDS-PAGE, followed by autoradiography. In lanes 1-5 the proteins incubated in parallel in the absence of caspases were 
loaded (control). The positions of molecular weight markers are indicated on the right and the positions of relevant polypeptides on 
the left. Closed arrowheads indicate full-length PM/Scl-75c-α and open arrowheads indicate the PM/Scl-75 cleavage product. Note 
that in this experiment the pCR4-TOPO-PM/Scl-75c-α cDNA (20) was used for in vitro transcription-translation of PM/Scl-75. Due to 
translation initiation at an internal start codon in the reticulocyte lysate a relatively high level of a second polypeptide was produced, 
which was demonstrated to represent a polypeptide initiated at methionine-85, thus corresponding to PM/Scl-75a-α.
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extension of PM/Scl-75 interacts with hRrp46p and 
wraps around both hRrp46p and OIP2 (hRrp43p) 
on the outer surface of the ring, demonstrating 
that the identified cleavage site of PM/Scl-75, 
which is located in the middle of this extension, 
is accessible for caspases. The observation that 
PM/Scl-75 is cleaved during apoptosis might also 
have implications for the activity and function 
of the exosome complex. Recently, it has been 
reported that the activity of the human exosome is 
restricted to the hRrp41p-PM/Scl-75 heterodimer. 
As a consequence, cleavage of PM/Scl-75 may 
influence the catalytic activity of the complex 
(26). Moreover, it has been shown that PM/Scl-75 
contains a nuclear localization signal (NLS), which 
plays a role in the nucleolar targeting of PM/Scl-75 
(14). The cleavage of PM/Scl-75 in apoptotic cells 
removes the NLS from the protein, which may 
change the subcellular distribution of the protein 
and the associated complex, as has been reported 
for the La autoantigen (27). Therefore, it is tempting 
to speculate that cleavage of PM/Scl-75 leads to an 
increased exosome concentration in the cytoplasm 
and/or nucleoplasm, which may be required for 
an enhanced degradation rate of a variety of RNA 
molecules in these compartments during apoptosis. 
Simultaneously, cleavage of PM/Scl-75 would result 
in the release of the exosome from the nucleolus 
leading to loss of exosome function in this cellular 
compartment. 
As described above, recent studies have led to the 
hypothesis that cell death induced modifications 
can generate neo-epitopes which trigger an 
autoimmune response. If the immune system 
is exposed to elevated and persistent levels of 
apoptotically modified PM/Scl-75, this could 
contribute to breaking the immunological tolerance 
to the exosome complex, leading to the production 
of autoantibodies to components of this complex. 
Therefore, it would be interesting to investigate 
whether the B-cell repertoires of PM/Scl patients 
in the early phase of the disease contain antibodies 
that are specifically reactive with the apoptotic PM/
Scl-75 protein fragment. Such autoantibodies which 
preferentially recognize apoptotically modified 
isoforms of the autoantigen have been shown to 
exist for the U1-70K protein (28;29).
Conclusions
This study shows that the autoantigenic exosome 
component PM/Scl-75 is specifically cleaved 
during apoptosis. A 45 kDa fragment of PM/Scl-
75 is generated in apoptotic Jurkat cells. This 
fragment, which corresponds to the N-terminal part 
of PM/Scl-75, is at least in part associated with the 
exosome complex. In vitro cleavage assays with 
different recombinant caspases suggest that several 
caspases can be responsible for the proteolytic 
cleavage of PM/Scl-75, although caspase-1 seems 
to be most effective. The caspase cleavage site 
was mapped in the C-terminal part of the protein at 
Asp369 (IILD369↓G). 
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Introduction
IIM (idiopathic inflammatory myopathies) represent 
a heterogeneous group of autoimmune diseases, 
characterized by skeletal muscle weakness, elevated 
serum levels of muscle enzymes and chronic 
inflammatory infiltrates. IIM are often diagnosed 
as polymyositis (PM), dermatomyositis (DM) or 
inclusion body myositis (IBM) (1). In patients 
suffering from PM or DM and scleroderma (Scl), 
termed the polymyositis/scleroderma overlap 
syndrome (PM/Scl), disease-specific autoantibodies 
have been shown to recognize a nucleolar complex 
of 11-16 proteins ranging from 18-110 kDa and 
serve as a important marker for the PM/Scl-overlap 
syndrome, where they are present in about a quarter 
of the patient sera. Anti-PM/Scl autoantibodies are 
also present in 6% of patients with PM or DM and 
in 2% of Scl patients (2). 
Further characterization of the anti-PM/Scl-positive 
sera led to identification of the main autoantigenic 
proteins, PM/Scl-100, a 100-110 kDa protein, 
and PM/Scl-75, a 50 kDa protein, which migrates 
aberrantly in SDS-PAGE due to a highly charged 
C-terminus (3;4). The major reactivity of anti-PM/
Scl-100 antibodies appeared to be directed to an 
alpha-helical element of this protein (5). Indeed, an 
ELISA based on this autoantigenic epitope proved 
to be a sensitive method to facilitate the diagnosis 
of patients with the PM/Scl-overlap syndrome (6). 
The autoantigenic epitope(s) of the PM/Scl-75 
protein is (are) less well defined although a recent 
study has provided evidence that a newly identified 
isoform of PM/Scl-75, termed PM/Scl-75c, contains 
a previously unidentified N-terminal region which 
is important for the autoantigenicity of the protein 
(7). 
In 1999, the PM/Scl-complex was shown to be 
Objective. To assess whether the recently discovered exosome-associated proteins, MPP6, C1D, 
KIAA0052/hMtr4p, hSki2p and hSki8p, are targeted by autoantibodies and to determine if these 
autoantibodies are accompanied by antibodies directed to the established exosome-associated 
autoantigens PM/Scl-75 and PM/Scl-100. 
Methods. Complementary DNAs encoding the recently identified human exosome-associated proteins 
were expressed as His-tagged fusion proteins in Escherichia coli. Sera of patients suffering from several 
different autoimmune diseases were analyzed for the presence of autoantibodies directed to these 
proteins in an ELISA assay. The ELISA data obtained for C1D were confirmed by western blot analysis 
using recombinant C1D. 
Results. All exosome-associated proteins were found to be targeted by autoantibodies, although the 
frequency by which such antibodies occur in patient sera is relatively low, with one exception, anti-C1D 
antibodies. Autoantibodies recognizing C1D were detected in 7/30 (23%) of the PM/Scl-overlap patients, 
which is similar to what has been reported for the established autoantigens PM/Scl-75c (28%) and PM/
Scl-100 (25%). Importantly, a number of PM/Scl-overlap patients was identified which had anti-C1D 
antibodies, but no anti-PM/Scl antibodies. Anti-C1D autoantibodies were found in only 2 of 198 patients 
with other diseases, which included polymyositis, dermatomyositis and scleroderma.
Conclusion. Our results demonstrate that the recently identified exosome-associated protein C1D is a 
major autoantigen in patients suffering from the PM/Scl-overlap syndrome and suggest that the use of 
recombinant C1D as an autoantibody target may aid the diagnosis of PM/Scl-overlap syndrome.
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the human counterpart of the yeast exosome, a 
complex consisting of RNA binding proteins and 
3’-5’ exoribonucleases, including Rrp45p (the yeast 
homologue of PM/Scl-75) and Rrp6p (the yeast 
homologue of PM/Scl-100), which is required for 
the processing and/or degradation of different types 
of RNAs (2). Besides PM/Scl-75 and PM/Scl-100, 
human homologues of all other yeast exosome 
components have been identified (8) and several 
of these components are also recognized by anti-
PM/Scl antibodies, although to a lesser extent than 
PM/Scl-75 and PM/Scl-100 (9). 
In recent years, several exosome-associated proteins 
have been identified which might be involved in 
processes such as the recruitment of the exosome 
to substrate RNAs. These proteins include MPP6 , 
C1D and KIAA0052, and were found to be required 
for efficient rRNA processing by the exosome. Since 
KIAA0052 was reported to be human homologue 
of yeast Mtr4p it will hereafter be referred to as 
hMtr4p (10-12). The recently described, hSki2p 
and hSki8p proteins are part of the hSki-complex, 
which was proposed to regulate cotranscriptional 
events such as mRNA quality control together with 
the exosome and hPAF complex (13). The hSki-
complex is related to the yeast Ski complex, which 
together with the exosome mediates 3’-5’ mRNA 
degradation in the cytoplasm (2).
The aim of this study was to assess whether the 
human exosome-associated proteins MPP6, C1D, 
hMtr4p, hSki2p and hSki8p, are targeted by 
autoantibodies. The presence and prevalence of 
such autoantibodies was investigated using sera 
from patients with the PM/Scl-overlap syndrome 
and various other diseases in a recombinant protein 
ELISA. 
Patients & Methods
Patients
Most patient sera were obtained from the 
departments of Rheumatology and Neurology of the 
University Medical Center St. Radboud, Nijmegen. 
The patients with PM, DM, Scl or overlap 
syndromes of Scl with either PM or DM (in this 
study referred to as PM/Scl-overlap) were classified 
according to the classification scheme by Bohan and 
Peter, as modified by Cronin et al. (14). Diagnoses 
were made according to established criteria and 
the same sera were also included in a previous 
study that assessed the prevalence of anti-exosome 
antibodies in these patients (7). A separate cohort of 
IIM sera was selected based upon the presence of 
anti-PM/Scl-100 and/or anti-PM/Scl-75c antibodies. 
To assess the disease specificity of the antibodies 
detected, sera from patients with systemic lupus 
erythematosus (SLE), multiple sclerosis (MS) and 
rheumatoid arthritis (RA) were analyzed. 
Expression and purification of recombinant 
proteins
The cDNA encoding MPP6 (GenBank acc. nr. 
NM_005792) was cloned into the pQE-32 vector 
(Qiagen); the cDNAs encoding C1D (GenBank 
acc. nr. NM_006333) and hSki8p (GenBank acc. 
nr. CR457333) were cloned into suitable pET-30 
vectors (Novagen, Madison, USA). Due to low 
expression levels of full-length recombinant hMtr4p 
and hSki2p proteins, deletion mutant constructs 
were generated using appropriate internal restriction 
sites. The cDNA fragment of hMtr4p (clone 
IRATp970F0129D6, provided by the I.M.A.G.E. 
consortium) was cloned into the pET-30b vector 
using the internal restriction site HindIII (this 
construct encodes the N-terminal 800 amino acids 
of hMtr4p); the cDNA fragment of hSki2 (GenBank 
acc. nr. Z48796) was cloned into the pET-30b 
vector using the internal restriction site SalI (this 
construct encodes the N-terminal 808 amino acids 
of hSki2p). 
The histidine-tagged recombinant proteins were 
expressed in E.coli BL21/pLysS cells and purified 
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by Ni2+-affinity chromatography using Ni-NTA 
Sepharose (QIAGEN,Germany). The purity of 
the recombinant proteins was determined by 
SDS–PAGE and quantified by a BCA protein 
assay kit (PIERCE, Rockford, USA). The proteins 
His-hSki8p, His-hSki2p and His-hMtr4p appeared 
to accumulate in the insoluble fraction of the 
corresponding bacterial lysate and were purified in 
the presence of 7 M urea. 
Enzyme linked immunosorbent assay (ELISA)
ELISAs were performed as described before (9), 
with the exception that the microtiter plates were 
blocked with 400 µl of ELISA blocking buffer 
(5% skimmed milk, PBS, 0.2% Tween-20). Serum 
samples were diluted 100-fold in ELISA blocking 
buffer. Tests were regarded positive if the OD 
exceeded the calculated cut-off level, which was 
determined by analyzing at least three negative 
control sera per plate with 99.9% confidence (15). 
All patient sera were tested in duplicate. 
Western blot analysis
For western blot analysis, recombinant His-C1D 
was separated by SDS-PAGE, and transferred 
to nitrocellulose membranes. The blots were 
blocked with western buffer (5% skimmed milk, 
PBS, 0.05% NP-40) and incubated with 1000-
fold diluted autoimmune patient sera in the same 
buffer. Subsequently, blots were incubated with 
a secondary antibody, rabbit-anti human IgG 
(DAKO immunoglobulins, Copenhagen, Denmark) 
diluted 2500-fold in western buffer, and a tertiary 
antibody, goat anti-rabbit IRDye 800CW (LI-COR 
Biosciences, Lincoln, USA) diluted 10.000-fold in 
western buffer. Bound antibodies were visualized 
with the Odyssey infrared imaging system (LI-COR 
Biosciences, Lincoln, USA). 
Results
C1D is a major autoantigen in patients with the 
PM/Scl-overlap syndrome
The autoantibody response to the recently identified 
exosome-associated proteins MPP6, C1D, hMtr4p, 
sera 
tested MPP6 C1D hMtr4p hSki2p hSki8p
PM/Scl-
75c
PM/Scl-
100
PM 44 0 (0)* 2 (4.5) 1(2.3) 2 (4.5) 0 (0) 0 (0) 1 (2.3)
DM 43 1 (2.3) 0 (0) 0 (0) 1 (2.3) 1 (2.3) 1 (2.3) 1 (2.3)
Scl 51 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (10) 1 (2) 
PM/Scl-overlap 30 0 (0) 7 (23) 2 (6.7) 0 (0) 1 (3.3) 8 (27) 7 (23)
MS 22 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4.5)
RA 22 0 (0) 0 (0) 0 (0) 1 (4.5) 0 (0) 1 (4.5) 2 (9.1)
SLE 22 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4.5) 0 (0)
IIM 
(PM/Scl-positive) 87 3 (3.4) 5 (5.7) 5 (5.7) 3 (3.4) 1 (1.1) 37 (43) 81 (93)
total 321 4 (1.2) 14 (4.4) 8 (2.5) 7 (2.2) 3 (0.9) 53 (17) 94 (29)
Table 1. Reactivity of patient sera with exosome-associated proteins
*Values represent number of positive sera (%)
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hSki2p and hSki8p was studied by ELISA assays 
using the sera of 44 patients with PM, 43 patients 
with DM, 51 patients with Scl, 30 patients with the 
PM/Scl-overlap syndrome, 22 patients with MS, 
22 patients with RA and 22 patients with SLE. 
Additionally, 87 IIM patient sera were analyzed 
that were selected based upon their reactivity with 
the established PM/Scl autoantigens, PM/Scl-75c 
(n=37/87), PM/Scl-100 (n=81/87) or both (n=31/
87). Table 1 summarizes the reactivity of these 
patient sera with each of the exosome-associated 
proteins analyzed. Autoantibodies to these proteins 
appeared to be most prevalent in the IIM and the 
PM/Scl-overlap group. In total, 1.3% (4/321) of the 
sera were reactive with MPP6, 4.4% (14/321) with 
C1D, 2.5% (8/321) with hMtr4p, 2.2% (7/321) with 
hSki2p and 1.0% (3/321) with hSki8p. Note that the 
recombinant hSki2p, hSki8p and hMtr4p proteins 
were isolated in the presence of urea, which may lead 
to a loss of autoantigenic epitopes due to (partial) 
denaturation of the protein. As a result, we cannot 
exclude the possibility that our data underestimate 
the autoantigenicity of these proteins. Interestingly, 
7 of the sera that were reactive with C1D were from 
PM/Scl patients (23%), which is comparable to the 
frequency by which PM/Scl-75c (27%) and PM/
Scl-100 (23%) are targeted by this patient group. 
Figure 1A illustrates the autoantibody levels to C1D 
in PM/Scl sera compared to the control sera used 
(the antibody ratio was calculated by dividing the 
observed reactivity by the cut-off value). 
To confirm the presence of anti-C1D autoantibodies 
in these sera, the sera were also analyzed by western 
blotting using recombinant His-C1D. The results 
in Figure 1B show that the ELISA data obtained 
with the PM/Scl-overlap (lanes 1-7) and PM sera 
(lanes 16,17) were confirmed by western blotting. 
In contrast, only 4 of the 5 anti-C1D-positive IIM 
sera (lanes 10-14) were reactive in this assay. As 
a control, several anti-C1D-negative sera were 
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Figure 1. Reactivity of patient sera with 
recombinant C1D
A) ELISA data of individual patient sera, 
suffering from different autoimmune diseases, 
with recombinant C1D. The cut-off value, 
which is indicated by the dotted line, was 
determined based upon the signals obtained 
with normal human sera. The antibody ratio is 
calculated by dividing the observed reactivity 
by the cut-off value multiplied by ten.
B) Western blot analysis of patient sera that 
recognize C1D in ELISA and some sera that 
are not reactive with C1D in ELISA. The blots 
contain recombinant His-tagged C1D protein. 
Lanes 1-9, PM/Scl-overlap sera; lanes 10-15, 
IIM sera; lanes 16-18, PM sera. The reactivity 
of these sera with C1D in ELISA is indicated 
above the lanes: positive (+) or negative (-). 
The arrow indicates the position of full-length 
recombinant His-tagged C1D. On the left the 
positions of molecular mass markers (kDa) 
are indicated. 
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also analyzed by western blotting but did not react 
with C1D (lanes 8, 9, 15 and 18). In general, sera 
displaying a high antibody ratio in ELISA also 
strongly reacted with C1D on blot.
Co-occurrence of autoantibodies directed to 
different exosome-associated proteins 
Since anti-PM/Scl-75c autoantibodies are often 
found in combination with anti-PM/Scl-100 
autoantibodies, we investigated the co-occurrence of 
autoantibodies directed to the exosome-associated 
proteins. However, most patient sera were found to
recognize only one of the exosome-associated 
proteins suggesting that there is no relation between 
the generation of antibodies to the proteins that 
interact in vivo and their targeting by autoantibodies. 
Six patient sera recognized two or more exosome-
associated proteins. Interestingly, the most 
frequently found combination was the recognition 
of hMtr4p and hSki2p (4 out of 6 sera), which are 
both members of a subfamily of putative RNA 
helicases and which are 37% identical at the amino 
acid sequence level (data not shown). 
The co-occurrence of anti-PM/Scl and anti-C1D 
antibodies in anti-PM/Scl positive IIM and PM/
Scl-overlap patient sera is illustrated in Figure 2. 
The majority of the IIM PM/Scl-positive sera was 
selected based upon their reactivity with PM/Scl-100, 
whereas some of these sera were selected because 
they contained autoantibodies to PM/Scl-75c. Two 
out of five anti-C1D positive sera in the anti-PM/Scl 
positive IIM cohort were also reactive with PM/Scl-
100, whereas the other three were reactive with both 
PM/Scl-100 and PM/Scl-75c. As expected no sera 
were reactive with C1D alone, since the IIM patient 
sera were selected for their reactivity with either 
PM/Scl-100 and/or PM/Scl-75c (Fig. 2A). For the 
30 PM/Scl-overlap sera 11 were reactive with at 
least one of the antigens. Five of these appeared to 
contain autoantibodies to PM/Scl-75c, PM/Scl-100 
as well as C1D. One serum was reactive with both 
PM/Scl-75c and PM/Scl-100, whereas no sera were 
found that were reactive with a combination of C1D 
and PM/Scl-75c or PM/Scl-100. More importantly, 
the other five PM/Scl-overlap sera were reactive 
with only one of the three antigens, PM/Scl-100 (1 
serum), PM/Scl-75c (2 sera) or C1D (2 sera). When 
the total group of PM/Scl-overlap patients analyzed 
in this study is taken into account 9 out of 30 sera 
were reactive with PM/Scl-75c and/or PM/Scl-
100 ( 30%). The inclusion of anti-C1D antibodies 
increases the frequency of PM/Scl-overlap-specific 
autoantibodies to 37%.
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C1D
5
2
21
0
1
0
B
A
PM/Scl-100 PM/Scl-75c
C1D
3
2 0
648
0*
28
Figure 2. Reactivity of PM/Scl-overlap and anti-PM/Scl-
positive IIM sera with PM/Scl-100, PM/Scl-75c and C1D
The co-occurrence of autoantibodies that recognize PM/Scl-
100, PM/Scl-75c and/or C1D is illustrated separately by a Venn 
diagram for the anti-PM/Scl-positive IIM sera (A) and for the 
PM/Scl-overlap sera (B). * Note that no anti-PM/Scl-positive IIM 
sera were reactive with C1D alone, since these sera were selected 
for their reactivity with either PM/Scl-100 and/or PM/Scl-75c.
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Discussion
In this study we showed that the exosome-associated 
proteins MPP6, C1D, hMtr4p, hSki2p and hSki8p 
are targeted by autoantibodies, although in most 
cases patient sera containing such autoantibodies 
are rare. C1D was found to be relatively frequently 
targeted by autoantibodies present in sera from 
PM/Scl-overlap patients. For these patients the 
PM/Scl-100 and –75c proteins are thought to carry 
the main autoantigenic epitopes making anti-PM/
Scl antibodies an important serological marker. 
However, many PM/Scl-sera stain several other 
proteins on western blot ranging from ~18 –110 
kDa. Interestingly, C1D is a nucleolar protein of 
approximately 18 kDa and our data showed that in 
some PM/Scl-overlap patients anti-C1D antibodies 
are present in the absence of anti-PM/Scl-75c 
and -100 antibodies. The presence of anti-PM/Scl 
antibodies in patient sera is generally monitored by 
ELISA using a recombinant PM/Scl-100 protein. The 
results of recent studies, however, suggested that the 
inclusion of recombinant full-length PM/Scl-75c or 
a peptide based on an autoantigenic epitope of PM/
Scl-100 can yield a more sensitive ELISA assay in 
comparison with the recombinant PM/Scl-100 alone 
(6;7). Although more PM/Scl-overlap sera have to 
be analyzed with the C1D antigen, our data indicate 
that also the use of C1D for autoantibody detection 
in PM/Scl-overlap sera may improve the sensitivity. 
Besides in PM/Scl-overlap sera, anti-C1D reactivity 
was only detected in 4.5% of PM sera (n=44) and 
5.7% of anti-PM/Scl-100 and/or anti-PM/Scl-75c 
positive IIM sera (n=87). None of the 160 DM, Scl, 
MS, RA and SLE sera contained detectable amounts 
of anti-C1D autoantibodies. These data strongly 
suggest that the production of these antibodies is 
specifically associated with the PM/Scl-overlap 
syndrome. 
The initial events which trigger an autoantibody 
response are still largely unknown. However, 
modifications occurring during cell death may 
generate neo-epitopes which elicit a primary 
autoimmune response. Indeed, PM/Scl-75c has been 
shown to be cleaved by caspases during apoptosis 
(manuscript submitted for publication), whereas 
PM/Scl-100 was found to be cleaved by purified 
granzyme B in vitro (16). It would be interesting to 
investigate whether or not the C1D protein is also 
modified during cell death, which might explain 
why autoantibodies are generated to this protein. 
Alternatively, the initial immune response might 
be directed to PM/Scl-100, which directly interacts 
with both the exosome core and C1D in vivo. In 
that scenario, intermolecular epitope spreading may 
lead to the generation of autoantibodies directed to 
C1D. In patients with anti-C1D antibodies, but no 
apparent PM/Scl-100 autoantibodies, the latter may 
remain undetected because the relevant epitope(s) 
is/are absent or masked in the recombinant PM/Scl-
100 protein. 
Taken together, the C1D protein is a major 
autoantigen in patients suffering from the PM/Scl-
overlap syndrome and the use of recombinant C1D 
may increase the number of PM/Scl patients reactive 
in disease-specific autoantibody tests. Additional 
research is required to clarify the precise role of the 
C1D protein in the generation of the autoimmune 
response in PM/Scl patients.
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Exosome stability
Structural analysis of the human exosome has 
revealed that the human exosome consists of at 
least nine polypeptides. Six RNase PH-like subunits 
(hRrp41p, hRrp42p, OIP2, PM/Scl-75, hRrp46p 
and hMtr3p) form a hexameric ring and the three 
proteins with an S1 (and KH) domain (hRrp4p, 
hRrp40p and hCsl4p) are positioned on top of this 
ring (1-3). So far, little is known about the role of 
individual human exosome subunits with regard to 
the assembly and stability of the entire complex. 
It was predicted that all the RNase PH subunits 
would be essential in maintaining a stable structure, 
since they all contribute to the core hexameric ring 
structure, whereas the S1 RNA-binding proteins 
on top of the ring were thought to be dispensable. 
Indeed, knock-down of the RNase PH-like subunit 
hRrp41p led to destabilization of the exosome 
complex (see Fig. 1). Surprisingly, PM/Scl-75, 
which is another RNase PH-like subunit, appeared 
to be non-essential for maintaining a stable ring 
structure (Chapter 2). This suggests that PM/Scl-
75 can be replaced by a similar RNase PH like 
subunit, such as hRrp42p or OIP2. Interestingly, 
purified exosome complexes from Drosophila 
lack a homologue of PM/Scl-75 as well as OIP2, 
supporting the idea that multiple copies of some 
RNase PH-like subunits can be present in a single 
ring structure (4). An alternative explanation would 
be that the RNAi mediated knock-down of PM/Scl-
75 preferentially affects a free pool of PM/Scl-75 
molecules but not the assembled exosome. 
Unexpectedly, knockdown of the S1/KH domain 
subunit hRrp4p led to co-depletion of other core 
exosome subunits (Chapter 2). This finding is in 
The exosome is a protein complex with 3’-5’ exoribonuclease activity that was initially identified in yeast 
by mutation of one of its protein components that resulted in defective 3’ end maturation of the 5.8S 
ribosomal RNA. Since then, many functions have been attributed to the exosome, all involving the precise 
3’ end processing of precursors to functional RNAs or the complete degradation of a substrate RNA. 
The structural characterization of the human exosome complex demonstrated that the components 
which are homologous to RNase PH assemble into a doughnut like structure, whereas the RNA-binding 
components are on top of this ring structure. In this thesis we have tried to answer some additional 
questions. In Chapter 2 the question how different exosome subunits contribute to complex stability 
is addressed. In addition, the existence of differently sized exosome-containing complexes is shown. 
The observation that the exosome is involved in many cellular processes also raised the question how 
the exosome is recruited to its different substrate RNAs. Studies to address this problem resulted in the 
identification of several proteins interacting with the exosome, which associate with different subsets of 
the exosome complex, as described in Chapters 3-5. 
Some components of the exosome complex are known to be autoantigenic in patients suffering from 
the PM/Scl overlap syndrome, although it is not fully understood how and why these autoantibodies are 
generated. In Chapter 6, we showed that the main autoantigen in PM/Scl patients, PM/Scl-75, is modified 
during apoptosis. Such an event may trigger the immune system and initiate autoimmunity. Moreover, 
one of the newly identified exosome-associated proteins, C1D, was found to be a major autoantigen 
in PM/Scl patients as well (Chapter 7). In this chapter, the data presented in the previous chapters are 
summarized and discussed. 
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agreement with reported in vitro reconstitution 
experiments in which it was shown that the 
interactions between RNase PH domain subunits are 
only stable in the presence of S1 domain proteins 
(5). As the S1 domain proteins each interact with 
two RNase PH domain subunits simultaneously, this 
mode of interaction is likely to stabilize the core 
complex.
The relative importance of the subunits for a stable 
complex appears to be different between different 
organisms. In the case of Archaea and the small 
parasite T. brucei, the S1 subunits were found 
to be dispensable for exosome stability (6;7). 
Surprisingly, TbRrp6 was found to be required 
for exosome stability in T. brucei, whereas the 
homologous PM/Scl-100 in the human situation is 
Figure 1. Assembly and trafficking of the exosome and several associated proteins
A schematic model of the assembly of the core exosome and its association with several other proteins. In the cytoplasm, the core of 
the exosome is assembled into a stable complex, which requires at least the RNase PH-like subunit hRrp41p (depicted as 41) and S1 
domain protein hRrp4p (depicted as 4), whereas a significant amount of PM/Scl-75 might be dispensable for a stable complex. Once 
imported into the nucleus (via the NLSs of hRrp41p and/or PM/Scl-75) the exosome is retained in this compartment. 
The C1D protein forms a heterodimer with PM/Scl-100 before it is imported into the nucleus, most likely via the NLS of the latter. Two 
other exosome-associated proteins, MPP6 and hMtr4p are independently transported to the nucleus, where they may form a complex 
together with C1D and PM/Scl-100 before interacting with the core exosome in either the nucleoplasm or nucleolus of the cell. 
cytoplasm
nucleoplasm
nucleolus
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core exosome
hMtr4p
C1D
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not. This discrepancy might be explained by the 
fact that TbRrp6 is believed to be a core exosome 
component and thus may have a slightly different 
function than the nuclear enriched PM/Scl-100 
protein in human cells (7;8).
Exosome subsets
While it has been established that exosome core 
subunits can associate with rather large high 
molecular weight complexes, the identity of these 
macromolecular complexes is still unclear (9-11). 
In the nuclear compartment of the eukaryotic 
cell, the core exosome subunits are distributed 
almost equally over ~10S and 60-80S complexes. 
In contrast, several exosome-associated proteins, 
including MPP6 and PM/Scl-100, both shown to 
be involved in pre-rRNA processing, are mainly 
found in 60-80S fractions (Chapters 2-3). Many 
components of pre-ribosomal complexes are also 
known to sediment as large, approximately 80S 
complexes and to be associated with the pre-rRNA. 
Attempts to demonstrate the association of the 
60-80S exosome complexes with pre-rRNA were 
unsuccessful so far, possibly due to the transient 
interaction of the exosome with the pre-rRNA or 
to the low abundance of both exosome proteins 
and pre-rRNAs in cells. Nevertheless, it remains 
tempting to speculate that the nuclear 60-80S 
exosome containing complexes are somehow 
associated with pre-ribosomal particles whereas the 
10S exosome complexes might be ‘free’ exosome 
particles. In the cytoplasm, the majority of core 
exosome subunits is found at ~10S (Chapters 2 and 
3). Small amounts of exosome core subunits as well 
as MPP6 and PM/Scl-100 can also be found in 60S 
complexes in the cytoplasm, but the high molecular 
weight peak in the cytoplasmic material is observed 
at 60S, whereas the peak with the nuclear material 
extends from 60S to 80S, suggesting that they 
represent different complexes. The identity of 
the 60S cytoplasmic complexes remains unclear, 
but these could represent the mRNA degradation 
machinery as has been described for several proteins 
involved in 5’-3’ mRNA decay (12-15). 
Localization and assembly of 
exosomes 
Localization of the human exosome
As the exosome has been implicated in 3’ end 
processing and/or 3’-5’ degradation of a wide 
variety of RNA substrates, the complex is found 
in both the nucleus and cytoplasm of a cell. The 
extensive nucleolar accumulation of the core 
exosome, as observed by immunofluorescence, 
is most easily explained by the large amount of 
ribosomal RNA in cells, all of which needs to be 
processed by the exosome in the nucleolus, which 
is a relatively small compartment in comparison 
to the nucleoplasm and cytoplasm. Therefore, the 
relatively low concentration of substrate RNAs 
in the nucleoplasm and cytoplasm may in part 
explain why these cellular compartments are only 
poorly visible in comparison to the nucleolus when 
staining for exosome components. Nevertheless, 
several biochemical fractionation experiments have 
shown that there is a significant cytoplasmic pool of 
exosome complexes (11) (Chapters 2 and 3), which 
is in agreement with the notion that the exosome is 
required for the 3’-5’ degradation of several classes 
of mRNA (Chapter 2). Proteins involved in 5’-3’ 
mRNA decay are known to localize to so-called 
‘processing bodies’ or ‘GW bodies’, which raised 
the question if these cytoplasmic foci are related 
to mRNA decay pathways such as nonsense-
mediated decay (NMD), ARE-mediated decay 
and/or RNA interference. Indeed, several studies, 
in both yeast and human cells, have suggested 
that these processing bodies are directly involved 
in RNA interference, microRNA function and 
mRNA turnover (15-18). The exosome, however, 
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does not localize to these processing bodies, even 
though it has been implicated in NMD as well as 
ARE-mediated decay (Chapter 2) (19-21). Recently, 
it was demonstrated that the 5’ intermediates 
generated by the RNA Induced Silencing Complex 
(RISC) are degraded by the exosome complex, 
whereas the 3’ mRNA fragments are degraded by 
Xrn1, a protein localized in the processing bodies 
(22;23). Although these studies provide a functional 
link between 5’-3’ and 3’-5’ degradation of mRNA 
fragments generated by RISC, it remains unclear 
if exosome-dependent decay occurs throughout 
the cytosol or in alternative processing bodies. A 
detailed study of the precise subcellular localization 
of the exosome core may provide more insight in 
the relation between the exosome and other RNA 
processing pathways. 
Localization of exosome associated proteins
Current knowledge about the mechanisms of 
substrate specificity of and recognition by the 
exosome is still very limited, although it is thought 
that the association of the core exosome with 
auxiliary proteins and their subcellular localization 
might play an important role. Indeed, in recent years 
several exosome-associated proteins have been 
identified which localize to different subcellular 
compartments. In yeast, the exoribonuclease Rrp6p 
was found to be exclusively associated with the 
nuclear exosome. For the human homologue of 
Rrp6p, PM/Scl-100, there has been some debate 
whether this protein is also restricted to the nucleus. 
We and others, however, found that PM/Scl-100, 
although enriched in the nucleus, is also clearly 
detectable in the cytoplasm by immunofluorescence 
and biochemical fractionation experiments. 
Moreover, we demonstrated that PM/Scl-100 is 
required to maintain normal levels of different 
classes of mRNA substantiating that human cells, 
in contrast to yeast, contain a pool of functional 
cytoplasmic PM/Scl-100 molecules (20) (Chapters 
2 and 3). 
The yeast exosome was found to associate with the 
nuclear RNA helicase Mtr4p, as well as with the 
cytoplasmic RNA helicase Ski2p. In human, two 
proteins were identified which showed structural 
similarities to both Mtr4p and Ski2p. The putative 
RNA helicase KIAA0052 was shown to co-purify 
with the exosome (1) and the Ski2w protein was 
reported to localize to the nucleoli and ribosomes 
(24). Since there were no clear differences in 
sequence homology between the yeast and human 
proteins, it remained unclear whether KIAA0052 or 
hSki2w represented the human orthologues of yeast 
Mtr4p or Ski2p. The results presented in Chapter 
3 demonstrate that KIAA0052 appears to be the 
human homologue of Mtr4p since it localized to 
the nucleus of the cell and was found to be required 
for pre-rRNA processing as has been reported 
for Mtr4p. In contrast to what has been reported 
Figure 2. Subcellular localization of KIAA0052/hMtr4 and hSki2w
HEp-2 cells were transiently transfected with constructs encoding hMtr4p/KIAA0052 (left panel), hSki2w (middle panel) or PM/Scl-
75 (right panel) fused to the C-terminus of EGFP. After overnight incubation, cell were fixed and the expressed fusion proteins were 
visualized by confocal fluorescence microscopy. 
EGFP-hMtr4p EGFP-hSki2w EGFP-PM/Scl-75
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previously, we found that hSki2w localized to the 
cytoplasm instead of the nucleolus (see Fig. 2). 
Preliminary results, show that hSki2w is required 
for maintaining normal mRNAs levels, strongly 
suggesting that it represents the human homologue 
of yeast Ski2p (unpublished results). 
In yeast, Ski2p is part of the Ski-complex, which 
exclusively localizes to the cytoplasm and is 
implicated in mRNA turnover (25-29). Recently, 
this complex has also been identified in human cells 
and, in contrast to yeast, the human Ski-complex is 
also present in the nucleoplasm were it was found 
to associate with the nuclear PAF complex. The 
PAF complex plays a key role in the setting of 
histone marks for active transcription, and is also 
required for maintaining proper poly(A) tail length. 
These data suggests that the human Ski-complex 
might have an additional, nuclear role in mRNA 
surveillance (30). 
Trafficking of the exosome and 
associated proteins
So far, only limited data is available about the 
assembly and trafficking of the exosome and its 
associated proteins. The core exosome components 
most likely assemble in the cytoplasm and the 
resulting complex is subsequently transported to 
the nucleus. This sequence of events is supported 
by the observation that knock-down of the core 
exosome components hRrp4p and hRrp41p leads 
to co-depletion of other exosome components in 
the cytoplasm (Chapter 2). Interestingly, once the 
exosome is imported into the nuclear compartment 
there appears to be no shuttling to the cytoplasm, 
suggesting that the nuclear retention of the exosome 
is tightly regulated (Chapter 2). Putative nuclear 
localization signals (NLS) within the core exosome 
have been identified in the sequences of PM/Scl-
75 and hRrp41p. Indeed, the putative nuclear 
localization signal of PM/Scl-75 was shown to be 
important for its accumulation into the nucleolus 
(31). Therefore, the observation that the apoptotic 
cleavage of PM/Scl-75 results in the loss of its NLS 
during apoptosis might have important implications 
for the subcellular distribution of the entire exosome 
complex. For example increased exosome levels 
in the cytoplasm, which may be required for an 
enhanced degradation rate of RNA molecules in 
this compartment during apoptosis (Chapter 6). 
In several exosome associated proteins, including 
hTrf4-2p, MPP6 and PM/Scl-100, putative nuclear 
localization signals have been identified (see 
Chapters 3-5). In yeast, deletion of the NLS of yeast 
Rrp6p resulted in a defect in the nuclear localization 
of the protein, suggesting that the protein is 
independently imported into the nucleus where it can 
associate with the exosome core (32). The nucleolar 
localization of both MPP6 and hMtr4p were also 
found to be independent of the presence of core 
exosome components and PM/Scl-100 (Chapter 4). 
In the amino acid sequence of hMtr4p no nuclear 
localization signal could be identified, suggesting 
that its import into the nucleus is regulated by a yet 
unidentified protein, or that hMtr4p uses a distinct 
nuclear import pathway which does not require 
a standard nuclear localization signal. Another 
nuclear exosome-associated protein which lacks a 
nuclear localization signal is C1D (Chapter 4). It 
is shown that, depletion of PM/Scl-100, but not of 
other exosome components, results in the abrogation 
of the nucleolar localization of C1D. Combined 
with the observation that PM/Scl-100 requires a 
functional NLS for its nuclear localization, this 
strongly suggests that C1D interacts with PM/Scl-
100 in the cytoplasm and is imported into the 
nucleus via a piggy-back mechanism (see Fig. 1). 
Taken together, the nuclear exosome-associated 
proteins can be transported to the nucleus via 
several mechanisms, most of which remain poorly 
understood.
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Regulation of exosome activity by 
associated proteins
One of most intriguing questions is how different 
classes of RNA can be distinguished by the exosome 
and how the activity of the exosome is regulated. The 
crystal structure of the Archaeal exosome revealed 
that an RNA substrate must be single-stranded to be 
able to enter the catalytic chamber of the exosome 
(33). However, as many exosome RNA substrates 
contain secondary structures protecting them from 
degradation, RNA helicases are very likely to 
contribute to the unwinding of substrate RNAs. 
Indeed, in yeast the DExH-box RNA helicase Mtr4p 
was shown to be required for most nuclear activities 
of the core exosome, with the exception of exosome 
activities that specifically require Rrp6p, such as the 
3’ end trimming of the 5.8S rRNA (34-37). In Chapter 
4 we described the cloning and characterization of 
the human homologue of Mtr4p, which was shown 
to be involved in the maturation of the 5.8S rRNA. 
In contrast to yeast however, knock-down of either 
PM/Scl-100, or core exosome components, or 
hMtr4 did not result in the accumulation of different 
5.8S rRNA precursors. This might be explained by 
depletion of the whole exosome from the site of 
processing regardless which component is depleted. 
Alternatively, it might be explained by different 
functional activities of these proteins in different 
organisms, similar to the Dis3p protein, which 
was shown to be responsible for all exosome core 
activity in yeast, whereas human hDis3p so far has 
not been shown to be associated with the human 
exosome (38). Other RNA helicases which have 
been shown to be required for exosome activity, 
include the above-mentioned DExH-box RNA 
helicase Ski2p which is required for most functions 
of the yeast cytoplasmic exosome (25;26;39) and 
the DExH-box RNA helicase, RHAU, which was 
shown to be specifically required for the turnover 
of mRNAs containing AU-rich elements (40). These 
studies show that RNA helicases fulfill an important 
function in substrate unwinding and to prepare an 
RNA substrate for degradation by the exosome. 
Another class of exosome-associated proteins 
consists of RNA-binding proteins, that can either 
inhibit the exonucleolytic activity of the exosome 
by binding to the RNA or recruit and activate the 
exosome. Sequence-specific auxiliary proteins 
include the AU-rich element (ARE) binding proteins 
(AUBPs), which regulate ARE-mRNA degradation. 
The exosome has been shown to interact with several 
proteins of this family, including the proteins KSRP, 
AUF1 and TTP, all of which can stimulate exosome 
mediated ARE-mRNA degradation in vitro (see 
Fig. 3). In contrast, the ARE-mRNA stabilizing 
factor HuR does not interact with the exosome 
(1). It is known that the KH motifs of KSRP can 
directly mediate RNA binding, mRNA decay, and 
interactions with the exosome (41). Another study 
showed that KSRP and HuR can compete for 
binding to the AU-rich element (ARE) of the human 
iNOS mRNA, whereas HuR and AUF1 can also 
bind to distinct, non-overlapping sites (42;43). Other 
sequence-specific RNA-binding proteins are Nrd1 
and Nab3, which can promote RNA degradation by 
the exosome. Several precursor RNAs are known 
to contain Nrd1-binding sites, which are normally 
removed during processing resulting in functional 
RNAs. If, however, processing is blocked and the 
Nrd1-binding site is not removed, the exosome 
is recruited by Nrd1 for rapid degradation of the 
aberrant transcript (44;45). 
A surveillance pathway in order to eliminate 
mRNAs with premature termination codons that 
might otherwise encode truncated proteins is 
termed nonsense-mediated decay (NMD). The Upf 
proteins, Upf1, Upf2 and Upf3x play a critical role 
in recognizing such mRNAs and were found to co-
immunopurify with several exosome components 
(see Fig. 3) . 
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Also several RNA-binding proteins with limited 
sequence-specificity have been identified. They 
can promote exosome activity on certain RNA 
substrates. For example, both C1D and MPP6 
interact directly with PM/Scl-100 and knock-
down of either C1D or MPP6 led to similar rRNA 
processing defects as observed with PM/Scl-100 
(Chapters 3 and 4). In yeast genetic depletion of 
Rrp47p (the yeast orthologue of human C1D) leads 
to a similar phenotype (with defects in sn(o)RNA 
and rRNA processing) as depletion of Rrp6p. Still, 
Rrp47p was not required for Rrp6p-dependent 
degradation of aberrant pre-mRNAs in the nucleus 
(46). This suggests that Rrp47p mediates substrate 
specificity for the exosome in the processing of 
stable small RNA molecules. Nevertheless, the 
Figure 3. Model of the association of the core exosome with auxiliary proteins 
In the nucleus 3’ end processing of several pre-rRNAs and sn(o)RNAs by the exosome requires several associating proteins, including 
the RNA helicase hMtr4p, the RNA-binding proteins C1D and MPP6 as well as the 3’-5’ exoribonuclease PM/Scl-100. Aberrant 
rRNAs, tRNAs and sn(o)RNAs are targeted by the TRAMP (hTrf4-2-hAir2-hMtr4 poladenylation)-complex, which might directly 
bind to the core exosome or require the other exosome-associated proteins. In the cytoplasm, the exosome requires the Ski complex 
(hSki2w–hSki3p–hSki7p-hSki8p) for the regular 3’-5’ turnover of mRNAs as well as the degradation of mRNAs containing a 
premature stop codon (nonsense-mediated decay). The nonsense mediated decay pathway also requires PM/Scl-100 and several Upf 
proteins which might associate with the exosome via the Ski-complex. The degradation of mRNAs containing AU rich sequence 
elements (AREs) by the exosome requires PM/Scl-100 as well as the AU-rich element binding proteins TTP, KSRP and AUF1 which 
directly bind the AU-rich sequence elements (AREs). 
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precise requirements for RNA recognition for both 
MPP6 and C1D remain unclear and will most likely 
require detailed structural analyses of these proteins 
and their complexes with RNA. An overview of 
major exosome-associated complexes and their 
functions is shown in Figure 3. 
In eukaryotes, poly(A) tails are known to be required 
for stability and translation of mRNAs. However, 
recent studies have shown that polyadenylation 
of non-coding RNAs such as snRNAs, snoRNAs, 
pre-rRNAs and pre-tRNAs, is actually promoting 
RNA degradation. Polyadenylation of such RNAs 
is performed by the recently identified TRAMP-
complex which can exist in different forms. In yeast, 
this complex always contains the RNA helicase 
Mtr4p as well as a poly(A) polymerase (which is 
either Trf4p or Trf5p). The complex also contains 
a putative RNA binding protein, Air2p. Another, 
related and homologous RNA binding protein, 
Air1p, did not co-purify with Trf4p or Mtr4p, but in 
vivo analyses suggested that Air1p can replace Air2p 
in the Trf complex (47-50). It is conceivable that 
different subsets of TRAMP complexes exist and 
that these play different roles in exosome-dependent 
RNA processing events. For example, Trf4p and 
Trf5p may polyadenylate different RNA substrates, 
whereas the putative RNA binding proteins Air1p 
and Air2p may recruit the exosome complex to 
different polyadenylated substrate RNAs. Indeed, it 
was shown that the Trf4 complex can polyadenylate 
immature, unmodified tRNAs more efficiently 
than correctly processed tRNAs, suggesting that 
it can distinguish between correctly matured and 
immature RNA species (49;51). How the TRAMP 
complex can identify specific substrates and 
stimulate degradation by the exosome is unclear. 
Most likely, the addition of a single-stranded 
poly(A) tail by Trf4/5p makes the RNA a better 
substrate for the exosome, whereas the interactions 
of Mtr4p and Air1/2p with the exosome makes the 
latter a more efficient exoribonuclease. So far, there 
is little evidence whether a similar complex exists 
in human cells, although knock-down of hTrf4-2p 
results in reduced exosome activity in vitro. This 
strongly suggests that hTrf4-2p represents the 
human homologue of Trf4p and/or Trf5p (Chapter 
5). Remarkably, hTrf4-2p appears to have no RNA 
polymerase activity and the activity of the yeast 
exosome is also stimulated by catalytically inactive 
Trf4/5p, which suggests that polyadenylation is 
not essential for activated degradation (48;50). 
Unraveling the complete molecular mechanism 
underlying substrate recognition by the TRAMP 
complex and to determine whether or not hTrf4-2p 
represents a part of the human TRAMP complex 
will need additional work. 
The exosome in disease
Autoimmune diseases are characterized by an 
immune response against self-antigens, which are 
often intracellular multi-component complexes. For 
most autoimmune diseases, it remains unclear if and 
how autoantibodies contribute to the pathogenesis, 
but the specific autoantibody responses are often 
strongly associated with the biologic phenotype 
of systemic autoimmune diseases, making the 
autoantibodies useful for diagnostic purposes. 
In patients suffering from the polymyositis/
scleroderma overlap syndrome (PM/Scl-overlap) 
the autoantibodies are predominately reactive with 
the exosome proteins PM/Scl-75 and PM/Scl-
100 (52-55). Several models have been proposed 
why patients develop these autoantibodies. In 
the molecular mimicry model, the initial immune 
response is directed against a non-self protein 
which may spread to self-proteins due to sequence 
and/or structural similarity, thereby triggering 
an autoimmune response. An alternative model 
hypothesizes that post-translational modification 
of self-proteins during cell-death, in combination 
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with a defective clearance of dying cells might 
play a role in the development of autoimmunity. 
For example, in apoptotic cells proteins can be 
‘unusually’ modified in many ways, including 
proteolytic cleavage by activated caspases. The 
modification of proteins might generate antigenic 
determinants to which no tolerance exists, and 
exposure of these modified antigens to the immune 
system might result in an immune response (56). 
Also for the main autoantigens in PM/Scl-overlap 
patients it has been suggested that they are modified 
during cell death. PM/Scl-100 has been shown to be 
cleaved by granzyme B in vitro, which is a serine 
protease that plays an important role in inducing 
apoptosis in target cells of cytotoxic T cells (57), 
whereas PM/Scl-75 was shown to be cleaved by 
caspases during apoptosis (Chapter 6). These studies 
support the hypothesis that apoptotic modifications 
of self-proteins contribute to the generation of an 
autoimmune response. 
Additionally, the genetic background of a patient 
appears to be an important factor for the development 
of these antibodies, since in their presence in PM/
Scl overlap patients is often correlated to MHC 
allele HLA-DR3 (58). 
The identification of a novel major autoantigen, 
C1D, in PM/Scl-overlap patients is described in 
Chapter 7. The production of anti-C1D antibodies 
was found to be specific for the PM/Scl-overlap 
syndrome, making C1D an interesting novel marker 
for diagnosis of this disease. As we found that C1D 
interacts directly with PM/Scl-100 (Chapter 4) it 
is tempting to speculate that the initial immune 
response might be directed to PM/Scl-100, and 
subsequently spreads intermolecularly to C1D, 
leading to the generation of anti-C1D antibodies. 
Alternatively, the generation of anti-C1D antibodies 
might also be triggered by modification of C1D 
during apoptosis, although additional studies will be 
required to determine the fate of C1D in apoptotic 
cells. 
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Summary
Initially, the human exosome was identified as an 
autoantigen in patients with the overlap syndrome 
of the systemic autoimmune disorders polymyositis 
(PM) and scleroderma (Scl). The corresponding 
autoantibodies are directed to several components 
of the human exosome and are referred to as 
anti-PM/Scl antibodies. Further characterization 
of the human exosome complex has shown that 
it is a multi-subunit complex containing 3’-5’ 
exoribonuclease activity that functions in both the 
nucleus and the cytoplasm of the cell. It has been 
shown to play a key role in the 3’ end processing as 
well as degradation of several classes of RNA.
This thesis describes the identification and 
characterization of several exosome-associated 
proteins required for a functional exosome complex. 
Further analysis of the exosome and its auxiliary 
proteins resulted in possible clues why they are the 
target of autoantibodies in patients suffering from 
the PM/Scl-overlap syndrome.
Following an overview of our current knowledge 
on the exosome (Chapter 1), the 2nd Chapter 
describes the identification of exosome subsets 
which are present in the cytoplasm and nucleus 
of the cell. Surprisingly, knock-down experiments 
indicated that the cytoplasmic exosome is more 
labile than the nuclear exosome. In addition, we 
observed that knock-down of hRrp41p or hRrp4p 
but not PM/Scl-100 or PM/Scl-75 leads to co-
depletion of other subunits, suggesting that these 
proteins play a crucial role in the maintenance of the 
complex. Although they apparently do not affect the 
stability of other exosome subunits, both PM/Scl-
100 and PM/Scl-75 were found to be required for 
maintaining normal levels of several different types 
of mRNA.
In Chapters 3 and 4, the identification of MPP6, 
C1D and KIAA0052/hMtr4p as proteins which 
associate with a subset of nuclear exosome 
complexes is reported. All these proteins co-
localize with the exosome subunit PM/Scl-100 and 
accumulate in the nucleoli of the cell. In agreement 
with this localization, knock-down experiments 
revealed that they are involved in the generation 
of the 3’ end of the 5.8S rRNA. Both MPP6 and 
C1D were found to display RNA-binding activity 
in vitro, strongly suggesting that they are required 
for the recruitment of the exosome to (some of) its 
substrate RNAs.
A human homologue of the yeast poly(A) 
polymerase Trf4p, a component of the TRAMP 
complex, is characterized in Chapter 5. We show 
that hTrf4-2p is a 75 kDa nuclear protein, which 
associates with the human exosome. Knock-down 
of hTrf4-2p by RNAi resulted in a reduced activity 
of purified exosome complexes, strongly suggesting 
that efficient RNA degradation by the exosome is 
dependent on the addition of a 3’ oligo(A) tail to 
substrate RNAs by hTrf4-2p.
Why the exosome is targeted by autoantibodies 
remains elusive but recent studies have suggested 
that in the dying cell molecular modifications occur 
which may alter self-components in such a way 
that a primary immune response is elicited once 
the immune system is exposed to such modified 
antigens. In Chapter 6 we show that the exosome 
component PM/Scl-75 is cleaved by caspases 
during apoptosis, which is the first report of a 
modified PM/Scl-autoantigen in dying cells. These 
observations indeed suggest that PM/Scl-75 may 
play a role in the generation of autoantibodies to 
the exosome complex. Cleavage of the PM/Scl-75 
protein occurs at an unusual caspase cleavage site 
in the C-terminal part of the protein and at least a 
fraction of the resulting N-terminal fragments of 
PM/Scl-75 remains associated with the exosome.
Besides the well-documented autoantigenic proteins 
in patients suffering from the PM/Scl-overlap 
syndrome, we demonstrate in Chapter 7 that the 
exosome-associated protein C1D is also frequently 
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targeted by autoantibodies from these patients 
suggesting that anti-C1D antibodies might be an 
additional useful marker in the diagnosis of the PM/
Scl-overlap syndrome.
In Chapter 8 the results obtained in this study are 
discussed in a broader context and some additional 
preliminary results are included.
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Samenvatting
Aanvankelijk was het humane exosoom 
geïdentificeerd als een autoantigeen in patiënten met 
het overlap syndroom van de systematische auto-
immuunziekten polymyositis (PM) en scleroderma 
(Scl). De bijbehorende autoantilichamen bleken 
te zijn gericht tegen verschillende componenten 
van het humane exosoom en zijn bekend als anti-
PM/Scl antilichamen. Verdere karakterisering van 
het humane exosoom heeft aangetoond dat het een 
complex is met 3’-5’ exoribonuclease activiteit 
bestaande uit meerdere componenten dat zowel in 
het cytoplasma als in de kern van de cel functioneert. 
Het is aangetoond dat het een sleutelrol heeft in 
zowel de maturatie van het 3’ uiteinde als het 
volledig afbreken van verschillende soorten RNA.
Dit proefschrift beschrijft de identificatie en 
karakterisering van verscheidende exosoom 
geassocieerde eiwitten die nodig zijn voor een 
functioneel exosoom complex. Verdere analyse 
van het exsoom en zijn geassocieerde eiwitten heeft 
geleid tot mogelijke aanwijzingen waarom ze het 
doelwit zijn van autoantilichamen in patiënten die 
lijden aan het PM/Scl-overlap syndroom.
Na een overzicht van onze huidige kennis over 
het exosoom (Hoofdstuk 1), wordt in het 2e 
hoofdstuk de identificatie van verschillende 
exosoom-populaties beschreven, die aanwezig zijn 
in het cytoplasma en de kern van de cel. Verder 
gaven knock-down experimenten aan dat het 
cytoplasmatische exosoom minder stabiel is dan het 
kern exosoom. Bovendien hebben we vastgesteld 
dat het inhiberen van hRrp41p of hRrp4p, maar 
niet van PM/Scl-100 of PM/Scl-75, leidt tot de 
destabilisatie van andere exosoom componenten, 
hetgeen suggereert dat ze een essentiële rol spelen 
in het handhaven van de integriteit van het complex. 
Hoewel, ze blijkbaar niet de stabiliteit van andere 
exosoom componenten beïnvloeden, blijken zowel 
PM/Scl-100 als PM/Scl-75 nodig te zijn voor het 
handhaven van normale waarden van verschillende 
types mRNA.
In de Hoofdstukken 3 en 4, wordt de identificatie 
van MPP6, C1D en KIAA0052/hMtr4p als eiwitten 
die associëren met een subpopulatie van het 
kern exosoom beschreven. Al deze eiwitten co-
localiseren met de exosoom component PM/Scl-100 
in de nucleolus van de cel. In overeenkomst met 
deze lokalisatie, hebben knock-down experimenten 
aangetoond dat ze betrokken zijn bij het genereren 
van het 3’ uiteinde van het 5.8S rRNA. Zowel MPP6 
als C1D blijken in vitro RNA-bindingsactiviteit te 
bezitten, wat sterk suggereert dat ze nodig zijn van 
het rekruteren van het exosoom naar (sommige) 
RNA-substraten.
Een humane homoloog van het gist 
poly(A)polymerase Trf4p, een component van het 
TRAMP-complex, wordt beschreven in Hoofdstuk 
5. We tonen aan dat hTrf4-2p een kerneiwit is van 75 
kDa, dat associeert met het humane exosoom. Het 
inhiberen van hTrf4-2p met RNAi resulteerde in 
een gereduceerde activiteit van gezuiverde exosoom 
complexen hetgeen suggereert dat efficiënte RNA 
afbraak door het exosoom afhankelijk is van de 
additie van een 3’ oligo(A) staart aan substraat-
RNAs door hTrf4-2p.
Waarom het exosoom het doelwit is van 
autoantilichamen blijft onduidelijk, maar recente 
studies suggereren dat in een stervende cel 
moleculaire modificaties plaatsvinden, waardoor 
‘eigen’ componenten zodanig verandert worden, 
dat er een primaire immuun respons wordt uitgelokt 
zodra het immuunsysteem is blootgesteld aan zulke 
gemodificeerde antigenen. In Hoofdstuk 6 laten we 
zien dat de exosoom component PM/Scl-75 wordt 
gekliefd door caspases tijdens apoptose. Dit is de 
eerste beschrijving van een gemodificeerd PM/
Scl-autoantigeen in stervende cellen. Bovendien 
suggereert deze observatie dat PM/Scl-75 een rol 
speelt in het genereren van autoantilichamen tegen 
het exosoom complex. Klieving van PM/Scl-75 eiwit 
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gebeurt op een ongewone caspase knipplaats in het 
C-terminale deel van het eiwit, waarbij een gedeelte 
van de N-terminale fragmenten geassocieerd blijft 
met het exosoom.
Naast de reeds beschreven autoantigene eiwitten 
in patiënten die leiden aan het PM/Scl-overlap 
syndroom, tonen we in Hoofdstuk 7 aan dat het 
exosoom-geassocieerde eiwit C1D ook vaak herkend 
wordt door autoantilichamen van deze patiënten 
waardoor de anti-C1D antilichamen mogelijk een 
interessante additionele marker kunnen zijn voor de 
diagnose van het PM/Scl-overlap syndroom.
In Hoofdstuk 8 worden de resultaten die zijn 
behaald in deze studie in een bredere context 
bediscussieerd.
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